Roger Weiss, MD

Topic:

Integrating behavioral therapy with pharmacotherapy in the treatment of patients with substance use disorders

Integrating behavioral therapy with pharmacotherapy in the treatment of patients with substance use disorders.

This talk will focus on the role of behavioral therapy in patients with substance use disorders who are also receiving pharmacotherapy for their SUD. The talk will review the general goals of behavioral therapy in this population and then review specific behavioral therapies that are used with specific medications for alcohol and opioid use disorders.

Objectives

Review the general principles of behavioral interventions in patients receiving pharmacotherapy for substance use disorders.
Review specific behavioral interventions that accompany disulfiram and naltrexone treatment of alcohol use disorder.
Review specific behavioral interventions that accompany buprenorphine treatment of opioid use disorder.

Roger Weiss, CV

Roger D. Weiss, M.D., is Professor of Psychiatry at Harvard Medical School and Chief of the Division of Alcohol, Drugs, and Addiction at McLean Hospital in Belmont, Massachusetts. He has been Principal Investigator on numerous NIDA or NIAAA grants, and has developed Integrated Group Therapy, an evidence-based treatment for patients with co-occurring bipolar disorder and substance use disorders. Dr. Weiss led a multi-site national study of the treatment of prescription opioid dependence, as part of the NIDA Clinical Trials Network, and is currently a Lead Investigator on the multi-site Retention, Duration, Discontinuation (RDD) study, examining optimal treatments for opioid use disorder.

Dr. Weiss has authored over 400 articles and book chapters as well as 4 books, is a member of numerous journal editorial boards, and has participated in prominent national committees, including serving as Vice Chair of the American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders. He also has served as substance use consultant to the Boston Red Sox. He was named a Member of Honor by the Spanish Society for Dual Disorders in 2011, and has received numerous other awards, including the H. David Archibald Award for Outstanding Research and/or Practice in the Addictions from The Centre for Addiction and Mental Health in Toronto (2007), the Jack H. Mendelson Research Award from McLean Hospital (2012), the Dan Anderson Research Award from the Hazelden Foundation (2012), the Anne M. Cataldo Excellence in Mentoring Award from McLean Hospital (2014), the Founders Award from the American Academy of Addiction Psychiatry (2023), and the Stuart T. Hauser, MD, PhD Mentoring Award from Harvard Medical School (2024).

EDUCATION:

1972 A.B. cum laude, Harvard College

1976 M.D. Tufts University School of Medicine

POSTDOCTORAL TRAINING:

1976‑1979 Resident in Psychiatry, McLean Hospital, Belmont, MA

1978‑1979 Resident, Department of Medicine (Consultation‑Liaison Psychiatry),

Peter Bent Brigham Hospital

1978‑1979 Fellow in Psychiatry, Massachusetts Institute of Technology

1978‑1979 Chief Resident, Outpatient Clinic, McLean Hospital

LICENSURE AND CERTIFICATION:

1978 Massachusetts License Registration, #42785

1980 American Board of Psychiatry and Neurology, Certificate

1993 Added Qualifications in Addiction Psychiatry, Certificate (renewed in 2003, 2013)

ACADEMIC APPOINTMENTS:

1976‑1979 Clinical Fellow in Psychiatry, Harvard Medical School

1979‑1980 Clinical Instructor in Psychiatry, Harvard Medical School

1980‑1985 Instructor in Psychiatry, Harvard Medical School

1986‑1990 Assistant Professor of Psychiatry, Harvard Medical School

1990‑2003 Associate Professor of Psychiatry, Harvard Medical School

2003- Professor of Psychiatry, Harvard Medical School

HOSPITAL APPOINTMENTS:

1979‑1986 Assistant Psychiatrist, McLean Hospital

1987‑1992 Associate Psychiatrist, McLean Hospital

1992‑ Psychiatrist, McLean Hospital

2010- Director, Partners HealthCare (renamed Mass General Brigham) Addiction Psychiatry Fellowship

2017- Co-Clinical Chair, Substance Use Disorder Initiative, Mass General Brigham

OTHER PROFESSIONAL POSITIONS AND MAJOR VISITING APPOINTMENTS:

1984‑1995, 2014- Substance Abuse Consultant, Boston Red Sox Baseball Club

1984‑1991 Substance Abuse Consultant, Health Data Institute, Lexington, MA

1986 Consultant, Massachusetts Department of Public Health: Division of Alcoholism and Drug Rehabilitation

1988 Visiting Professor Program, University of Pittsburgh School of Medicine

1988‑1990 Substance Abuse Consultant, The Better Homes Foundation, Needham, MA

1988‑1990 Substance Abuse Consultant, Center for Consumer Healthcare Information, Irvine, CA

1991‑1997 Board of Advisors, Institute for Health Psychology, Dedham, MA

1993‑1994 Consultant, World Health Organization Cocaine Project

1995-1997 Consultant, Florida Department of Corrections

1995 Visiting Professor, King Saud University, Riyadh, Saudi Arabia

2012- Executive Committee, Section on Dual Disorders, World Psychiatric Association

2013- Associate Faculty Member, Ariadne Labs, Harvard University

2017- Mentee-Mentor Matching Program, Harvard Medical School

2018- Mentor, KL2/Catalyst Medical Research Investigator Training (CMeRIT) program,

Harvard Medical School

HOSPITAL AND HEALTH CARE ORGANIZATION SERVICE RESPONSIBILITIES:

1979‑1980 Psychiatrist in Charge (half‑time), Codman I (a general psychiatric unit),

McLean Hospital

1980-1985 Psychiatrist in Charge, Drug Dependence Treatment Unit, McLean Hospital

1986-1988 Director, Alcohol and Drug Abuse Treatment Center, McLean Hospital

1988‑2009 Clinical Director, Alcohol and Drug Abuse Program, McLean Hospital

2009- Chief, Division of Alcohol, Drugs, and Addiction, McLean Hospital

MAJOR ADMINISTRATIVE RESPONSIBILITIES:

2009-present Chief, Division of Alcohol, Drugs, and Addiction, McLean Hospital

Responsible for overall administration of the Division. The Division consists of the Alcohol, Drug, and Addiction Treatment Program (including a 21-bed hospital inpatient unit, 4 residential treatment programs with a total of 53 beds, a partial hospital program, an outpatient program, and a consultation program), a large clinical research program, and an extensive clinical and research training program.

MAJOR COMMITTEE ASSIGNMENTS:

McLean Hospital:

1976‑1979 Resident Evaluation Committee

1984 Committee on Impaired Employees

1984‑1985, 1988-1990 Clinical Case Conference Committee

1986‑1989 Infections Committee

1988‑1992 Clinical Operations Committee

1989‑1993 Quality Assurance Committee

1989‑1993 Utilization Review Committee

1989‑2004 Resident Selection Committee

1990- Research Committee

1992‑2005 Patient Care Coordinating Committee

1993 General Executive Committee

2001-2005 Continuing Education Committee

2008-2009 President’s Cabinet

Harvard University/Harvard Medical School:

1986‑1988 HMS Committee on AIDS

1998-2001 Harvard University Mind/Brain/Behavior Substance Abuse Working Group

1999-2001 Faculty Fellow, Harvard University Mind/Brain/Behavior Program

1998-1999 HMS Review Committee, Division on Addictions

2006-2009 Promotions, Reappointments, and Appointments Committee

Partners HealthCare System, Inc.:

1996-2001 Co-Chair, Substance Abuse Work Group

1999-2001 Mental Health Research Committee

1999-2001 Mental Health Education Committee

2018- Co-Clinical Lead for Substance Use Disorder Initiative, Population Health Management

Regional:

1982‑ Committee on Alcoholism and the Addictions, Massachusetts Psychiatric Society, Member

1982‑1985 Impaired Physicians’ Committee, Massachusetts Psychiatric Society, Member

2018- Member, Massachusetts Medical Society Physician Health Services Clinical Advisory Committee

National:

1986‑1989 Research Committee, American Academy of Psychiatrists in Alcoholism and Addictions, Member

1988‑ Special Review Committees, National Institute on Drug Abuse, Member

1988‑1994 Advisory Board, DSM‑IV Work Group on Alcohol and Substance Abuse, Member

1989‑1990 Scientific Programs and Research Committee, American Academy of Psychiatrists in Alcoholism and Addictions, Co-Chair

1991‑1995 Scientific Program Committee, American Academy of Addiction Psychiatry, Chair

1992‑1995 American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders, Member

1996-2001 National Institute on Drug Abuse Initial Review Group Member: Treatment Research Subcommittee

1999-2001 Research Section, American Academy of Addiction Psychiatry, Chair

1999-2005 Committee for Added Qualifications in Addictions, American Board of Psychiatry and Neurology, Member

2001-2007 American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders, Vice Chair

2003-2007 Treatment Research Subcommittee, National Institute on Drug Abuse Initial Review

Group (NIDAIRG), Member

2017- National Advisory Committee, Research in Addiction Medicine Scholars Program

2019- Member, Planning Committee, VA State of the Art Conference on Effective Management of Pain and Addiction: Strategies to Improve Opioid Safety

2020- American Board of Psychiatry and Neurology- Addiction Psychiatry Article-Based Continuing Certification Committee

PROFESSIONAL SOCIETIES:

1979-2002 American Psychiatric Association (Fellow, 1988)

1979‑ Massachusetts Psychiatric Society, Member

1985‑1993 American Society of Addiction Medicine, Member

1985‑ American Academy of Addiction Psychiatry (formerly American Academy of Psychiatrists in Alcoholism and Addictions), Member

1986‑1993 American Psychopathological Association, Member

1987‑1989 AIDS Task Force, Harvard Medical School, Department of Psychiatry, Member

1998- College on Problems of Drug Dependence, Member

2003- American Psychiatric Association, Distinguished Fellow

COMMUNITY SERVICE RELATED TO PROFESSIONAL WORK:

1996- Board of Directors, Greater Boston Council on Alcoholism

1999- Vice President, Greater Boston Council on Alcoholism

EDITORIAL BOARDS:

Editorial Board Member

1992‑ American Journal of Drug and Alcohol Abuse

1998- Journal of Clinical Psychiatry

1999- Harvard Review of Psychiatry, Field Editor

1999- Editorial Advisory Committee, Trastornos Adictivos (Addictive Disorders)

1999- American Journal on Addictions (Associate Editor for Book Reviews)

2001-2004 Current Psychiatry Reports, Substance Use Disorders Editor

2001-2015 Current Psychiatry

2010- Frontiers in Affective Disorders

2010- Journal of Dual Diagnosis

2013- Substance Use Disorders Section Editor, Current Treatment Options in Psychiatry

2014 Guest Editor, Special Issue on Prescription Drug Abuse, Journal of Substance Abuse Treatment

2015 Guest Editor, Special Issue on Substance Use Disorders, Harvard Review of Psychiatry

2015- Current Addiction Reports

Reviewer

1985‑ Journal of Nervous and Mental Disease

1986‑ Annals of Allergy

1987‑ Social Science and Medicine

1988‑ Journal of Studies on Alcohol

1988‑ New York State Journal of Medicine

1989‑ JAMA

1989‑ JAMA Psychiatry

1989‑ Journal of Psychiatric Research

1990‑ Drug and Alcohol Dependence

1990‑ American Journal on Addictions

1991‑ Addiction

1991‑ American Journal of Psychiatry

1994‑ Harvard Review of Psychiatry

1994- Journal of Clinical Psychiatry

1996- New England Journal of Medicine

AWARDS AND HONORS:

1969 Detur Book Award

1969 John Harvard Scholarship

1978 Nominee, Laughlin Fellowship, American College of Psychiatrists

1979 National Psychiatric Endowment Fund Award

1988 Fellow, American Psychiatric Association

1996 Partners in Excellence Award, Partners HealthCare System, Inc.

1999 Author, Distinguished Scholar Series, American Journal on Addictions

1999, 2000 Faculty Member, American Psychiatric Association Research Colloquium

for Junior Investigators

2003 Distinguished Fellow, American Psychiatric Association

2007 14th Annual H. David Archibald Award for Outstanding Research and/or Practice in the Addictions, Centre for Addiction and Mental Health, Toronto

2011 Member of Honor, Spanish Society for Dual Disorders

2012 Jack H. Mendelson Memorial Research Award

2012 Dan Anderson Research Award, Hazelden Foundation

2014 Anne M. Cataldo Excellence in Mentoring Award, McLean Hospital

2016-18 Named to “America’s Top Doctors”

2016-19, 2020- “Boston’s Best Doctors,” Boston Magazine

2023 Eric Hadar Distinguished Lecture, Columbia University

2023 Founders Award, American Academy of Addiction Psychiatry

2024 Stuart T. Hauser Mentorship Award, Harvard Medical School

2024 Jim Appleyard Lecture, 16^th Geneva Conference on Person Centered Medicine, International College of Person Centered Medicine

2024 Best poster award, 8^th World Congress, World Association on Dual Disorders

RESEARCH, TEACHING, AND CLINICAL CONTRIBUTIONS:

Narrative Description of Research:

I have focused my research and clinical interests on the evaluation and treatment of 1) patients with cocaine dependence, and 2) substance dependent patients with psychiatric illness. In the 1980s, I was among the first researchers to report the high rate of psychiatric disorders in drug dependent patients. At that time, psychiatrists had little interest in addiction; my work helped to emphasize the importance of psychiatric expertise in treating this population. I next conducted a number of studies that were highly relevant to the daily practice of addiction treatment. Indeed, part of my strength as a researcher has come from my extensive clinical experience as director of the addiction treatment program at McLean Hospital since 1980. This experience has taught me the types of questions that clinicians face regularly; my research has thus focused on these issues-. For example, my work has focused on the process of making psychiatric diagnoses in substance dependent patients (e.g., the utility of various standardized diagnostic instruments, depression rating scales, and biological markers) as well as the importance of recognizing heterogeneity within the substance dependent population (e.g., gender differences in cocaine abusers, differences related to the primary drug of choice).

I worked with Dr. Lisa Najavits to develop and test a treatment for drug dependent women with

Post-traumatic Stress Disorder. As PI of the Harvard site of the NIDA Collaborative Cocaine Treatment Study, the largest controlled study of psychosocial treatment of cocaine dependence ever conducted, I was the first researcher to examine the role of self-help attendance among cocaine dependent patients. I was PI of the Harvard site of the NIAAA-funded Project COMBINE, a multicenter site examining optimal combinations of pharmacotherapy and psychotherapy for alcohol dependent patients, and was PI for the Harvard site on a NIDA-funded study of Genetics of Cocaine Dependence.

In recent years, my work has evolved from an emphasis on evaluation to a focus on treatment strategies for discrete subgroups of substance dependent and dually diagnosed patients. Recently, I developed the first treatment designed specifically for patients with coexisting bipolar disorder and substance dependence. I conducted three studies of this treatment, including two randomized controlled trials, both of which demonstrated the efficacy of Integrated Group Therapy. Integrated Group Therapy has been cited by the National Institute on Drug Abuse as one of the five promising treatments for patients with co-occurring psychiatric illness and substance dependence. I am now PI for the Northern New England Node of the NIDA Clinical Trials Network, a multisite study designed to develop and implement drug abuse treatment studies in community treatment programs. As part of that network, I led the multi-site Prescription Opioid Addiction Treatment Study; the largest study ever conducted examining treatments for patients dependent upon prescription opioids.

Research Funding Information:

Past

1986-1991 NIDA P50 DA04059 Co-Investigator Polydrug Abuse in Women: NIDA Clinical Research Center

1989-1994 NIDA R29 DA05944 PI Predictors of Outcome in Cocaine Dependence

1989-1995 NIDA R18 DA-6116 Co-Investigator Treatment Efficacy for Drug Abuse and AIDS Prevention

1991-1999 NIDA U10 DA07693 PI Psychosocial Treatment of Cocaine

Use Disorder

1992-2004 Dr. Ralph and Marian C. PI Research on Substance Abuse

Falk Medical Research Trust

1993-2000 NIDA R01 DA08631 Co-PI Group Cognitive Behavior Therapy for Dual

Diagnosis Women

1994-1998 NIDA R01 DA09400 PI A Relapse Prevention Group for Bipolar

Substance Abusers

1995-1998 NIAAA R29 AA09881 Co-Investigator Gender Differences in Recovery from Alcohol Dependence

1995-1998 NIDA Y01 DA50038 Consultant NIDA/VA Substance Abuse Medication Development Center

1995-1999 NIDA R01 DA09657 Co-Investigator Cocaine Effects: Ethnic, Gender and

Hormonal Factors

1996-1999 NIMH R01 MH54317 Consultant Substance Abuse Comorbidity in First-Episode

Mania

1997-2007 NIDA K02 DA00326 PI Independent Scientist Award: Treatment of

Drug Dependence and Psychiatric Illness

1997-2007 NIAAA U10 AA11756 PI Combined Behavioral and Pharmacologic

Treatment of Alcoholism

1998-2001 NIAAA R21 AA12181 Co-Investigator Cognitive-Behavior Therapy for PTSD/AUD Adolescent Girls

1998-2001 NIMH R01 MH58288 Co-Investigator Mental Illness, Comorbidity and Mortality

Diagnosis Women

1998-2004 NIMH N01 MH80001 Co-Investigator; Systematic Treatment Enhancement Program Substance Abuse for Bipolar Disorder

Pathway Leader

1999-2004 NIDA R01 DA12849 Harvard Site PI Genetics of Cocaine Dependence

Substance Abusers

1999-2004 NIMH R01 MH58170 Consultant Substance Abuse in First-Episode Mania

2002-2007 NIDA U10 DA15831 PI NIDA Clinical Trials Network: Harvard

University Northern New England Node

2002-2008 NIDA R01 DA15434 Co-Investigator Recovery Group for Women with Substance Use Disorders

2002-2008 NIDA R01 DA15968 PI Modifying Group Therapy for Bipolar Disorder and Substance Abuse

2003-2006 NIAAA R21 AA13423 Consultant Reliability Generalization of Alcohol Research. Screening Measures

2008-2012 NIDA R01 DA15434 Co-Investigator Recovery Group for Women with Substance Use Disorders

2009-2012 NARSAD Consultant/Mentor Combination of Marinol and Clonidine for

Marijuana Dependence in Schizophrenia

(Kevin Hill, PI)

2009-2012 Adam Corneel Young Consultant/Mentor Nabilone for Cannibis Dependence: Imaging

Investigators Award and Neuropsychological Performance

(McLean Hospital) (Kevin Hill, PI)

2008- Harvard Medical School Consultant/Mentor Cognitive-Behavioral Therapy for Comorbid

Marijuana Dependence and Nicotine Dependence (Kevin Hill, PI)

2009-2011 NIMH R01 MH083684 Consultant Evaluation of Tobacco Treatment Strategies

for Inpatient Psychiatry (Judith Prochaska, PI)

2007- 2017 NIDA K24 DA022288 PI Mentoring in Drug Abuse and Dual Diagnosis

2017-2019 NIDA R21 DA041682 PI Opioid Use and Abuse in the Dialysis Population

2018- 2021 NIMH R43 MH119672 Consultant MHealth for Patient Self-Management in Opioid

Use Disorder (Charles Bowden, PI)

Present

1991- NIDA T32 DA07252 Program Faculty Drug Abuse Research Training Program

2002- NIDA UG1 DA15831 PI NIDA Clinical Trials Network: New England Consortium Node

2020- HRSA T25HP37602 Co-Investigator Addiction Medicine Fellowship

2018- 5R01DA044167 Co-Investigator Using a Novel Comprehensive Linked Dataset to Determine Early Predictors of Opioid Overdose

Report of Current Research Activities:

I am a PI of the New England Consortium Node of the NIDA Clinical Trials Network (CTN). The CTN is a nationwide effort by NIDA to improve the overall quality of drug abuse treatment by forging a partnership between academic research centers and community drug abuse treatment programs as well as general medical settings. . Researchers and community treatment program clinicians work with each other to develop and carry out research studies in community programs. As part of that network, I led the multi-site Prescription Opioid Addiction Treatment Study: the largest study ever conducted examining treatments for patients dependent upon prescription opioids. I am currently testing treatments for patients with opioid use disorder in the multi-site Retention, Duration, Discontination (RDD) trial, including the first prospective study of patients who are stable on buprenorphine and are tapering off the medication.

Report of Teaching

Local Contributions:

Medical School Courses

1986‑1988 Expert Faculty Resource, Life Cycle course, New Pathways Program, Harvard Medical School

1986‑ Faculty, Harvard Medical School course 700 MJ: Psychopathology and Introduction to Clinical

Psychiatry; Lecturer on substance use disorders: 12-20 students, two hours

1989-1991 Faculty, Harvard Medical School course on Clinical Pharmacology and Therapeutics; Lecturer

2002- on pharmacotherapy of substance use disorders: 25 students, one hour

1993- Faculty, Harvard Medical School course on Substance Abuse: Addictive Process, Teach seminar on

treatment of substance use disorders once per course: approximately 10 students, one hour

1995 Nominee, Harvard Medical School Award for Excellence in Mentoring

Graduate Medical Courses

1978‑1979 Seminar Leader, McLean Hospital Outpatient Clinic, McLean Hospital

1982‑ Seminar Leader, Taught seminars on substance use disorders for first and second year psychiatric residents, McLean Hospital; 10 residents, six hour-long seminars per year

1985‑ Seminar Leader, Taught seminars on substance use disorders for psychiatric residents at Beth Israel

Hospital, Brockton Veterans Administration Hospital, Massachusetts Mental Health Center, Longwood Residency Program; approximately 10 residents, up to two seminars a year (none in some years)

Invited Teaching Presentations (since 1992)

03/06/1992 Harvard Medical School/Cambridge Hospital, Understanding and Treating the Addictions

Conference, “A Clinical Approach to the Dually Diagnosed Patient”

05/14/1992 McLean Hospital Continuing Education, “Dual Diagnosis: Evaluation and Treatment”

09/18/1992 Harvard Medical School Division on Addictions, “Cocaine Abuse and Dependence”

03/04/1994 Harvard Medical School/Cambridge Hospital, Treating the Addictions: Clinical Controversies

Conference, “Why Integrate Psychopharmacological and Psychological Treatment Approaches with

Substance Abusers”

03/01/1995 Harvard Longwood Psychiatry/Resident Training – Medical Psychiatry Seminar,

“Cocaine/Stimulants”

03/31/1995 McLean Hospital Academic Conference, “Cocaine Abuse: A Clinical Update”

04/19/1996 McLean Hospital, Substance Abuse and Violence Conference, “Cocaine and Alcohol Abuse”

10/10/1996 Harvard Community Health Plan, Geriatric Mental Health Training Series, “Evaluation and

Treatment of Alcohol or Drug Problems in Older Individuals”

10/25/1996 Harvard Medical School, Addiction Medicine: A Course for Clinicians, “Cocaine Abuse and

Dependence”

12/12/1996 Harvard University Health Services Grand Rounds, “Update on Cocaine Abuse”

04/18/1997 McLean Hospital, Bipolar Disorder: Comorbid Disorder, Diagnosis and Pharmacological

Management Conference, “Bipolar Disorder with Substance Abuse”

05/29/1997 McLean Hospital Academic Conference, “Update on Pharmacotherapy of Substance Use Disorders

and Dual Disorders”

09/12/1997 Harvard Medical School/Cambridge Hospital Suicide Symposium, “Substance Abuse and Suicide”

10/25/1997 Harvard Medical School Addiction Medicine conference, “Cocaine”

04/10/1998 McLean Hospital Academic Conference, “Pharmacotherapy of Substance Use Disorders and Dually

Diagnosed Patients”

05/05/1998 Harvard Medical School Consolidated Department of Psychiatry DMH Teleconference Series,

“Dual Diagnosis – Management and Comorbidity Issues”

12/10/1998 McLean Hospital, Psychopharmacology Grand Rounds, “Pharmacotherapy of Patients with

Substance Use Disorders and Dually Diagnosed Patients”

06/23/1999 Harvard University Kennedy School of Government seminar Merging Perspectives on Drugs and

Crime: A Cross-Agency Approach, “Treatment of Substance Use Disorders”

07/20/2000 Harvard University Kennedy School of Government seminar Merging Perspectives on Drugs and

Crime: A Cross-Agency Approach, “Treatment of Substance Use Disorders”

11/01/2001 Harvard University Health Services: “Substance Abuse and Mood Disorders”

10/18/2002 Harvard Medical School Division on Addictions Course on Addiction Medicine: New Strategies for a

New Millennium: “New Behavioral Therapies for Drug Dependence”

01/16/2003 McLean Hospital Academic Conference, “Substance Abuse and Mood Disorders”

06/27/2003 McLean Hospital/Harvard Medical School Psychiatry in 2003 Conference, “Treatment of Patients

with Substance Use Disorders and Psychiatric Illness”

02/19/2004 McLean Hospital/Harvard Medical School Pharmacology and Clinical Therapeutics Course,

“Pharmacologic Management of Substance Abuse”

02/15/2005 Harvard Medical School Longwood Psychiatry Grand Rounds, “Treatment of Patients with Mood

Disorders and Substance Abuse”

03/04/2005 Harvard Medical School/Cambridge Hospital Addictions Conference, Boston, MA, “Integrated

Treatment for Mood and Substance Use Disorders: Understanding Personality Problems and

Addictions”

03/31/2005 McLean Hospital Grand Rounds, “The Treatment of Patients with Substance Abuse and Bipolar

Disorder”

02/09/2006 McLean Hospital Grand Rounds, “The Treatment of Alcohol Dependence”

06/15/2006 McLean Hospital Psychiatry in 2006 Conference, “Treatment of Patients with Substance Use

Disorders and Psychiatric Illness”

03/24/2011 McLean Hospital Grand Rounds, Crossroads in Psychiatry Series: “Developing New Medications for

Addiction, From Rats to Humans: Successes and Challenges.”

04/07/2011 Tufts University School of Medicine, “Cocaine”

Continuing Medical Education Courses

1987- Faculty of McLean Hospital Board Review Course – Lecturer on substance use disorders, typically two

hour-long presentations per year, 5 hours of preparation per year.

2010 Co-Director, Addictions 2010, a two-day symposium put on by McLean Hospital to review new findings in addiction research.

2011 Co-Director, Addictions 2011, a two-day symposium put on by McLean Hospital to review new findings in addiction research.

2012 Co-Director, Addictions 2012, a two-day symposium put on by McLean Hospital to review new findings in addiction research.

2013 Co-Director, Addictions 2013, a two-day symposium put on by McLean Hospital to review new findings in addiction research.

2014 Co-Director, Addictions 2014, a two-day symposium put on by McLean Hospital to review new findings

in addiction research.

Lecturer in the following Harvard Medical School Continuing Medical Education Course

Brigham & Women’s Hospital Intensive Review of Internal Medicine Course (twice)

Addiction Medicine Course (several times)

Cambridge Hospital Treating the Addictions Course (several times)

Massachusetts General Hospital Bipolar Disorder Mini-Fellowship (several times)

Massachusetts General Hospital Adolescent Substance Use Disorders Course

Cambridge Hospital Suicide Course

McLean Hospital Board Review, State-of-the-Art, Psychopharmacology Courses (many times)

Advisory and Supervisory Responsibilities in Clinical or Laboratory Setting

1979‑ Supervisor of medical students and psychiatric residents, McLean Hospital; supervised

residents who rotate through the Substance Abuse Clinical Service; typically 50-70 hours per

year depending on number of residents.

1999- Have overseen addiction psychiatry fellowship at McLean Hospital, and have supervised fellows in

addiction psychiatry, one hour per week; Partners Addiction Psychiatry Fellowship became ACGME

certified in 1999; director of fellowship at McLean Hospital, typically 80 hours per year.

Have acted as Mentor for several psychiatrists who were entering a clinical or research

career in the addictions.

Leadership Roles

1987 Course organizer and lecturer, McLean Hospital/Harvard Medical School symposium on “Cocaine”

1998- Member, “Mind, Brain, and Behavior” Substance Abuse Working Group, Harvard University

1998- Member, Advisory Group on Division on Addictions, Harvard Medical School

1998 Course organizer and lecturer, McLean Hospital symposium on “New Developments in the Treatment of

Substance Use Disorders”

2000- Board of Honors Tutors, Harvard University Department of Psychology (Faculty of Arts and Sciences)

Names of Advisees or Trainees

Current:

Timothy Benson, M.D.

Alisa Busch, M.D.

Hilary Connery, M.D., Ph.D.

Aaron Frenz, M.D.

Kevin Hill, M.D., M.P.H.

William Jaffee, Ph.D.

Monika Kolodziej, Ph.D.

Sharon Levy, M.D.

Christina Meade, Ph.D.

Sherry Nykiel, M.D.

Michael Ostacher, M.D.

Jennifer Sharpe Potter, Ph.D., M.P.H.

Past:

1987 Yifrah Kaminer, M.D.

1987-1989 Susan McElroy, M.D.

1988-1990 Steven Adelman, M.D.

1989-1990 Stephen Strakowski, M.D.

1989-1990 Peggy S. Stephens, M.D.

1991-1992 Roxanne Bartel, M.D.

1991-1993 S. Nassir Ghaemi, M.D.

1991-2001 Lisa M. Najavits, Ph.D.

1992-1993 Jose Martinez-Raga, M.D.

1992-2001 Shelly F. Greenfield, M.D., M.P.H.

1994-1995 James D. Wines, M.D.

1996-1997 Randy Gollub, M.D.

1996-1997 Hans Breiter, M.D.

1997-1998 Michael Hufford, Ph.D.

2000-2001 S. Pirzada Sattar, M.D.

2001-2002 Olivera Bogunovic, M.D.

2001-2006 Grace O’Leary Hennessy, M.D.

2005-2008 Sumita Manwani, M.D.

Regional, National or International Contributions:

Invited Presentations (since 1991)

01/31-02/02/1991 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Clinical Approaches to Alcohol and Drug Abuse”

03/13/1991 Lawyers Concerned for Lawyers, Boston, MA, “Substance Abuse”

03/18/1991 Mount Auburn Hospital Department of Medical Education, Cambridge, MA, “Cocaine”

04/06/1991 University of Tennessee, Knoxville, TN, “Clinical Approaches to Alcohol and Drug Abuse”

04/18/1991 Florida Spring Symposium, “Clinical Approaches to Alcohol and Drug Abuse”

04/30/1991 Mount Auburn Hospital Grand Rounds, Cambridge, MA, “Adolescent Alcohol and Drug Abuse”

05/20/1991 Edgehill Newport, RI, Northeastern Conference on Alcoholism and Drug Dependence,

08/26-30/1991 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Clinical Approaches to Alcohol and Drug Abuse”

10/02/1991 State University of New York Health Science Center Grand Rounds, Brooklyn, NY,

“Substance Abuse and Psychiatric Disorders: A Clinical Approach to the Dual Diagnosis Patient”

10/09/1991 Massachusetts Psychiatric Society, Boston, MA, “Alcohol and Drug Abuse”

10/24/1991 Charles River Hospital Grand Rounds, Wellesley, MA, “Substance Abuse and Psychiatric Illness: Clinical Approaches to the Dual Diagnosis Patient”

11/22/1991 Salem Hospital Grand Rounds, Salem, MA, “Cocaine”

02/11/1992 Pembroke Hospital Academic Conference Series, Pembroke, MA, “Diagnosis and Treatment of

the Dually Diagnosed Patient”

05/22/1992 Brockton Veterans Administration Hospital, Brockton, MA, “A Clinical Approach to the Dually

Diagnosed Patient”

06/10/1992 New England Deaconess Hospital, Boston, MA, “Alcohol and Drug Abuse”

06/20/1992 University of Barcelona Medical School, “Substance Abuse and Psychiatric Illness”

07/30/1992 Newton-Wellesley Hospital, Newton, MA, “Dual Diagnosis in the Treatment of Substance Abuse”

08/24-28/1992 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Clinical

Approaches to Alcohol and Drug Abuse”

09/17/1992 Cape Cod Symposium on Addictive Disorders, “A Clinical Approach to the Dual Diagnosis Patient”

09/29/1992 Brigham and Women’s Hospital Grand Rounds, Boston, MA, “Dual Diagnosis”

10/14/1992 St. Thomas Medical Center, Akron, OH, “Diagnosis and Treatment of Alcoholism and Other

Addictive Disorders with Coexisting Psychopathology”

10/23/1992 University of Connecticut Health Center, Master Therapists Symposium, “Clinical Approaches

to Alcohol and Drug Abuse”

11/04/1992 American Society of Addiction Medicine, Second National Roundtable on Patient Placement Criteria Conference, Crystal City, VA

11/09/1992 St. Francis Medical Center, Pittsburgh, PA, Conference, “Dual Diagnosis: Cocaine Addiction

and Psychiatric Disorders”

03/10/1993 Melrose-Wakefield Hospital, Melrose, MA, “Diagnosis and Treatment of Cocaine Abuse”

08/23-27/1993 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia “Therapeutic

Approaches to Alcohol and Drug Abuse”

09/30/1993 North River Foundation, Inc., Cape Cod Symposium on Addictive Disorders, “New Clinical and Research Findings in Cocaine Dependence”

11/17/1993 Marlborough Hospital, Marlborough, MA, “Dual Diagnosis: Substance Dependence and

Psychiatric Disorders”

11/18/1993 Massachusetts Institute of Technology Medical Department, Cambridge, MA, “Alcohol and

Drug Abuse”

02/07/1994 Massachusetts Mental Health Center, Boston, MA, Resident Training, “Clinical Aspects of

Cocaine/Stimulants”

03/15/1993 Royal Ottawa Hospital, Ottawa University Medical School Grand Rounds, “Dual Diagnosis: Cocaine Dependence and Psychiatric Disorders”

05/11/1993 Dartmouth Psychiatric Research Center, “Cocaine Dependence”

04/30/1993 Brown University Center for Alcohol and Addiction Studies, “Assessment of Axis II Disorders”

11/08-09/1993 Council of State Governments, Center for Substance Abuse Treatment Seminar, Santa Fe, NM,

“Treatment for Alcohol and Other Drug Abuse”

01/27-28/1994 Council of State Governments, Center for Substance Abuse Treatment Seminar, St. Thomas, Virgin Islands, “Dual Diagnosis and the Rationale for Assessment,” “Patient Matching and Preventing Relapse,” “Pharmacotherapy’s Role in Alcohol and Other Drug Treatment”

05/05/1994 Newton-Wellesley Hospital, Newton, MA, “New Findings on Cocaine Abuse”

05/06/1994 Massachusetts Mental Health Center, Boston, MA, Psychopharmacology Lecture Series,

“Cocaine Clinical and Research Update”

05/12/1994 Dual Disorders Conference, Orlando, FL, “Personality Disorders and Substance Abuse”

07/11-15/1994 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia “Therapeutic

Approaches to Alcohol and Drug Abuse”

07/22/1994 Continuing Medical Education, Inc. Conference, Baltimore, MD, “Cocaine and

Stimulant Abuse: A Clinical Update,” “Substance Abuse and Personality Disorders”

09/09-10/1994 St. Francis Medical Center, Pittsburgh, PA, “Clinical Overview of Cocaine”

10/13/1994 New England Educational Institute Santa Fe Symposia, “Therapeutic Approaches to

Alcohol and Drug Abuse”

11/04/1994 Oklahoma Department of Mental Health and Substance Abuse Services, Oklahoma City, OK,

“Substance Abuse and Psychiatric Disorders: A Clinical Approach to the Dually Diagnosed Patient”

11/10/1994 University of Southern Maine, Portland, Cocaine Workshop, “Cocaine Update”

02/02/1995 Western Regional Dual Disorder Conference, San Diego, CA, “Personality Disorders and Substance Abuse”

03/08/1995 Medical Center of Central Massachusetts, Worcester, “Dually Diagnosed Patients”

03/10/1995 North Shore Medical Center, Salem, MA, “Major Mental Illness and Substance Abuse”

03/20/1995 Boston College School of Nursing – Advanced Pharmacology course, “Psychopharmacologic

Treatment of Substance Use Disorders and Dual Diagnosis”

04/07/1995 Ochsner Clinic, New Orleans, LA, Psychiatry Grand Rounds, “Substance Abuse and Personality Disorders”

04/07/1995 Continuing Medical Education, Inc. Conference, New Orleans, LA, “Substance Abuse

and Personality Disorders,” “Improved Psychotherapy for Substance Abusers”

04/20-21/1995 Ohio Psychological Association, “New Developments in the Treatment of the Addictions”

04/26/1995 Florida Center for Addictions, Tampa, FL, “Personality Disorders and Addictions Chemically

Dependent Patient”

06/02/1995 Brockton Veterans Medical Center, Brockton, MA, “Substance Abuse: How Do We Effectively and Creatively Use Our Resources?”

06/15/1995 Continuing Education Association of the Southeast, Mobile, AL, “Substance Abuse and Psychiatric Illness: A Clinical Approach to the Dually Diagnosed Patient”

06/29/1995 Hospital of St. Raphael, New Haven, CT, “Advances in Treatment of Cocaine Dependence”

08/01/1995 Big Brother Association of Greater Boston, Boston, MA, “Substance Abuse”

08/21-25/1995 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia “Therapeutic

Approaches to Alcohol and Drug Abuse”

08/31/1995 St. Louis VA Medical Center, St. Louis, MO, “Substance Abuse: An Integrative Model of Addictions Treatment”

11/12/1995 King Saud University Hospital, College of Medicine, Riyadh, Saudi Arabia, “Drug and Alcohol Abuse: Etiology and Diagnosis,” “Drug and Alcohol Abuse: Course and Treatment”

11/27/1995 Cambridge Hospital Grand Rounds, Cambridge, MA, “Cocaine Abuse – A Clinical Update”

02/05/1996 Boston College School of Nursing – Advanced Pharmacology course, “Psychopharmacologic

Treatment of Substance Abuse Disorders and Dual Diagnosis”

03/28/1996 Mental Health Associates of Greater Springfield, Springfield, MA, “Psychopharmacology of Dually Diagnosed Patients”

04/26/1996 University of Oregon, “Cocaine and Crack”

05/29/1996 University of Cincinnati College of Medicine Grand Rounds, “Cocaine Abuse: An Update”

07/25/1996 Berkshire Area Health Education Center, 12^th Annual Berkshire Medical Conference, Hancock, MA, Special Challenges in General Medicine, “Therapeutic Approaches to Drug Abuse”

08/19-23/1996 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Therapeutic

Approaches to Alcohol and Drug Abuse”

10/05/1996 Continuing Medical Education, Inc. Conference, San Antonio, TX, “Substance Abuse and Mood Disorders,” “Psychotherapy for Substance Use Disorders”

11/20/1996 Cambridge Hospital, Cambridge, MA, Advanced Psychopharmacology Seminar, “Dual Diagnosis Patients”

11/22/1996 Oklahoma Department of Mental Health and Substance Abuse Services, Norman, OK, “Outpatient Models for the Chemically Dependent”

02/10/1997 Boston College Advanced Psychopharmacology course, “Psychopharmacologic Treatment of

Substance Use Disorders and Dual Diagnosis”

02/20/1997 University of Massachusetts Medical School, Worcester, MA, Psychiatry Grand Rounds,

“Psychotherapy of Patients with Substance Use Disorders”

04/24/1997 Baystate Medical Center, Springfield, MA, Grand Rounds, “Treating Dual Diagnosis Patients on an Adult Psychiatry Inpatient Unit”

07/30/1997 Texas Commission on Alcohol and Drug Abuse, Austin, TX, “Cocaine: A Clinical Update”

08/10-17/1997 Brigham & Women’s Hospital, Boston, MA, Intensive Review of Internal Medicine, “Substance Abuse”

08/18-22/1997 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Therapeutic

Approaches to Alcohol and Drug Abuse”

09/15-17/1997 Florida Department of Corrections Dual Diagnosis Training Project

09/25/1997 Continuing Medical Education, Inc. Conference, Scottsdale, AZ, “Recent Advances in Substance Abuse and Mood Disorders

09/26/1997 Department of Mental Health, Commonwealth of Massachusetts, Dual Diagnosis Conference,

“Dual Diagnosis: Elements of Pharmacotherapy”

10/18/1997 National Football League Players Association Program for Substances of Abuse–Approaches to

Treatment of Substance Use Disorders Conference, Burlington, VT, “Substance Abuse and Mood Disorders”

11/15/1997 Massachusetts Psychiatric Society, Psychopharmacology Update Conference, “Psychopharmacological Management of Bipolar Patients Who Are Abusing Alcohol and Drugs”

02/09/1998 Boston College Prescribing Practices for Psychopharmacology course, “Psychopharmacologic

Treatment of Substance Abuse”

02/12/1998 University of Massachusetts Medical Center, Worcester, MA, “Substance Abuse and Mood Disorders”

03/13/1998 Kentucky Psychiatric Association, Keynote Speaker, “Psychotherapy for Substance Use Disorders”

04/21/1998 National GAINS Center Training, Tucson, AZ, “Treatment of Co-Occurring Disorders”

05/13/1998 Brigham & Women’s Hospital, Boston, MA, Addiction Lecture Series, “Therapeutic Approaches

to Alcohol and Substance Abuse”

05/27/1998 Center for Mental Health, Waltham, MA, “Pharmacotherapy of Substance Use Disorders and

Dually Diagnosed Patients”

06/18/1998 National GAINS Center Training, Montgomery County, PA, “Treatment of Co-Occurring Disorders”

07/27-31/1998 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Therapeutic

Approaches to Alcohol and Drug Abuse”

08/12/1998 Brigham & Women’s Hospital, Boston, MA, Intensive Review of Internal Medicine, “Drug and

Alcohol Abuse”

10/21/1998 Quincy Mental Health Center, Quincy, MA, “Substance Abuse”

10/23/1998 New Hampshire Psychological Association Workshop, Concord, NH, “Therapeutic Approaches

to Alcohol and Drug Abuse”

10/26-27/1998 Portland, OR Mental Health Center, “Treatment of Co-Occurring Disorders”

11/12/1998 Tufts University School of Medicine, Boston, MA, 2^nd Year Students, Addiction Medicine

Lecture, “Cocaine and Stimulants”

11/16/1998 Westwood Lodge Hospital Psychopharmacology Seminar, Westwood, MA, “Substance Abuse

and Bipolar Disorder”

02/08/1999 Boston College Prescribing Practices for Psychopharmacology course, “Pharmacologic Treatment

of Substance Use Disorders and Dual Diagnosis”

03/09/1999 Lahey Clinic Psychiatric Grand Rounds, Burlington, MA, “Substance Abuse and Mood Disorders”

03/11/1999 Deaconess-Waltham Hospital, Waltham, MA, “Pharmacotherapy of Patients with Substance

Use Disorders and Dually Diagnosed Patients”

04/05/1999 Veterans Administration Outpatient Clinic, Boston, “Substance Abuse and Depression:

A Clinical Overview”

04/15/1999 St. Francis Medical Center Psychiatric Grand Rounds, Pittsburgh, PA, “Bipolar Disorder and

Substance Abuse”

05/06/1999 Maryland Addictions Directors Council Inc., Ocean City, MD, “Clinical Implications of Working with Populations with Co-Occurring Disorders”

05/19/1999 Bryce Hospital, Tuscaloosa, AL, “Treatment of Patients Dually Diagnosed with Substance Abuse and Psychiatric Illness”

07/06/1999 Boston University School of Public Health, Center for Substance Abuse Prevention Faculty

Development Program, “Substance Abuse Treatment Modalities and Their Effectiveness”

08/16-20/1999 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Therapeutic

Approaches to Alcohol and Drug Abuse”

09/15/1999 The Institute of Living, Hartford, CT, Grand Rounds “Psychotherapy of Cocaine Dependence:

The National Institute on Drug Abuse Collaborative Cocaine Treatment Study”

10/07/1999 Brockton VA Medical Center, Brockton, MA, Grand Rounds, “Substance Abuse in Bipolar Illness”

11/08/1999 Tufts University School of Medicine, Boston, MA, 2^nd Year medical students, “Cocaine and

Other Psychostimulants”

11/10/1999 Spectrum Health Services, Hamden, CT, “Bipolar and Substance Use Disorders”

11/15/1999 Pittsburgh Psychiatric Society, “Comorbid Substance Abuse in the Seriously Mentally Ill”

12/13/99 Massachusetts Commission for the Blind, Boston, MA, “Alcohol and Substance Abuse”

02/03/2000 Newton-Wellesley Hospital, Newton, MA, “Psychotherapy of Substance Use Disorders”

02/07/2000 Boston College Prescribing Practices for Psychopharmacology course, “Pharmacologic Treatment of Substance Use Disorders and Dual Diagnosis”

03/10/2000 Continuing Medical Education, Inc. Conference, New Orleans, LA: “Psychotherapy of Substance Use Disorders,” “Substance Abuse and Mood Disorders”

03/30/2000 Boston University Medical Center, “Substance Abuse and Bipolar Disorder”

04/25/2000 Medical University of South Carolina, “Substance Abuse and Mood Disorders”

06/14/2000 Mental Health Association of Franklin County, Columbus, OH, “Substance Abuse and Mood

Disorders”

06/30/2000 Massachusetts General Hospital, Boston, MA, “Bipolar Disorder and Substance Abuse”

08/21-25/2000 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Therapeutic

Approaches to Alcohol and Drug Abuse”

09/13/2000 Albany Medical College Grand Rounds, Albany, NY, “Substance Abuse and Mood Disorders”

09/29/2000 University of Western Ontario, Stratford, Ontario, Canada, “New Approaches to Treating Alcohol and Drug Abuse”

10/11-12/00 Philadelphia Office of Mental Health/Mental Retardation, Philadelphia, PA, “Co-Occurring

Disorders”

10/26/00 Central New York Addiction Psychiatry Conference, State University of New York, Syracuse, NY, “Bipolar Disorder and Substance Abuse”

01/19/2001 Dartmouth Medical School Research Conference, “Establishing a Residential Treatment Program for Dually Diagnosed Patients”

04/30/2001 Boston College Prescribing Practices for Psychopharmacology course, “Pharmacologic Treatment of Substance Use Disorders and Dual Diagnosis”

08/06-10/2001 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Therapeutic

Approaches to Alcohol and Drug Abuse”

10/31/2001 Tufts University School of Medicine, Boston, MA, 2^nd Year medical students, “Cocaine and Other Psychostimulants”

12/05/2001 New York University School of Medicine, “Substance Abuse and Mood Disorders”

04/01/2002 Boston College Prescribing Practices for Psychopharmacology course, “Pharmacologic Treatment of Substance Use Disorders and Dual Diagnosis”

05/07/2002 Stanford University School of Medicine, “Substance Abuse and Mood Disorders”

08/05-09/2002 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Substance Abuse and Dual Diagnosis: New Treatment Approaches”

11/18/2002 Tufts University School of Medicine, Boston, MA, 2^nd Year medical students, “Cocaine and Other Psychostimulants”

02/07/2003 Columbia University, Department of Psychiatry Grand Rounds, New York, NY, “Substance Abuse and Mood Disorders”

02/20/2003 Brockton VA Hospital, Brockton, MA, Grand Rounds: “Substance Abuse and Mood Disorders”

04/08/2003 Westwood Lodge Hospital, Westwood, MA, Academic Conference, “Substance Abuse and Mood Disorders” Disorder

04/10/2003 Silver Hill Hospital, New Canaan, CT, Update in Addiction Psychiatry and Pain Management”

04/24/2003 St. Francis Health System, Tulsa, OK, “Substance Abuse and Dual Diagnosis: New Treatment

Approaches”

10/29/2003 Zucker Hillside Hospital, New York, “Substance Abuse and Mood Disorders”

01/09/2004 Feldman Lectures, Grey Nuns Hospital, Edmonton, Alberta, Canada, “Treatment Strategies for

Patients with Substance Abuse and Dual Diagnosis”

06/02/2004 CAB Health and Recovery Services, Peabody, MA, “Substance Abuse and Mood Disorders”

01/13/2005 Tewksbury Hospital, Tewksbury, MA, Substance Abuse Lecture Series, “Treatment of Patients with Substance Abuse and Bipolar Disorder”

02/01/2005 Dartmouth-Hitchcock Medical Center, Lebanon, NH, Grand Rounds, “Substance Abuse and Bipolar Disorder”

03/08/2005 Westwood Lodge Hospital, Westwood, MA, “The Treatment of Alcohol Dependence”

05/13/2005 Institute Philippe Pinel de Montreal, Montreal, Canada, “Substance Abuse and Dual Diagnosis: New Treatment Approaches”

09/27/2005 Tufts University School of Medicine, Boston, MA, “Cocaine Addiction”

10/27/2005 Tufts Health Care Institute Opioid Conference, Boston, MA, “Opioid Abuse Resistance”

11/16/2005 Northwest Association for Psychiatric Education and Advancement, New Brunswick, Canada,

“Substance Abuse and Dual Diagnosis: New Treatment Approaches”

12/08-11/2005 American Academy of Addiction Psychiatry 16^th Annual Meeting and Symposium, Scottsdale, AZ, “The Interface between Pain and Addiction” (Chair)

12/19/2005 Bournewood Hospital, Brookline, MA, Grand Rounds, “Bipolar Disorder and Substance Abuse”

08/10-13/2006 American Psychological Association Annual Convention, New Orleans, LA, “Characterizing Chronic Pain in Opioid Dependent Patients” (Poster)

11/29/2006 Melrose Wakefield Hospital, Melrose, MA, Grand Rounds, “Substance Abuse: The Treatment of Alcohol Dependence”

12/07-10/2006 American Academy of Addiction Psychiatry 17^th Annual Meeting and Symposium, St. Petersburg, FL, “The Interface Between Pain and Addiction: New Horizons” (Chair)

01/04/2007 University of Massachusetts School of Medicine Psychiatry, Worcester, MA, Grand Rounds, “The Treatment of Patients with Bipolar and Substance Abuse”

02/16/2007 North Shore Medical Center, Salem, MA, Psychiatry Grand Rounds, “Treatment of Alcohol

Dependence”

03/05/2007 Tufts University School of Medicine, Boston, MA, Psychiatry Grand Rounds, “The Treatment of Patients with Bipolar and Substance Abuse”

3/30 03/30/2007 University Psychiatric Institute, Quebec City, Canada, “The Treatment of Patients with Bipolar and Substance Use Disorders”

04/18/2007 Centre for Addiction and Mental Health, Toronto, 14th Annual H. David Archibald Lecture for

Outstanding Research and/or Practice in the Addictions, “The Treatment of Patients with Bipolar and Substance Use Disorders”

05/05-07/2007 American Pain Society 26^th Annual Scientific Meeting, Washington, DC, “Case-Control Study on Risk Factors for Prescription Opioid Abuse among Patients with Pain”

11/15-18/2007 Association for Behavioral and Cognitive Therapies Annual National Scientific Conference,

Philadelphia, PA, “Chronic Pain Severity in Opioid-Dependent Patients”

06/17/2008 College on Problems of Drug Dependence 2008 Annual Meeting, San Juan, Puerto Rico, “Adolescents with Attention Deficit Disorders and Co-Occurring Substance Use Disorders: Referral Sources and Recruitment in a Multi-Site Clinical Trial”

06/17/2008 College on Problems of Drug Dependence 2008 Annual Meeting, San Juan, Puerto Rico,

“Methodological Issues in Designing a Clinical Trial for Opioid Analgesic Dependence: Defining the Population”

10/10-12/2008 16^th Annual Santa Fe Symposia for Mental Health Professionals, Santa Fe, New Mexico,

“Substance Abuse and Dual Diagnosis: New Treatment Approaches”

11/20-21/2008 Tufts Health Care Institute, Tufts University School of Medicine, Boston, MA, Conference on

Co-Ingestion of Alcohol with Prescription Opioids, Boston, MA, “Treatment of Patients with

Co-Occurring Alcohol and Prescription Opioid Misuse” (Discussant)

01/06-07/2009 National Institute on Drug Abuse, Bethesda, MD, “Addressing Substance Abuse and Comorbidities Among Military Personnel, Veterans and Their Families: A Research Agenda, “Treatments for Substance Abuse and Comorbidities” (Discussant)

02/24/2009 “Treatment of Patients with Bipolar Disorder and Substance Abuse,” University of Massachusetts Grand Rounds at Westborough State Hospital, February 24, 2009.

04/24-25/2009 Harvard Medical School, Psychopharmacology 2009: A Master Class Course, Boston, MA, “Substance Abuse.”

04/26/2009 The American Association for the Treatment of Opioid Dependence National Conference, New York, NY, “Opioid Analgesics and Pain in Opioid Dependence Treatment – New Research Findings, Clinical Implications”

04/26/2009 The American Association for the Treatment of Opioid Dependence National Conference, New York, NY, “Opioid Analgesic Dependence and Pain: The NIDA Clinical Trials Network Prescription Opioid Addiction Treatment Study”

05/04/2009 Massachusetts Department of Public Health-Bureau of Substance Abuses Services and AdCare

Educational Institute, Boston, MA, Innovations in Addictions: Research to Recovery Conference, “Researchers and Practitioners Working in Partnership to Strengthen Service Delivery”

05/13/2009 The International Meeting of the All-Party Parliamentary Group on Drug Misuse, London, England, “Using Research to Improve Drug Abuse Treatment: The National Institute on Drug Abuse Clinical Trials Network”

05/14-16/2009 The 6th UK/European Symposium on Addictive Disorders, London, England, “Treatment of patients with Bipolar Disorder and Substance Dependence

06/03-04/2009 University of Rochester Medical Center, IMMPACT X: Initiative on Methods, Measurement and Pain Assessment in Clinical Trials, Arlington, VA

06/20-25/2009 College on Problems of Drug Dependence 71^st Annual Meeting, Reno/Sparks, NV, “Use of an

Adaptive Treatment Research Design in a CTN Study of Prescription Opioid Dependence Treatment”

06/20-25/2009 College on Problems of Drug Dependence 71^st Annual Meeting, Reno/Sparks, NV, “A

Double-Blind Placebo-Controlled Trial of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with Attention Deficit Hyperactivity Disorder”

07/21/2009 Department of Psychiatry Grand Rounds, Mayo Clinic, Rochester, MN, “Treatment of Patients with Bipolar Disorder and Substance Abuse”

07/27-31/2009 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Substance Abuse and Dual Diagnosis: New Treatment Approaches”

09/14-15/2009 NIAAA R-13 Conference, Integrated Group Therapy for Patients with Bipolar and Substance Use Disorder, Fairlee, VT, “Toward Optimal Treatment for Schizophrenia and Co-Occurring Alcohol Use Disorders”

09/17/2009 Tufts University School of Medicine, “Cocaine”

10/22-24/2009 American Society of Addiction Medicine 2009 Course on the State of the Art in Addiction Medicine, Washington, DC, “Implications of the Prescription Opioid Addiction Treatment Study (POATS)”

11/04/2009 St. Elizabeth’s Hospital Grand Rounds, Brighton, MA, “Treatment of Patients with Bipolar Disorder and Substance Abuse”

11/20/2009 Association for Behavioral and Cognitive Therapies 43^rd Annual Convention Association for

Behavioral and Cognitive Therapies, New York, NY, “The National Institute on Drug Abuse Clinical Trials Network Prescription Opioid Addiction Treatment Study: Characteristics of Individuals With and Without Chronic Pain”

12/15-16/2009 NIDA Science Meeting/Workshop, “Clinically Meaningful Substance Abuse Treatment Outcome Measure for Effectiveness Trials,” Bethesda, MD, “Primary Outcome Measures”

04/01/2010 Tufts University School of Medicine, “Cocaine”

05/22-26/2010 The National Institute on Drug Abuse Clinical Trials Network “Prescription Opioid Addiction Treatment Study,” presented at the 163^rd Annual Meeting of the American Psychiatric Association, New Orleans, LA

05/22-26/2010 “Group Therapy Treatment of Bipolar Disorder and Addiction,” presented at the 163^rd Annual Meeting of the American Psychiatric Association, New Orleans, LA

07/12-17/2010 “The Multi-Site NIDA Clinical Trials Network Prescription Opioid Addiction Treatment Study: Outcomes and Implications, College on Problems of Drug Dependence 72^nd Annual Meeting, Scottsdale, AZ, Symposium Chair and Speaker

07/19-23/2010 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Substance Abuse and Dual Diagnosis: New Treatment Approaches”

09/13-16/2010 Speaker and Co-Chair, “Comorbidity of Mood Disorders and Alcohol Dependence: Course and

Treatment” 2010 World Congress, International Society for Biomedical Research on Alcoholism, Paris, France

09/26-30/2010 47^th Congress of the German Psychological Society, Bremen, Germany, “The Treatment of Patients with Bipolar Disorder and Substance Abuse” (Invited Lecturer)

10/03-07/2010 12^th Annual Meeting of the International Society of Addiction Medicine, Milan, Italy, “Innovative Strategies for Opioid Dependence Treatment,” Symposium Chair and Speaker

11/09/2010 University of Texas at San Antonio, Grand Rounds, “The Treatment of Bipolar Disorder and Substance Abuse”

12/02-05/2010 American Academy of Addiction Psychiatry 21^st Annual Meeting and Symposium, Boca Raton, FL, “Prescription Opioid Dependence: New Evidence on Treatment,” Symposium Chair and Speaker

01/05/2011 “Integrated Group Therapy for Bipolar Disorder and Substance Abuse,” presented at Yale University School of Medicine, Division of Substance Abuse

02/14/2011 “The Prescription Opioid Addiction Treatment Study,” presented at the University of Pennsylvania Treatment Research Center

03/04/2011 13^th Annual Fundamentals of Addiction Medicine conference, Tulalip, Washington, “The Prescription Opioid Addiction Treatment Study”

03/18/2011 Columbia University, Psychiatry Grand Rounds, New York, NY, “The Treatment of Prescription Opioid Dependence

04/07/2011 Tufts University School of Medicine, “Cocaine”

04/29-30/2011 “Treatment of Alcohol and Drug Abuse” in Psychopharmacology 2011: A Master Class, Harvard Medical School, Department of Continuing Education

06/09/2011 “Efficacy of buprenorphine for prescription opioid addiction,” presented at Tufts Health Care Institute

06/16-18/2011 “Treatment of Patients with Substance Use Disorders and Psychiatric Illness, “ Psychiatry in 2011, McLean Hospital, Boston, MA, Course Director and Speaker, Addiction 2011 Symposium

06/18-23/2011 Weiss R, Potter J, Griffin M, Connery H, Ling W: Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction Treatment Study, Presented at the College on Problems of Drug Dependence 73rd Annual Meeting, Hollywood, FL

06/18-23/2011 Copersino ML, Schretlen DJ, Lukas SE, Fitzmaurice G, Sokoloff J, Weiss RD: Neurocognitive Functioning among Patients Receiving Treatment for Substance Use Disorders: Sociodemographic and Drug Use Characteristics. Presented at the College on Problems of Drug Dependence 73rd Annual Meeting, Hollywood, FL. Workshop Discussant: Drug use treatment outcomes: A systematic approach to selection and measurement in clinical trials research. Presented at the College on Problems of Drug Dependence 73rd Annual Meeting, Hollywood, FL

07/13/2011 “What the National Institute on Drug Abuse’s Clinical Trials Network can do for you,” 2011 NIATx Summit and The State Associations of Addiction Services (SAAS) Conference, Boston, MA

07/18-22/2011 New England Educational Institute, Pittsfield, MA, Cape Cod Summer Symposia, “Substance Abuse and Dual Diagnosis: New Treatment Approaches”

01/31/2012 “Primary findings and clinical implications of the NIDA-CTN-0030 Prescription Opioid Addiction Treatment Study (POATS),” NIDA/SAMHSA Blending Initiative, Great Falls, MT

06/08/2012 “Treatment of patients with substance abuse and bipolar disorder,” Four Winds Hospital Grand

Rounds, Katonah, NY

09/06/2012 “Treatment of prescription opioid dependence,” at University of Buffalo 8^th Comprehensive Review of Psychiatry Conference, Niagara Falls, NY

12/19/2012 CTN Webinar: “Helping patients with substance use disorders and pain,” Produced by the National Drug Abuse Treatment Clinical Trials Network’s Clinical Coordinating Center (co-presented with J.S. Potter)

01/31/2013 “Treatment of prescription opioid dependence. Grand Rounds presentation at McLean Hospital, Belmont, MA

04/04/2013 “Treatment of patients with substance use disorders and co-occurring psychiatric illness.” Harvard University Mental Health Service Grand Rounds

04/10/2013 “Treatment of prescription opioid dependence,” Psychiatry Grand Rounds, Elmhurst Hospital

Elmhurst, NY

04/19-20/2013 “Treatment of Alcohol and Drug Abuse,” Psychopharmacology 2013: a master class, presented

by Harvard Medical School, Boston, MA

04/25-28/2013 “The prescription opioid addiction treatment study: secondary analyses,” presented at the 44^th annual medical-scientific conference of the American society of addiction medicine, Chicago, IL

05/21/2013 “Patient characteristics that predict buprenorphine-naloxone treatment outcome for prescription opioid dependence: results from a multi-site study,” American Psychiatric Association 166^th Annual Meeting, San Francisco, CA

06/13/2013 “Treatment of alcohol and drug abuse,” Internal Medicine: Comprehensive Review and Update 2013, Harvard Medical School, Boston, MA

06/27/2013 “Treatment of prescription opioid dependence,” Hazelden Foundation, Center City, MN

09/27/2013 “Treatment of Prescription Opioid Dependence”, North Shore Medical Center Grand Rounds, Salem, MA

10/25/2013 “Characteristics and treatment outcomes in prescription opioid-dependent patients with and without co-occurring psychiatric disorder,” Oral communication presented at the III International Congress on Dual Disorders, Barcelona, Spain

12/05/2013 “Treatment of benzodiazepine dependence,” presented at the 24th annual meeting of the American Academy of Addiction Psychiatry, Scottsdale, AZ, Dec. 5-8, 2013

12/12/2013 “Treatment of prescription opioid dependence,” Boston University School of Medicine, Boston, MA

02/26/2014 “Treatment of prescription opioid dependence,” Bedford VA Hospital, Bedford, MA

03/15/2014 “Treatment of prescription opioid dependence,” American Physician Institute Master Psychopharmacology Conference, Naples, FL

04/04/2014 “Treatment of prescription opioid dependence,” Emerson Hospital Department of Medicine Grand Rounds, Concord, MA

05/04/2014 “CTN and the use of buprenorphine for addiction to opioid analgesics,” American Psychiatric Association 167^th Annual Meeting, New York, NY

05/17/2014 “Prescription opioid dependence,” McLean Hospital/Harvard Medical School Addictions in 2014 Conference, Cambridge, MA

09/18/2014 “Treatment of prescription opioid dependence,” Using Evidence-Based Practices in Community Settings: The NIDA/SAMHSA Blending Initiative Conference, Marlborough, MA

10/17/2014 “Psychopharmacology Update in the Treatment of Substance Use Disorders,” American Physician Institute Master Psychopharmacology Conference, Pasadena, CA

01/10/2015 “Pharmacotherapy of Alcohol Use Disorders,” Global Medical Education First Annual Psychopharmacology Update, Ft. Lauderdale, FL

01/25-28/2015 “Treating the patient who wants to cut down, not abstain,” Psychotherapy Associates 41st Annual Winter Symposium: “Addictive Disorders, Behavioral Health and Mental Health,” Colorado Springs, CO

01/25-28/2015 “The Treatment of Patients with Mood Disorders and Substance Use Disorders,” Psychotherapy Associates 41st Annual Winter Symposium: “Addictive Disorders, Behavioral Health and Mental Health,” Colorado Springs, CO

04/03/2015 “Cocaine,” Tufts University School of Medicine, Boston, MA

04/17/2015 “Treatment of Prescription Opioid Dependence: New Findings, Long-Term Follow-Up, and the Role of Dual Disorders,” Spanish Society of Dual Pathology IV International Congress of Dual Disorders: Addictions and Other Mental Disorders, Barcelona, Spain

5/11/2015 “Treatment of Substance Use Disorders and Mental Illness,” Riverside Community Care

5/13/2015 “Treatment of Prescription Opioid Dependence,” Brockton VA Hospital Grand Rounds, Brockton, MA

7/16/2015 “Review of DSM-5 Substance Use Disorders; Cocaine Use Disorders; Alcohol Use Disorders Pharmacotherapy,” American Physician Institute Comprehensive Review of Addiction Medicine, Chicago, IL

8/24-28/2015 “Alcohol and Substance Abuse Treatment,” Harvard Medical School Summer Seminars, Edgartown, MA

Professional Leadership Roles Related to Teaching

1992 Organized first review course in addiction psychiatry for the American Academy of Addiction Psychiatry

1997- Chairman, Assessment Committee on Substance Abuse for Psychiatry, Core Clerkship and

Psychiatry 700 MJ, Harvard Medical School

Report of Clinical Activities

Description of Clinical Practice

I treat primarily substance dependent patients and individuals with coexisting substance dependence and psychiatric illness. I have a small practice, which primarily involves consultation on complex cases.

Patient Load

As Chief of the McLean Hospital Division of Alcohol and Drug Abuse, I oversee the treatment of patients with substance use disorders and patients dually diagnosed with substance use disorders and coexisting psychiatric disorders. The program attracts patients with complex interactions between substance use and psychiatric illness, with a significant number of regional, national and some international referrals.

Clinical Contributions

I was the first Psychiatrist in Charge of the Drug Dependence Treatment Unit at McLean Hospital (1980),

and have developed the Alcohol and Drug Abuse Treatment Program from an inpatient-based program to a comprehensive continuum of care consisting of inpatient, residential, partial hospital, outpatient, consultative, and off-campus treatment.

Other Relevant Information

I am frequently asked to speak on clinical treatment of patients with substance use disorders both locally, regionally, nationally, and internationally; I have been asked to perform case consultations in a variety of different settings; I have been asked on several occasions to travel to other countries to see substance dependent patients; and I have consulted to other treatment programs regarding program development. For example, I was among several candidates invited to Johns Hopkins Health System in 1994 when they were considering hiring a consultant to help them plan changes in their addiction program.

BIBLIOGRAPHY

Original Reports:

Weiss RD, Goldenheim PD, Mirin SM, Hales CA, Mendelson JH. Pulmonary dysfunction in cocaine smokers.

Am J Psychiatry 1981;138: 1110‑1112.

Mirin SM, Weiss RD, Michael J. Alcohol abuse in patients dependent on other drugs.

Psychiatr Annals 1982;12: 430‑433.

Weiss RD, Pope HG Jr, Mirin SM. Treatment of chronic cocaine abuse and attention deficit disorder,

Residual type, with magnesium pemoline. Drug Alcohol Depend 1985;15: 69‑72.

Weiss RD, Mirin SM. Substance abuse as an attempt at self‑medication. Psych Med 1985;3: 357‑367.

Weiss RD, Mirin SM, Michael JL, Sollogub A. Psychopathology in chronic cocaine abusers.

Am J Drug Alcohol Abuse 1986;12(1): 17‑29.

Weiss RD, Tilles DS, Goldenheim PD, Mirin SM. Decreased single breath carbon monoxide diffusing

capacity in cocaine freebase smokers. Drug Alcohol Depend 1987;19: 271‑276.

Griffin ML, Weiss RD, Mirin SM, Wilson H, Bouchard‑Voelk B. The use of the Diagnostic Interview

Schedule in drug dependent patients. Am J Drug Alcohol Abuse 1987;13: 281‑291.

Mirin SM, Weiss RD, Michael J, Griffin ML. Psychopathology in substance abusers: Diagnosis and

treatment. Am J Drug Alcohol Abuse 1988;14: 139‑157.

Mendelson JH, Teoh SK, Lange U, Mello NK, Weiss R, Skupny A, Ellingboe J. Anterior pituitary, adrenal and gonadal hormones during cocaine withdrawal. Am J Psychiatry 1988;145: 1094‑1098.

Weiss RD. Relapse to cocaine abuse after initiating desipramine treatment. JAMA 1988;260: 2545‑2546.

Weiss RD, Gawin FH. Protracted elimination of cocaine metabolites in long term high‑dose cocaine abusers.

Am J Medicine 1988;85: 879‑880.

Weiss RD, Mirin SM, Griffin ML, Michael JL. Psychopathology in cocaine abusers: Changing trends.

J Nerv Ment Dis 1988;176: 719‑725.

Weiss RD, Mirin SM, Griffin ML, Michael JL. A comparison of alcoholic and non‑alcoholic drug abusers. J Stud Alcohol 1988;49: 510‑515.

Griffin ML, Weiss RD, Mirin SM, Lange U. A comparison of male and female cocaine abusers.

Arch Gen Psychiatry 1989;46: 122‑126.

Weiss RD, Mirin SM. The dual diagnosis alcoholic: Evaluation and treatment. Psychiatr Annals 1989;19: 261‑265.

Adelman SA, Weiss RD. What is therapeutic about inpatient alcoholism treatment? Hosp Community

P sychiatry 1989;40: 515‑519.

Mirin SM, Weiss RD. Genetic factors in the development of alcoholism. Psychiatr Annals 1989;19: 239‑242.

Weiss RD, Griffin ML, Mirin SM. Diagnosing major depression in cocaine abusers: The use of depression rating scales. Psychiatry Res 1989;28: 335‑343.

Teoh SK, Mendelson JH, Mello NK, Weiss R, McElroy S, McAfee, B. Hyperprolactinemia and risk for

relapse of cocaine abuse. Biol Psychiatry 1990;28: 824‑829.

Weiss RD, Mirin SM. Psychological and pharmacological treatment strategies in cocaine dependence.

Ann Clin Psychiatry 1990;2: 239‑243.

Mirin SM, Weiss RD, Griffin ML, Michael JL. Psychopathology in drug abusers and their families.

Compr Psychiatry 1991;32: 36‑51.

Kroft CL, Gescuk B, Woods BT, Mello NK, Weiss RD, Mendelson JH. Brain ventricular size in female

alcoholics: An MRI study. Alcohol 1991;8: 31‑34.

Weiss RD, Mirin SM, Frances RJ. The myth of the typical dual diagnosis patient. Hosp Community

Psychiatry 1992;43: 107‑108.

Greenfield SF, Weiss RD, Griffin ML. Patients who use drugs during inpatient substance abuse treatment.

Am J Psychiatry 1992;149: 235‑239.

Weiss RD, Mirin SM, Griffin ML. Methodological considerations in the diagnosis of coexisting psychiatric

disorders in substance abusers. Br J Addict 1992;87: 179‑187.

Hudson JI, Weiss RD, Pope HG Jr, McElroy SL, Mirin SM. Eating disorders in hospitalized substance

abusers. Am J Drug Alcohol Abuse 1992;18: 75‑85.

Weiss RD, Collins DA. Substance abuse and psychiatric illness: The dually diagnosed patient.

Am J Addict 1992;1(2): 93‑99.

Weiss RD, Griffin ML, Mirin SM. Drug abuse as self‑medication for depression: An empirical study.

Am J Drug Alcohol Abuse 1992;18: 121‑129.

Weiss RD, Griffin ML, Hufford C. Severity of cocaine dependence as a predictor of relapse to cocaine use.

Am J Psychiatry 1992;149: 1595‑1596.

Weiss RD, Mirin SM, Griffin ML, Gunderson JG, Hufford C. Personality disorders in cocaine dependence. Compr Psychiatry 1993;34(3): 145‑149.

Najavits LM, Weiss RD. Variations in therapist effectiveness in the treatment of patients with substance use disorders: An empirical review. Addiction 1994;89: 679‑688.

Weiss RD, Hufford C, Mendelson JH. Serum prolactin levels and treatment outcome in cocaine dependence.

Biol Psychiatry 1994;35: 573‑574.

Najavits LM, Weiss RD. The role of psychotherapy in the treatment of substance use disorders. Harvard Review of Psychiatry 1994;2: 84‑96.

Weiss RD, Griffin ML, Hufford C. Craving in hospitalized cocaine abusers as a predictor of outcome.

Am J Drug Alcohol Abuse 1995;21(3): 289-301.

Greenfield SF, Weiss RD, Tohen M. Substance abuse and the chronically mentally ill: A description of dual diagnosis treatment services in a psychiatric hospital. Community Ment Health J 1995;31: 265-277.

Weiss RD, Najavits LM, Muenz LR, Hufford C. 12-Month test-retest reliability of the Structured Clinical

Interview for DSM-III-R Personality Disorders (SCID-II) in cocaine dependent patients. Compr Psychiatry 1995;36: 384-389.

Mirin SM, Batki SL, Bukstein O, Isbell PG, Kleber H, Schottenfeld RS, Weiss RD, Yandow VW. Practice

guidelines for the treatment of patients with substance use disorders: Alcohol, Cocaine, Opioids.

Am J Psychiatry 1995;152 Supple: 11: 5-59.

Najavits LM, Weiss RD, Liese BS. Group cognitive-behavioral therapy for women with PTSD and substance use disorder. J Subst Abuse Treat 1996;13(1): 13-22.

Weiss RD, Martinez-Raga J, Hufford C. The significance of a coexisting opioid use disorder in cocaine dependence: an empirical study. Am J Drug Alcohol Abuse 1996;22(2): 173-184.

Najavits LM, Griffin ML, Luborsky L, Frank A, Weiss RD, Liese BS, Thompson HT, Nakayama E, Siqueland L, Daley D, Onken LS. Therapists’ emotional reactions to substance abusers: A new questionnaire and initial findings. Psychotherapy 1996;32: 669-677.

Weiss RD, Griffin ML, Najavits LM, Hufford C, Kogan J, Thompson HJ, Albeck JH, Bishop S, Daley DC, Mercer D, Siqueland L. Self-Help activities in cocaine dependent patients entering treatment: Results from the NIDA Collaborative Cocaine Treatment Study. Drug Alcohol Depend 1996;43: 79-86.

Barber JP, Frank A, Weiss RD, Blaine J, Siqueland L, Moras K, Calvo N, Chittams J, Mercer D, Salloum I.

Prevalence and correlates of personality disorder diagnoses among cocaine dependent outpatients.

J Pers Dis 1996;10: 297-311.

Gorski NP, Nouraldin H, Dube DM, Preffer FI, Dombrowski DM, Villa EM, Lewandrowski KB, Weiss RD,

Hufford C, Laposata M. Reduced fatty acid ethyl ester synthase activity in the white blood cells of alcoholics. Alcohol Clin Exp Res 1996;20(2): 268-274.

Weiss RD, Martinez-Raga J, Griffin ML, Greenfield SF, Hufford C. Gender differences in cocaine dependent patients: a six-month follow-up study. Drug Alcohol Depend 1997;44: 35-40.

Weiss RD, Griffin ML, Hufford C, Muenz LR, Najavits LM, Jansson SB, Kogan J, Thompson HJ. Early

prediction of initiation of abstinence from cocaine: use of a craving questionnaire. Am J Addict

1997;6: 224-231.

Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken L, Muenz L, Thase MF, Weiss RD,

Gastfriend DR, Woody G, Barber JP, Butler SF, Daley D, Bishop S, Najavits LM, Lis J, Mercer D, Griffin ML, Moras K, Beck AT. The NIDA collaborative cocaine treatment study: rationale and methods.

Arch Gen Psychiatry 1997;54: 721-726.

Najavits LM, Weiss RD, Shaw SR. The link between substance abuse and posttraumatic stress disorder in

women: a research review. Am J Addict 1997;6: 273-283.

Weiss RD, Najavits LM, Greenfield SF, Soto JA, Shaw SR, Wyner D. Validity of substance use self-reports

in dually diagnosed outpatients. Am J Psychiatry 1998: 155: 127-128.

Najavits LM, Weiss RD, Reif S, Gastfriend DR, Siqueland L, Barber JP, Butler SF, Thase M, Simon Onken L.

The Addiction Severity Index as a screen for trauma and posttraumatic stress disorder. J Stud Alcohol

1998;59: 56-62.

Maas LC, Lukas SE, Kaufman MJ, Weiss RD, Daniels SL, Rogers VW, Kukes TJ, Renshaw PF. Functional

Magnetic Resonance Imaging of human brain activation during cue-induced cocaine craving. Am J Psychiatry 1998;155: 124-126.

Najavits LM, Gastfriend DR, Barber JP, Reif S, Muenz LR, Blaine J, Frank A, Crits-Christoph P, Thase M,

Weiss RD. Cocaine dependence with and without PTSD Among Subjects in the National Institute on Drug

Abuse collaborative cocaine treatment study. Am J Psychiatry 1998;155: 214-219.

Greenfield SF, Weiss RD, Muenz LR, Vagge LM, Kelly JF, Bello LR, Michael J. The effect of depression on

return to drinking: a prospective study. Arch Gen Psychiatry 1998;55: 259-265.

Weiss RD, Greenfield SF, Najavits LM, Soto JA, Wyner D, Tohen M, Griffin ML. Medication compliance

among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998;59: 172-174.

Najavits LM, Weiss RD, Shaw SR, Muenz LR. “Seeking safety”: Outcome of a new cognitive-behavioral

psychotherapy for women with posttraumatic stress disorder and substance dependence. J Traumatic Stress

1998;11: 437-456 .

Tohen M, Greenfield SF, Weiss RD, Zarate CA, Vagge LM. The effect of comorbid substance use

disorders on the course of bipolar disorder: A review. Harvard Rev Psychiatry 1998;6: 133-141.

Siqueland L, Crits-Christoph P, Frank A, Daley D, Weiss RD, Chittams J, Blaine U, Luborsky L. Predictors

of dropout from psychosocial treatment of cocaine dependence. Drug Alcohol Depend 1998;52: 1-13.

Weiss RD, Najavits LM, Greenfield SF. A relapse prevention group for patients with bipolar and substance

use disorders. J Subst Abuse Treat 1999;16(1): 47-54.

Barber JP, Luborsky L, Crits-Christoph P, Thase ME, Weiss R, Frank A, Onken L, Gallop R. Therapeutic

alliance as a predictor of outcome in treatment of cocaine dependence. Psychotherapy Research 1999;9: 54-73.

Siqueland L, Horn A, Moras K, Woody G, Weiss R, Blaine J, Bishop S, Barber J, Thase M. Cocaine-induced

mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine dependent sample.

Am J Addict 1999;8: 165-169.

Wines JD, Weiss RD. Opioid withdrawal during risperidone treatment. J Clin Psychopharmacol 1999;19: 265-267.

Najavits LM, Weiss RD, Shaw SR: A clinical profile of women with posttraumatic stress disorder and substance dependence. Psychology of Addictive Behaviors 1999;13: 98-104.

Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken L, Muenz L, Thase ME, Weiss RD,

Gastfriend DR, Woody G, Barber JP, Butler SF, Daley D, Salloum I, Bishop S, Najavits LM, Lis J, Mercer D,

Griffin ML, Moras K, Beck AT. Psychosocial treatments for cocaine dependence: results of the National

Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 1999;56: 493-502.

Rounsaville BJ, Weiss RD, Carroll KM. Options for managing psychotropic medications in drug-abusing patients participating in behavioral therapies clinical trials. Am J Addict 1999;8: 178-189.

Greenfield SF, Hufford MR, Vagge LM, Muenz L, Costello M, Weiss R. The relationship of self-efficacy

expectancies to relapse among alcohol dependent men and women: a prospective study. J Stud Alcohol

2000;61: 345-351.

Weiss RD, Griffin ML, Greenfield SF, Najavits LM, Wyner D, Soto JA, Hennen JA. Group therapy for

patients with bipolar disorder and substance dependence: results of a pilot study. J Clin Psychiatry

2000;61: 361-367.

Weiss RD, Griffin ML, Gallop R, Onken LS, Gastfriend DR, Daley D, Crits-Christoph P, Bishop S, Barber JP.

Self-help group attendance and participation among cocaine dependent patients. Drug Alcohol Depend

2000;60: 169-177.

Weiss RD, Greenfield SF, Griffin ML, Najavits LM, Fucito LM. The use of collateral reports for patients

with bipolar and substance use disorders. Am J Drug Alcohol Abuse 2000;26(3): 369-378.

Najavits LM, Weiss RD, Nelson SR, Dierberger A. Psychotherapists’ views of treatment manuals. Professional Psychology: Research and Practice 2000;31(4): 404-408.

Weiss RD, Griffin ML, Gallop R, Luborsky L, Siqueland L, Frank A, Onken LS, Daley DC, Gastfriend DR.

Predictors of self-help group attendance in cocaine dependent patients. J Stud Alcohol 2000;61: 714-719.

Weiss RD, Kolodziej ME, Najavits LM, Greenfield SF, Fucito LM. Utilization of psychosocial treatments by patients diagnosed with bipolar disorder and substance dependence. Am J Addict 2000;9: 314-320.

Dickey B, Azeni H, Weiss R, Sederer L. Schizophrenia, substance use disorder and medical co-morbidity.

J Mental Health Policy Econ 2000;3: 1: 1327-1333.

Barber JP, Luborsky L, Gallop R, Crits-Christoph P, Frank A, Weiss RD, Thase ME, Connolly MB, Gladis M,

Foltz C, Siqueland L. Therapeutic alliance as a predictor of outcome and retention in the National Institute on

Drug Abuse Collaborative Cocaine Treatment Study. J Consult Clin Psychol 2001;69: 119-124.

Crits-Christoph P, Siqueland L, McCalmont E, Weiss RD, Gastfriend DR, Frank A, Moras K, Barber JP,

Blaine J, Thase ME. Impact of psychosocial treatments on associated problems of cocaine dependent patients.

J Consult Clin Psychol 2001;69(5): 825-830.

Greenfield SF, Kolodziej ME, Sugarman DE, Muenz LR, Vagge LM, He DY, Weiss RD. History of abuse

and drinking outcomes following inpatient alcohol treatment: a prospective study. Drug Alcohol Depend

2002;67: 227-234.

Dickey B, Normand ST, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness and substance use

disorders. Psychiatric Services 2002;53: 861-867.

Kanayama G, Cohane GH, Weiss RD, Pope HG Jr. Past anabolic-androgenic steroid use among men admitted

for substance abuse treatment: an underrecognized problem? J Clin Psychiatry 2003;64: 156-160.

Greenfield SF, Hennessy G, Sugarman D, Weiss R. What general psychiatrists ask addiction psychiatrists: A

review of 381 substance abuse consultations in a psychiatric hospital. Am J Addict 2003;12: 18-28.

Weiss RD, Griffin ML, Mazurick C, Berkman B, Gastfriend DR, Frank A, Barber JP, Blaine J, Salloum I,

Moras K. The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use.

Am J Psychiatry 2003;160: 1320-1325.

Greenfield SF, Sugarman DE, Muenz LR, Patterson MD, He DY, Weiss RD. The relationship between

educational attainment and relapse among alcohol-dependent men and women: a prospective study. Alcohol Clin Exp Res 2003;27: 1278-1285.

Crits-Christoph P, Gibbons MBC, Barber JP, Gallop R, Beck AT, Mercer D, Tu X, Thase ME, Weiss RD,

Frank A. Mediators of Outcome of Psychosocial Treatments for Cocaine Dependence. J Consult Clin Psychol 2003;71(5): 918-925.

The COMBINE Study Research Group. [1] Testing combined pharmacotherapies and behavioral interventions in

alcohol dependence (The COMBINE Study): A pilot feasibility study. Alcohol Clin Exp Res 2003;27(7): 1123-1131.

The COMBINE Study Research Group. 1 Testing combined pharmacotherapies and behavioral interventions in

alcohol dependence: Rationale and methods. Alcohol Clin Exp Res 2003;27(7): 1107-1122.

Dickey B, Normand ST, Drake R, Weiss RD, Azeni H, Hanson A. Limiting inpatient substance use treatment:

What are the consequences? Medical Care Research and Review 2003;60(3): 332-346.

Weiss RD, Kolodziej M, Griffin ML, Najavits LM, Jacobson LM, Greenfield SF. Substance use and perceived

symptom improvement among patients with bipolar disorder and substance dependence. J Affect Disord 2004;79: 279-283.

Najavits LM, Sullivan TP, Schmitz M, Weiss RD, Lee CSN. Treatment utilization of women with PTSD and

substance dependence. Am J Addict 2004;13: 215-224.

Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction

2004;99: 1382-1392.

Najavits LM, Sonn J, Walsh M, Weiss RD. Domestic violence in women with PTSD and substance abuse.

Addict Behav 2004;29: 707-715.

Najavits LM, Gotthardt S, Weiss RD, Epstein M. Cognitive distortions in the dual diagnosis of PTSD and

substance use disorders. Cognitive Therapy and Research 2004;28: 159-172.

Najavits LM, Ghinassi F, Van Horn A, Weiss RD, Siqueland L, Frank A, Thase ME, Luborsky L, Onken LS.

Therapist satisfaction with four manual-based treatments on a national multisite trial: an exploratory study.

Psychotherapy, Theory, Research, Practice, Training 2004;41: 26-34.

Potter JS, Hennessy G, Borrow JA, Greenfield SF, Weiss RD. Substance use histories in patients seeking

treatment for CR oxycodone dependence. Drug Alcohol Depend 2004;76: 213-215.

Humphreys K, Wing S, McCarty D, Chappel J, Gallant L, Haberle B, Horvath AT, Kaskutas LA, Kirk T,

Kivlahan D, Laudet A, McCrady BS, McLellan AT, Morgenstern J, Townsend M, Weiss R. Self-help organizations for alcohol and drug problems: Toward evidence-based practice and policy. J Subst Abuse Treat 2004;26: 151-158.

Weiss RD. Treating patients with bipolar disorder and substance dependence: lessons learned. J Subst Abuse

Treat 2004;27: 307-312.

Weiss RD, Jaffee WB, de Menil VP, Cogley CB. Group therapy for substance use disorders: What do we

know? Harvard Rev Psychiatry 2004;12: 339-350.

Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E,

Nierenberg AA, Calabrese JR, Sachs GS, Pollack MH; STEP-BD Investigators. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol 2004;24(5): 512-520.

Weiss RD, Ostacher M, Otto MW, Calabrese JR, Fossey M, Wisniewski SR, Bowden C, Nierenberg AA,

Pollack MH, Salloum I, Simon NM, Thase ME, Sachs GS. Does recovery from substance use disorder matter

in patients with bipolar disorder? J Clin Psychiatry 2005;66: 730-735.

Gelernter J, Panhuysen C, Weiss R, Brady K, Hesselbrock V, Rounsaville B, Poling J, Wilcox M, Farrer L,

Kranzler, HR. Genomewide linkage scan for cocaine dependence and related traits: significant linkages for a

cocaine-related trait and cocaine-induced paranoia. Am J Med Genet B Neuropsychiatr Genet 2005: 136: 45-52.

Weiss RD, LoCastro JS, Swift R, Zweben A, Miller WR, Longabaugh R, Hosking JD. The use of a

“psychotherapy with no pills” treatment condition as part of a combined pharmacotherapy-psychotherapy

research study of alcohol dependence. J Stud Alcohol 2005;15(Suppl): 43-49.

Pettinati HM, Weiss RD, Dundon W, Miller WR, Donovan D, Ernst DB, Rounsaville BJ. A structured

approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol 2005;15(Suppl): 170-178.

Greenfield SF, Sugarman DE, Nargiso J, Weiss RD. Readability of patient handout materials in a nationwide

sample of alcohol and drug abuse treatment programs. Am J Addict 2005;14: 339-345.

Kolodziej ME, Griffin ML, Najavits LM, Otto MW, Greenfield SF, Weiss RD. Anxiety disorders among

patients with co-occurring bipolar and substance use disorders. Drug Alcohol Depend 2005;80: 251-257.

Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD.

Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11: 315-337.

Weiss RD, Griffin ML, Gallop RJ, Najavits LM, Frank A, Crits-Christoph P, Thase ME, Blaine J, Gastfriend

DR, Daley D, Luborsky L. The effect of twelve-step self-help group attendance and participation on drug use

outcomes among cocaine-dependent patients. Drug Alcohol Depend 2005;77: 177-184.

Najavits LM, Schmitz M, Gotthardt S, Weiss RD. Seeking safety plus exposure therapy: an outcome study on

dual diagnosis men. J Psychoactive Drugs 2005;27: 425-435.

Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD,

Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA 2006;295: 2003-2017.

Kalayasiri R, Kranzler HR, Weiss R, Brady K, Gueorguieva R, Panhuysen C, Yang B-Z, Farrer L, Gelernter J,

Malison RT. Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. Drug Alcohol

Depend 2006;84: 77-84.

Yu Yi CP, Kranzler HR, Hesselbrock V, Rounsaville B, Weiss R, Brady K, Farrer LA, Gelernter J. Intronic

variants in the DOPA Decarboxylase (DDC) Gene are associated with smoking behavior in European-

Americans and African-Americans. Hum Mol Genet 2006;15: 2192-2199.

Gelernter J, Panhuysen C, Wilcox M, Hesselbrock V, Rounsaville B, Poling J, Weiss R, Sonne S, Zhao H,

Farrer L, Kranzler HR. Genomewide linkage scan for opioid dependence and related traits. Am J Hum Genet 2006;78: 759-769.

Harned MS, Najavits LM, Weiss RD. Self-harm and suicidal behavior in women with comorbid PTSD and

substance dependence. Am J Addict 2006;15(5): 392-395.

Ostacher MJ, Nierenberg AA, Perlis RH, Eidelman P, Borrelli DJ, Tran TB, Ericson GM, Weiss RD, Sachs GS. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder.

J Clin Psychiatry 2006;67: 1907-1911.

Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, Reilly-Harrington NA, Frank E, Nierenberg

AA, Marangell LB, Sagduyu K, Weiss RD, Miyahara S, Thase ME, Sachs GS, Pollack MH. Prospective 12-

month course of bipolar disorder in outpatients with and without comorbid anxiety disorder. Br J Psychiatry 2006;189: 20-25.

Fossey MD, Otto MW, Yates WR, Wisniewski SR, Gyulai L, Allen MH, Miklowitz DJ, Coon KA, Ostacher M,

Neel J, Thase ME, Sachs GS, Weiss RD. Validity of the distinction between primary and secondary substance

use disorder in patients with bipolar disorder: Data from the First 1000 STEP-BD participants. Am J Addict

2006;15(2): 138-143.

Weiss RD, Kueppenbender KD. Combining psychosocial treatment with pharmacotherapy for alcohol

dependence. J Clin Psychopharmacol 2006;26(Suppl)1: S37-S42.

Miller WR, Baca C, Compton WM, Ernst D, Manuel JK, Pringle B, Schermer CR, Weiss RD, Willenbring ML,

Zweben A. Addressing substance abuse in health care settings. Alcohol Clin Exp Res 2006;30(2): 292-302.

Najavits LM, Gallop RJ, Weiss RD. Seeking Safety therapy for adolescent girls with PTSD and substance use

disorder: A randomized controlled trial. J Behav Health Serv Res 2006;33(4): 453-463.

Gelernter J, Yu Y, Weiss R, Brady K, Panhuysen C, Yang BZ, Kranzler HR, Farrer L. Haplotype spanning

TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum Mol Genet 2006;15: 3498-3507.

Barber JP, Gallop R, Crits-Christoph P, Frank A, Thase ME, Weiss RD, Connolly Gibbons MB. The role of

therapist adherence, therapist competence, and the alliance in predicting outcome of individual drug counseling:

Results from the NIDA Collaborative Cocaine Treatment Study. Psychotherapy Research 2006;16: 229-240.

Kleber HD, Weiss RD, Anton RF Jr, George TP, Greenfield SF, Kosten TR, O’Brien CP, Rounsaville BJ,

Strain EC, Ziedonis DM, Hennessy G, Connery HS, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty

MT, Johnson BR, Nininger JE, Summergrad P, Woods SM, Yager J, Pyles R, Cross CD, Peele R, Shemo JP,

Lurie L, Walker RD, Barnovitz MA,Gray SH, Saxena S, Tonnu T, Kunkle R, Albert AB, Fochtmann LJ, Hart

C, Regier D. Work group on substance use disorders; American Psychiatric Association; Steering Committee on Practice Guidelines. Treatment of Patients with Substance Use Disorders, Second edition. American Psychiatric Association. Am J Psychiatry 2007;164(4 Suppl): 5-123.

Bender RE, Griffin ML, Gallop RJ, Weiss RD. Assessing negative consequences in patients with substance use

and bipolar disorders: Psychometric properties of the Short Inventory of Problems (SIP). Am J Addict

2007;16: 503-509.

Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, Doreau, HR, Hennen JA. A

randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry 2007;164: 100-107.

Meade CS, Weiss, RD. Substance abuse as a risk factor for HIV sexual risk behavior among persons with

severe mental illness: Review of evidence and exploration of mechanisms. Clin Psychol Sci Prac 2007;

14: 23-33.

Manwani SG, Szilagi KA, Zablotsky B, Hennen J, Griffin ML, Weiss RD. Adherence to pharmacotherapy in

bipolar disorder patients with and without co-occurring substance use disorders. J Clin Psychiatry 2007;

68: 1172-1176.

Pomykacz B, Mao M, Weiss RD, Teter CJ. A review of brief medication-adherence instruments used in

patients with schizophrenia and bipolar disorder. Harvard Rev Psychiatry. 2007 Sep-Oct; 15(5): 259-63.

Shields AL, Howell RT, Potter JS, Weiss RD. The Michigan Alcoholism Screening Test and its shortened

forms: a meta-analytic inquiry into score reliability. Subst Use Misuse 2007;42: 1783-1800.

Jaffee WB, Trucco E, Levy S, Weiss RD. Is this urine really negative? A systematic review of tampering

methods in urine drug screening and testing. J Subst Abuse Treat 2007;33: 33-42.

Gelernter J, Panhuysen C, Weiss R, Brady K, Poling J, Krauthammer M, Farrer L, Kranzler HR. Genomewide

linkage scan for nicotine dependence: Identification of a novel chromosome 5 risk locus. Biol Psychiatry 2007;61: 119-126.

Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD,

Passik SD, Schnoll SH, Sellers E, Travers D, Weiss R. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23: 648-660.

Miller CS, Shields AL, Campfield D, Wallace KA, Weiss RD. Substance use scales of the Minnesota

Multiphasic Personality Inventory: An exploration of score reliability via meta-analysis. Educational and Psychological Measurement 2007;67: 1052-1065.

Meade CS, Graff FS, Griffin ML, Weiss RD: HIV risk behavior among patients with co-occurring bipolar and

substance use disorders: associations with mania and drug abuse. Drug Alcohol Depend. 2008;92: 296-300. PMID: 17850993. PMCID: PMC2262843.

Kranzler HR, Wilcox M, Weiss RD, Brady K, Hesselbrock V, Rounsaville B, Farrer L, Gelernter J: The

validity of cocaine dependence subtypes. Addict Behav 2008;33: 41-53. PMID: 17582692. PMCID: PMC2111173.

Kolodziej ME, Griffin ML, Bender R, Weiss RD: Assessment of depressive symptom severity among patients

with co-occurring bipolar disorder and substance dependence. J Affect Disord 2008;106: 83-89. PMCID: PMC2275203.

The COMBINE Study Research Group.²Cost and cost-effectiveness of the COMBINE study in alcohol-

dependent patients. Arch Gen Psychiatry 2008;65: 1214-21. PMCID: PMC3095105.

The COMBINE Study Research Group. [2] Combined pharmacotherapies and behavioral interventions for

alcohol dependence (The COMBINE Study): Examination of posttreatment drinking outcomes. J Stud Alcohol Drugs 2008;69(1): 5-13. PMID: 18080059.

Potter JS, Prather K, Weiss RD. Physical pain and associated clinical characteristics in treatment-seeking

patients in four substance use disorder treatment modalities. Am J Addict 2008;17(2): 121-125. PMID: 18393055.

Potter JS, Shiffman SJ, Weiss RD: Chronic pain severity in opioid-dependent patients. Am J Drug Alcohol

Abuse 2008;23(1): 101-107. PMCID: PMC3579615.

Schatzberg AF, Weiss RD, Brady KT, Culpepper L. Bridging the clinical gap: Managing patients with co-

occurring mood, anxiety, and alcohol use disorders: CNS Spectr 2008;13(4Suppl6): 3. PMID: 18408653.

Bieber CM, Fernandez K, Borsook D, Brennan MJ, Butler SF, Jamison RN, Osgood E, Sharpe-Potter J,

Thomson HN, Weiss RD, Katz NP: Retrospective accounts of initial subjective effects of opioids in patients

treated for pain who do or do not develop opioid addiction: a pilot case-control study. Exp Clin

Psychopharmacol. 2008;16(5): 429-434. PMCID: PMC3153468.

Shields AL, Campfield DC, Miller CS, Howell RT, Wallace K, Weiss RD: Score reliability of adolescent

alcohol screening measures: A meta-analytic inquiry. J Child Adolesc Subst Use 2008;17: 75-97.

Arias AJ, Gelernter J, Chan G, Weiss RD, Brady KT, Farrer L, Kranzler HR. Correlates of co-occurring

ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders.

Addict Behav. 2008;33: 1199-1207. PMCID: PMC2532519.

Jaffee WB, Trucco E, Teter C, Levy S, Weiss RD: Focus on alcohol and drug abuse: ensuring validity in urine

drug testing. Psychiatr Serv. 2008 Feb; 59(2):140-2. PMID: 18245154.

Graff FS, Griffin ML, Weiss RD: Predictors of dropout from group therapy among patients with bipolar and

substance use disorders. Drug Alcohol Depend. 2008 Apr 1; 94(1-3):272-5. PMID: 18162331. PMCID: PMC2268018.

Yu Y, Kranzler HR, Panhuysen C, Weiss RD, Poling J, Farrer LA, Gelernter J0: Substance dependence low

density whole genome association study in two distinct American populations. Hum Genet. 2008 Jun; 123(5): 495-506. PMID: 18438686. PMCID: PMC3428017.

Worley M, Gallop R, Gibbons MB, Ring-Kurtz S, Present J, Weiss RD, Crits-Christoph P: Additional

treatment services in a cocaine treatment study: level of services obtained and impact on outcome. Am J Addict. 2008 May-Jun; 17(3): 209-17. PMID: 18463998. PMCID: PMC2794690.

Levy B, Monzani BA, Stephansky MR, Weiss RD: Neurocognitive impairment in patients with co-occurring

bipolar disorder and alcohol dependence upon discharge from inpatient care. Psychiatr Res. 2008 Oct; 161(1): 28-35. PMCID: PMC3145337.

Zweben A, Pettinati HM, Weiss RD, Youngblood M, Cox CE, Mattson ME, Gorroochurn P, Ciraulo D:

Relationship between medication adherence and treatment outcomes: the COMBINE study. Alcohol Clin Exp Res. 2008 Sep; 32(9):1661-9. PMID: 18616687. PMCID: PMC2574640.

Ernst DB, Pettinati HM, Weiss RD, Donovan DM, Longabaugh R: An Intervention for treating alcohol

dependence: Relating elements of medical management to patient outcomes with implications for primary care.

Ann Fam Med. 2008 Sep-Oct; 6(5): 435-40. PMID: 18779548. PMCID: PMC2532776.

Weiss RD, O’Malley SS, Hosking JD, LoCastro JS, Swift R. Do patients with alcohol dependence respond to

placebo? Results from the COMBINE study. J Stud Alcohol Drugs. 2008 Nov; 69(6): 878-84. PMID: 18925346. PMCID: PMC2575123.

Jaffee WB, Griffin ML, Gallop R, Meade CS, Graff F, Bender RE, Weiss RD. Depression precipitated by alcohol use in patients with co-occurring bipolar and substance use disorders. J Clin Psychiatry. 2009 Feb; 70(2): 171-6. Epub 2008 Dec 30. PMID: PMCID: PMC2713748.

Gelernter J, Kranzler HR, Panhuysen C, Weiss RD, Poling J, Farrer L. Dense genomewide linkage scan for

alcohol dependence in African Americans: significant linkage on chromosome 10. Biol Psychiatry.

2009 Jan 15; 65(2): 111-5. PMID: 18930185. PMCID: PMC2646253.

Levy B, Stephansky MR, Dobie KC, Monzani BA, Medina AM, Weiss RD. Duration of inpatient admission

predicts cognitive functioning at discharge in patients with bipolar disorder. Compr Psychiatry. 2009 Jul-Aug; 50(4):322-6. PMCID: PMC3146314.

Jaffee WB, Bailey GL, Lohman M, Riggs P, McDonald L, Weiss RD. Methods of recruiting adolescents with

psychiatric and substance use disorders for a clinical trial. Am J Drug Alcohol Depend. 2009; 35(5): 381-4. PMCID: PMC3153470.

Ford JD, Gelernter J, DeVoe JS, Zhang W, Weiss RD, Brady K, Farrer L, Kranzler HR. Association of

psychiatric and substance use comorbidity with cocaine dependence severity and treatment

utilization in cocaine-dependent individuals. Drug Alcohol Depend. 2009 Jan 1; 99(1-3): 193-203. PMID: 18775607. PMCID: PMC2745327.

Farrer LA, Kranzler HR, Yu Yi CP, Weiss RD, Brady KT, Anton R, Cubells JF, Gelernter J. Association of

Variants in MANEA with cocaine-related behaviors. Arch Gen Psychiatry. 2009 Mar; 66(3): 267-74. PMID: 19255376. PMCID: PMC2758158.

McGovern MP, Lambert-Harris C, Acquilano S, Xie H, Alterman AI, Weiss RD. A cognitive behavioral

therapy for co-occurring substance use and post-traumatic stress disorder. Addict Behav. 2009 Oct; 34(10): 892-7. PMID: 19395179. PMCID: PMC2720425.

Wasan AD, Butler SF, Budman SH, Fernandez K, Weiss RD, Greenfield SF, Jamison RN. Does report of

craving opioid medication predict aberrant drug behavior among chronic pain patients? Clin J Pain. 2009 Mar-Apr; 25(3):193-8. PMID:19333168. PMCID: PMC2664529.

Zuo L, Kranzler HR, Luo X, Yang BZ, Weiss R, Brady K, Poling J, Farrer L, Gelernter J. Interaction between

two independent CNR1 variants increases risk for cocaine dependence in European Americans: a replication

study in family-based sample and population-based sample. Neuropsychopharmacology. 2009 May; 34(6): 1504-13. PMID 19052543. PMCID: PMC2879626.

Meade CS, McDonald LJ, Graff FS, Fitzmaurice GM, Griffin ML, Weiss RD. A prospective study examining

the effects of gender and sexual/physical abuse on mood outcomes in patients with co-occurring bipolar I and substance use disorders. Bipolar Disord. 2009 Jun; 11(4): 425-33. PMID: 19392857. PMCID: PMC2908240.

Zhang H, Kranzler HR, Weiss RD, Luo X, Brady KT, Anton RF, Farrer LA, Gelernter J. Pro-

opiomelanocortin gene variation related to alcohol or drug dependence: evidence and replications across

family- and population-based studies. Biol Psychiatry. 2009 Jul 15; 66(2):128-36. PMID: 19217079. PMCID: PMC2896237.

Griffin ML, Kolodziej ME, Weiss RD. Measuring principal substance of abuse in comorbid patients for clinical

research. Addict Behav. 2009 Oct; 34(10): 826-9. PMID: 19285810. PMCID: PMC2720415.

Meade CS, McDonald LJ, Weiss RD. HIV risk behavior in opioid dependent adults seeking detoxification

treatment: an exploratory comparison of heroin and oxycodone users. Am J Addict. 2009 Jul-Aug; 18(4): 289-93. PMID: 19444732. PMCID: PMC2905052.

Wu LT, Ringwalt CL, Weiss RD, Blazer DG. Hallucinogen-related disorders in a national sample of

adolescents: the influence of ecstasy/MDMA use. Drug Alcohol Depend. 2009 Sep; 104(1-2): 156-66. PMID: 19500920. PMCID: PMC2733917.

Weiss RD, Griffin ML, Jaffee WB, Bender RE, Graff FS, Gallop RJ, Fitzmaurice GM. A “community-friendly”

version of Integrated Group Therapy for patients with bipolar disorder and substance dependence: a randomized

controlled trial. Drug Alcohol Depend 2009 Oct 1; 104(3): 212-9. PMID: 19573999. PMCID: PMC2735139.

Niciu MJ, Chan G, Gelernter J, Arias AJ, Douglas K, Weiss R, Anton RF, Farrer L, Cubells JF, Kranzler HR.

Subtypes of major depression in substance dependence. Addiction. 2009 Oct; 104(10): 1700-9. PMID: 19681804. PMCID: PMC2980795.

Copersino ML, Fals-Stewart W, Fitzmaurice G, Schretlen D, Sokoloff J, Weiss RD. Rapid cognitive screening

of patients with substance use disorders. Exp Clin Psychopharmacol. 2009 Oct; 17(5): 337-44. PMCID: PMC3144764.

Xie P, Kranzler HR, Poling J, Stein MB, Anton RF, Brady K, Weiss RD, Farrer L, Gelernter J. Interactive

effect of stressful life events and the serotonin transporter 5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent populations. Arch Gen Psychiatry 2009 Nov; 66(11): 1201-9, PMID: 19884608. PMCID: PMC2867734.

Hughes JR, Weiss RD. Are differences in guidelines for the treatment of nicotine dependence and for the

treatment of non-nicotine substance dependence justified? Addiction. 2009 Dec; 104(12):1951-7. PMCID:PMC3127200.

Panhuysen CL, Kranzler HR, Yu Y, Weiss RD, Brady K, Poling J, Farrer LA, Gelernter J. Confirmation and

generalization of an alcohol-dependence locus on chromosome 10g. Neuropsychopharmacology

2010 May; 35(6): 1325-1332. PMID: 20147890. PMCID: PMC2855759.

Weiss RD, Potter JS, Provost SE, Huang Z, Jacobs P, Hasson A, Lindblad R, Connery HS, Prather K, Ling W.

A multi-site, two-phase, prescription opioid addiction treatment study (POATS): Rationale, Design, and

Methodology. Contemp Clin Trials 2010;31(2): 189-99. PMID: 20116457. PMCID: PMC2831115.

Ling W, Jacobs P, Hillhouse M, Hasson A, Thomas C, Freese TE, Sparenborg S, McCarty D, Weiss RD, Saxon

AJ, Cohen AJ, Straus MM, Brigham GS, Liu DS, McLaughlin P, Tai B. From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treat. 2010;38(suppl 1): S53-S60. PMID: 20307796. PMCID: PMC2853172.

Meade CS, Lukas SE, McDonald LJ, Fitzmaurice GM, Eldridge JA, Merrill N, Weiss RD. A randomized trial

of transcutaneous electric acupoint stimulation as adjunctive treatment for opioid detoxification. J Subst Abuse

Treat. 2010 Jan; 38(1): 12-21. PMID: 19574017. PMCID: PMC2789908.

Douglas KR, Chan G, Gelernter J, Arias AJ, Anton RF, Weiss RD, Brady K, Poling J, Farrer L, Kranzler HR.

Adverse childhood events as risk factors for substance dependence: partial mediation by mood and anxiety

disorders. Addict Behav. 2010 Jan; 35(1): 7-13. PMID: 19720467. PMCID: PMC2763992.

Levy B, Weiss RD. Neurocognitive impairment and psychosis in bipolar I disorder during early remission

from an acute episode of mood disturbance. J Clin Psychiatry 2010 Feb. 71(2): 201-6. PMCID: PMC3143061.

Potter JS, Prather K, Kropp F, Byrne M, Sullivan CR, Mohamedi N, Copersino ML, Weiss RD. A method to

diagnose opioid dependence resulting from heroin versus prescription opioids using the Composite International

Diagnostic Interview. Contemp Clin Trials. 2010 Mar; 31(2): 185-8. PMID: 20079463. PMCID: PMC3579622.

Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD. Predictors of buprenorphine-naloxone

dosing in a 12-week treatment trial for opioid-dependent youth: Secondary analyses from a NIDA Clinical

Trials Network study. Drug Alcohol Depend 2010 Mar 1; 107(2-3): 253-6. PMID: 19948382. PMCID: PMC2821971.

Kalayasiri R, Gelernter J, Farrer L, Weiss R, Brady K, Gueorguieva R, Kranzler HR, Malison RT. Adolescent

cannabis use increases risk for cocaine-induced paranoia. Drug Alcohol Depend. 2010 Mar 1; 107(2-3):196-

PMID: 19944543. PMCID: PMC2821949.

Ostacher MJ, Perlis RH, Nierenberg AA, Calabrese J, Stange JP, Salloum I, Weiss RD, Sachs GS; for STEP-

BD Investigators. Impact of substance use disorders on recovery from episodes of depression in bipolar

disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder

(STEP-BD). Am J Psychiatry. 2010 Mar; 167(3): 289-97. PMID: 20008948. PMCID: PMC2918249.

Potter JS, Chakrabarti A, Domier CP, Hillhouse MP, Weiss RD, Ling W. Pain and continued opioid use in

individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the NIDA Clinical Trials Network. J Subst Abuse Treat . 2010 Jun; 38(Suppl 1): S80-6, PMCID: PMC3150507.

Upadhyay J, Maleki N, Potter J, Elman I, Rudrauf D, Knudsen J, Wallin D, Pendse G, McDonald L, Griffin M,

Anderson J, Nutile L, Renshaw P, Weiss R, Becerra L, Borsook D. Alterations in brain structure and functional

connectivity in prescription opioid-dependent patients. Brain. 2010 Jul; 133(Pt7): 2098-114. PMCID: PMC2912691.

Meade CS, Weiss RD, Fitzmaurice GM, Poole SA, Subramaniam GA, Patkar AA, Connery HS, Woody GE.

HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA Clinical Trials Network

multi-site study. JAIDS. 2010 Sep 1: 55(1): 65-72. PMCID: PMC3148945.

Liebschutz JM, Saitz R, Weiss RD, Averbuch T, Schwartz S, Meltzer EC, Claggett-Borne E, Cabral H, Samet
Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. J Pain. 2010 Nov; 11(11): 1047-55. PMID: 20338815. PMCID: PMC 2892730.

Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD,

Leimberger JD, Lewis DF, Dorer EM. Impact of attention-deficit/ hyperactivity disorder (ADHD)

treatment on smoking cessation intervention in ADHD smokers: a randomized, double-bind, placebo-controlled trial. J Clin Psychiatry. 2010 Dec; 71(12):1680-8. PMCID: PMC3151610.

Potter JS, Donovan DM, Weiss RD, Gardin J, Lindblad R, Wakim P, Dodd D. Site selection in community-

based clinical trials for substance use disorders: strategies for effective site selection. Am J Drug Alcohol Depend. 2011;37: 400-7, PMID: 21854283. PMCID: PMC3160724.

Hamdi NR, Levy M, Jaffee WB, Chisholm SM, Weiss RD. Implementing an adapted version of the Job

Seekers’ Workshop in a residential program for patients with substance use disorders. J Addict Med. 2011; 5(2): 148-152. PMID: 21643458. PMCID: PMC3107016.

Zanarini MC, Frankenburg FR, Weingeroff J, Reich DB, Fitzmaurice G, Weiss RD. The course of substance

use disorders in patients with borderline personality disorder and Axis II comparison subjects: A 10-year follow-up study. Addiction. 2011 Feb;106(2):342-8. PMID:21083831. PMCID:PMC3222933.

Levy B, Medina AM, Hintz K, Weiss R. Ecologically valid support for the link between cognitive and

psychosocial functioning in bipolar disorder. J Psychiatr Res 2011 Feb 28;185: 353-7. PMID: 20674041 PMCID: PMC3146310.

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN,

Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinksi AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011 Dec;68(12):1238-1246. PMID:22065255. PMCID:PMC3470422.

Levy S, Knight JR, Moore T, Weinstein Z, Sherritt L, Weiss RD. Acceptability of drug testing in an outpatient

substance abuse program for adolescents. J Adolesc Health. 2011 Mar; 48(3):229-33. PMID: 21338892. PMCID: PMC3052946.

McDonald LJ, Griffin ML, Kolodziej ME, Fitzmaurice GM, Weiss RD. The impact of drug use in social

networks of patients with substance use and bipolar disorders. Am J Addict 2011 Mar-Apr; 20: 100-5. PMID: 21314751 PMCID: PMC3071143.

Teter CJ, Falone AE, Bakaian AM, Tu C, Ongur D, Weiss RD. Medication adherence and attitudes in patients

with bipolar disorder and current versus past substance use disorder. Psychiatry Res. 2011 Dec 30;190(2-3):253-8. PMID:21696830. PMCID:PMC3663075.

Ittiwut R, Listman JB, Ittiwut C, Cubells JF, Weiss RD, Brady K, Oslin D, Farrer LA, Kranzler HR, Gelernter J.

Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in

European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):651-60. PMID:21656904. PMCID: PMC3864552.

Carroll KM, Ball SA, Jackson R, Martino S, Petry NM, Stitzer ML, Wells EA, Weiss RD. Ten take home

lessons from the first ten years of the CTN and ten recommendations for the future. Am J Drug Alcohol Abuse. 2011 Sep;37(5):275-82. PMID:21854269. PMCID:PMC3232679.

Subramaniam GA, Warden D, Minhajuddin A, Fishman MJ, Stitzer ML, Adinoff B, Trivedi M, Weiss R, Potter

J, Poole SA, Woody GE. Predictors of abstinence: NIDA multi-site buprenorphine/naloxone treatment trial in opioid dependent youth. J Am Acad Child Adolesc Psychiatry. 2011 Nov;50(11):1120-8. PMCID: PMC3786351.

Meade CS, Fitzmaurice GM, Sanchez AK, Griffin ML, McDonald LJ, Weiss RD: The relationship of manic

episodes and drug abuse to sexual risk behavior in patients with co-occurring bipolar and substance use disorders: a 15-month prospective analysis. AIDS Behav. 2011 Nov; 15(8):1829-33. PMID: 20859672. PMCID: PMC3191230.

Levy B, Manove E, Weiss RD. Recovery of cognitive functioning in patients with co-occurring bipolar disorder

and alcohol dependence during early remission from an acute mood episode. Ann Clin Psychiatry. 2012 May;24(2):143-54. PMID: 22563570. PMCID: PMC3349462.

Copersino ML, Schretlen DJ, Fitzmaurice G, Lukas SE, Faberman J, Sokoloff J, Weiss RD. Effects of cognitive

impairment on substance abuse treatment attendance: predictive validation of a brief cognitive screening

measure. Am J Drug Alcohol Abuse 2012: May;38(3):246-50. PMID:22443860. PMCID:PMC3593077.

Putnins SI, Griffin ML, Kolodziej ME, Fitzmaurice GM, Weiss RD. Poor sleep at baseline predicts worse mood

outcomes in patients with co-occurring bipolar disorder and substance dependence. J Clin Psychiatry. 2012 May;73 (5):703-8. PMID: 22313797. PMCID: PMC3349805.

Wasan AD, Ross EL, Michna E, Chen LQ, Holcomb C, Chibnik L, Greenfield S, Weiss R, Jamison RN.

Craving of prescription opioids in patients with chronic pain: a longitudinal outcomes trial. J Pain. 2012 Feb;13(2):146-54. PMID:22245713. PMCID: PMC3274819.

Kolodziej ME, Muchowski PM, Hamdi NR, Morrissette P, McGowan AJ, Weiss RD. Adaptation of the patient

feedback survey at a community treatment setting. Am J Addict; 2012 Jan-Feb;21(1):63-71. PMID:22211348. PMCID: PMC3699190.

Ittiwut C, Yang BZ, Kranzler HR, Anton RF, Hirunsatit R, Weiss RD, Covault J, Farrer LA, Gelernter J:

GABRGI and GABRA2 variation associated with alcohol dependence in African Americans. Alcohol Clin Exp Res. 2012 Apr;36(4):588-93. PMID: 21919924. PMCID: PMC3250564.

Turk DC, O’Connor AB, Dworkin RH, Chaudhry A, Katz NP, Adams EH, Brownstein JS, Comer SD, Dart R, Dasgupta N, Denisco RA, Klein M, Leiderman DB, Lubran R, Rappaport BA, Zacny JP, Ahdieh H, Burke LB, Cowan P, Jacobs P, Malamut R, Markman J, Michna E, Palmer P, Peirce-Sandner S, Potter JS, Raja SN, Rauschkolb C, Roland CL, Webster LR, Weiss RD, Wolf K. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. 2012 Oct ;153(10):1997-2008. PMID: 22770841. PMCID: PMC3617214.

DeVido JJ, Weiss RD: Treatment of the depressed alcoholic patient. Curr Psychiatry Rep. 2012

Dec;14(6):610-8. PMCID: PMC3712746.

Hill KP, Rice LS, Connery HS, Weiss RD: Diagnosing and treating opioid dependence. J Fam Pract.

2012 Oct;61(10):588-97. PMID: 23106060.

Keuroghlian AS, Barry AS, Weiss RD: Circadian Dysregulation, Zolpidem Dependence, Withdrawal

Seizure in a Resident Physician Performing Shift Work. Am J Addict. 2012; 21(6): 576-577. PMCID: PMC3744365.

Farren CK, Hill KP, Weiss RD: Bipolar disorder and alcohol use disorder: a review. Current Psychiatry

Reports 2012 Dec; 14(6): 659-66. PMID: 22983943. PMCID: PMC3730445.

Kiluk BD, Dreifuss JA, Weiss RD, Morgenstern J, Carroll KM. The Short Inventory of Problems – Revised

(SIP-R): Psychometric properties within a large, diverse sample of substance use disorder treatment seekers. Psychology of Addictive Behaviors. 2013 Mar; 27(1): 307-14. PMID: 22642856. PMCID:PMC3820151.

McHugh RK, Kaufman JS, Frost KH, Fitzmaurice GM, Weiss RD: Positive affect and stress reactivity in

alcohol-dependent outpatients. J Stud Alcohol Drugs. 2013 Jan; 74 (1): 152-7. PMID: 23200161. PMCID: PMC3517258.

Katz NP, Birnbaum H, Brennan MJ, Freedman JD, Gilmore GP, Jay D, Kenna GA, Madras BK, McElhaney L, Weiss RD, White AG.PhD: Prescription opioid abuse: challenges and opportunities for payers. Am J Manag

Care. 2013 Apr;19(4):295-302. PMID: 23725361. PMCID: PMC3680126.

Hill KP, Toto L, Lukas SE, Weiss RD, Trksak G, Rodolico JM, Greenfield SF. Cognitive behavioral therapy

and the nicotine transdermal patch for dual nicotine and cannabis dependence: a pilot study. Am J Addict. 2013 May-Jun;22(3):233-8. PMID: 23617864. PMCID: PMC3641687.

Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, Haddox JD, Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya ID, O’Brien C, Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AS, Weiss RD, Turk DC, Dworkin RH: Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013 Nov;154(11):2287-96. PMID: 23792283.

Levy B, Medina AM, Weiss RD. Cognitive and psychosocial functioning in bipolar disorder with and without

psychosis during early remission from an acute mood episode: a comparative longitudinal study. Compr

Psychiatry. 2013 Aug;54(6):618-26. PMID:23357126. PMCID: PMC4076957.

Dreifuss JA, Griffin ML, Frost K, Fitzmaurice GM, Potter JS, Fiellin DA, Selzer J, Hatch-Maillette M, Sonne SC, Weiss RD. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug Alcohol Depend.2013 July 1; 131 (1-2), 112-118; PMID 23333292. PMCID 3638044.

Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese M: Benzodiazepine use

during buprenorphine treatment for opioid dependence: clinical and safety outcomes. Drug Alcohol Depend. 2013 Oct 1;132(3):580-6. PMID: 23688843. PMCID: PMC3916951.

Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, Woody GE, Weiss RD:

Association of cannabis use with opioid outcomes among opioid-dependent youth. Drug and Alcohol Dependence. 2013 Sep; 132(1-2): 342-5. PMID:23528523. PMCID:PMC3724203.

McHugh RK, Devito EE, Dodd D, Carroll KM, Potter JS, Greenfield SF, Connery HS, Weiss RD: Gender

differences in a clinical trial for prescription opioid dependence. J Subst Abuse Treat. 2013 Jul;45(1):38-43.

PMID: 23313145. PMCID: PMC3626739.

Nielsen S, Hillhouse M, Weiss RD, Mooney L, Potter JS, Lee J, Gourevitch MN, Ling W: The relationship

between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. Am J Addict. 2013 Jul-Aug; 23(4): 343-8. PMID: 24112096. PMCID: PMC4151625.

Kiluk BD, Dreifuss JA, Weiss RD, Horigian VE, Carroll KM: Psychometric properties of a

Spanish-language version of the Short Inventory of Problems. Psychol Addict Behav. 2013 Sep;27(3):893-900. PMID:23772760. PMCID: PMC3820151.

Schuman-Olivier Z, Connery H, Griffin ML, Wyatt SA, Wartenberg AA, Borodovsky J, Renner JA, Weiss RD:

Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013 Nov-Dec;22(6):574-80. PMID: 24131165. PMCID: PMC3801272.

McHugh RK, Park S, Weiss RD: Cue-induced craving in dependence upon prescription opioids and heroin. 2014 Sep;23(5):453-8. PMID: 24628912. PMCID: PMC4163930.

Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ. Emerging adult-age status predicts poor buprenorphine treatment retention. 2014 Sep;47(3):202-12. PMID: 24953168. PMCID: PMC4180514.

Suzuki J, Matthews M, Brick D, Nguyen MT, Jamison R, Ellner A, Tishler, L, Weiss RD.

Implementation of a collaborative care management program with buprenorphine in primary care: A comparison between opioid-dependent patients and patients with chronic pain using opioids nonmedically. J Opioid Manag. 2014 May-Jun;10(3):159-68. Erratum in: J Opioid Manag. 2014 Sep-Oct;10(5):302. Wasan, Ajay D [added]. PMCID:PMC4085743.

Griffin ML, Dodd DR, Potter JS, Rice LS, Dickinson W, Sparenborg S, Weiss RD: Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder. Am J Drug Alcohol Abuse. 2014 Mar;40(2):157-62. PMID: 24219166. PMCID: PMC3947491.

Meade CS, Bevilacqua LA, Moore ED, Griffin ML, Gardin JG, Potter JS, Hatch-Maillette M, Weiss RD:

Concurrent substance abuse is associated with sexual risk behavior among adults seeking treatment for prescription opioid dependence. Am J Addict. 2014 Jan; 23(1): 27-33. PMID: 24313238. PMCID: PMC3914665.

McHugh RK, Hu M-C, Campbell ANC, Hilario EY, Weiss RD, Hien DA: Changes in Sleep Disruption in the Treatment of Co-Occurring Posttraumatic Stress Disorder and Substance Use Disorders. J Trauma Stress. 2014 Feb; 27(1): 82-9. PMID: 24473926. PMCID: PMC4096867.

Levy S, Weiss R, Sherritt L, Ziemnik R, Spalding A, Van Hook S, Shrier LA. An electronic screen for triaging adolescent substance use by risk levels. JAMA Pediatr. 2014 Sep;168(9):822-8. doi: 10.1001/jamapediatrics.2014.774.

McHugh, RK, Sugarman DE, Kaufman JS, Park S, Weiss RD, Greenfield SF: Readability of self-report alcohol misuse measures. J Stud Alcohol Drugs. 2014 Mar; 75(2): 328-34. PMID: 24650827. PMCID: PMC3965686.

McHugh RK, Fitzmaurice GM, Carroll KM, Griffin ML, Hill KP, Wasan AD, Weiss RD: Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. Drug Alcohol Depend. 2014 Dec; 145: 121-126. PMID: 25454409. PMCID: PMC4254575.

Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ. Emerging adult age status predicts poor buprenorphine treatment retention. 2014 Sep; 47(3): 202-12. PMID: 24953168. PMCID: PMC4180514.

McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, Matthews AG, Sharma G, Van Veldhuisen P, Vandrey RG, Levin FR, Weiss RD, Lindblad R, Allen C, Mooney LJ, Haynes L, Brigham GS, Sparenborg S, Hasson AL, Gray KM: Achieving Cannabis Cessation – Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemporary Clinical Trials. 2014 Nov; 39(2): 211-23. PMID: 25179587. PMCID: PMC4252394.

Weiss RD, Potter JS, Griffin ML, McHugh RK, Haller D, Jacobs P, Gardin J, Fischer D, Rosen KD: Reasons

for opioid use among patients with dependence on prescription opioids: The role of chronic pain. J Subst Abuse

Treat. 2014 Aug; 47(2): 140-5. PMID: 24814051. PMCID: PMC4074437.

Weiss RD, Griffin ML, Potter, JS, Dodd DR, Dreifuss JA, Connery HS, Carroll KM: Who benefits from

additional drug counseling among prescription opioid dependent patients receiving buprenorphine-naloxone and standard medical management? Drug Alcohol Depend. 2014 Jul; 140: 118-22. PMID: 24831754. PMCID: PMC4053488.

Macias Konstantopoulos ML Dreifuss JA, McDermott KA, Parry BA, Howell ML, Mandler RN, Fitzmaurice GM, Bogenschutz MP, Weiss RD. Identifying Patients With Problematic Drug Use in the Emergency Department: Results of a Multisite Study. Ann Emerg Med. 2014 Nov; 64(5): 516–525. PMCID: PMC4252835

McDermott KA, Griffin ML, Connery HS, Hilario EY, Fiellin DA, Fitzmaurice GM, Weiss RD: Initial response

as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid dependent

population. Journal of Clinical Psychiatry. 2015 Feb; 76(2): 189-94. PMID: 25562462. PMCID: PMC4352119.

Hilario EY, Griffin ML, McHugh RK, McDermott KA, Connery HS, Fitzmaurice GM, Weiss RD: Denial of

urinalysis-confirmed opioid use in prescription opioid dependence, J Subst Abuse Treat. 2015 Jan; 48(1): 85-90. PMID: 25115135. PMCID: PMC4250346.

Potter JS, Dreifuss, JA, Marino EN, Provost SE, Dodd DR, Rice LS, Fitzmaurice GM, Griffin ML, Weiss RD:

The multi-site Prescription Opioid Addiction Treatment Study: 18-month outcomes. J Subst Abuse Treatment, 2015 Jan;48(1):62-9. PMID: 25189089. PMCID: PMC4250351.

Northrup TF, Stotts AL, Green C, Potter JS, Marino E, Walker R, Weiss RD, Trivedi M: Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model. Addictive Behaviors. 2015 Feb; 41:20-8. PMID: 25282598. PMCID: PMC4252696.

Suzuki J, DeVido J, Kalra I, Mittal L, Shah S, Zinser J, Weiss RD: Initiating buprenorphine treatment for hospitalized patients with opioid dependence: A case series. Am J Addict. 2015 Jan; 24(1): 10-4. PMID: 25823630.

DeVido J, Bogunovic O, Weiss RD: Alcohol use disorders in pregnancy. Harvard Review of Psychiatry. 2015 Mar-Apr; 23(2): 112-21. PMID: 25747924.

Hearon BA, Pierce CL, Björgvinsson T, Fitzmaurice GM, Greenfield SF, Weiss RD, Busch AB: Improving the efficiency of drug use disorder screening in psychiatric settings: validation of a single-item screen. Am J Drug Alcohol Abuse. 2015 Mar; 41(2): 173-6. PMID: 25700005.

Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, Srisarajivakul EN, Dodd DR, Dreifuss JA, McHugh RK, Carroll KM: Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend. 2015 May; 150: 112-119. PMID: 25818060. PMCID: PMC4407806.

Griffin ML, Bennett HE, Fitzmaurice GM, Hill KP, Provost SE, Weiss RD. Health-related quality of life among prescription opioid-dependent patients: Results from a multi-site study. Am J Addict 2015; 24:308-314. PMID: 25808055.

Keuroghlian AS, Reisner SL, White JM, Weiss RD. Substance use behaviors and treatment of substance use disorders in a community sample of transgender adults. Drug Alcohol Depend 152: 139-146, 2015.

Nosyk B, Bray JW, Wittenberg E, Aden B, Eggman AA, Weiss RD, Potter J, Ang A, Hser Y-I, Ling W, Schackman BR. Short-term health-related quality of life improvement during opioid agonist treatment. Drug Alcohol Depend 157: 121-128, 2015.

Sylvia LG, Gold AK, Stange JP, Peckham AD, Kansky C, Deckersbach T, Calabrese JR, Weiss RD,

Perlis R, Nierenberg AA, Ostacher MJ. A Randomized, Placebo-Controlled Trial of Adjunctive Topiramate for Alcohol Dependence in Bipolar Disorder. Am J Addict 2016 Mar; 25(2): 94-8. PMID:

PMCID: PMC4791182.

McHugh RK, Fitzmaurice GM, Griffin ML, Anton RF, Weiss RD. Association between a brief alcohol craving measure and drinking in the following week. Addiction 2016; 111: 1004-1010.

Copersino ML, Price JS, Frost KH, Vitaliano GD, Blaise deBF, Lukas SE, Weiss RD, Janes AC.Default mode network functional reorganization during early abstinence in polysubstance using emerging adults treated for opioid dependence. Journal of Neuropsychiatry and Clinical Neurosciences, in press.

McHugh RK, Mashoon Y, Weiss RD. Cue-Induced Craving to Paraphernalia and Drug Images in Opioid Dependence. Am J Addict 2016 25: 105–109.

McHugh RK, Weiss RD, Cornelius M, Martel MO, Jamison RN, Edwards RR. Distress intolerance and prescription opioid misuse among patients with chronic pain. Journal of Pain 17: 806-814, 2016.

Hill KP, Weiss RD. Minimal Physical Health Risk Associated With Long-Term Cannabis Use-But Buyer Beware (Commentary). JAMA 315:2338-2339, 2016.

Griffin ML, McDermott KA, McHugh RK, Fitzmaurice GM, Jamison RN, Weiss RD: Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain. Drug Alcohol Depend, 2016; 163: 216-221.

Griffin ML, McDermott KA, McHugh RK, Fitzmaurice GM, Weiss RD: Grit in patients with substance use disorders. Am J Addict 25: 652–658, 2016.

Karakula SL, Weiss RD, Griffin ML, Borges AM, Bailey AJ, McHugh RK: Delay discounting in opioid use disorder: differences between heroin and prescription opioid users. Drug Alcohol Depend 169: 68-72, 2016.

Mackie SE, McHugh RK, McDermott K, Griffin ML, Winkelman JW*, Weiss RD* (co-senior authors): Prevalence of restless legs syndrome in detoxification from alcohol and opioids. J Subst Abuse Treat 79: 35-39, 2017.

Votaw, V.R., Wittenauer, J., Connery, H.S., Weiss, R.D., & McHugh, R.K. Perceived risk of heroin use among nonmedical prescription opioid users. Addictive Behaviors 65: 218–223, 2017

McHugh, RK, Votaw V, Bogunovic O, Karakula SL, Griffin ML, Weiss RD. Anxiety sensitivity and nonmedical benzodiazepine use among adults with opioid use disorder. Addictive Behaviors 65: 283–288, 2017

McHugh RK, Votaw VR, Fulciniti F, Connery HS, Griffin ML, Monti PM, Weiss RD. Perceived barriers to smoking cessation among adults with substance use disorders. J Subst Abuse Treat 74:

48-53, 2017.

Greenfield SF, Weiss RD. Addiction-25 years later. Harv Rev Psychiatry 25(3): 97-100. May/Jun 2017.

Weiss RD, Rao V. The Prescription Opioid Addiction Treatment Study: What have we learned?

Drug Alcohol Depend 173 Suppl 1: S48-S54, 2017.

Carroll KM*, Weiss RD* (co-first authors). The role of behavioral interventions in buprenorphine maintenance treatment: A review. Am J Psychiatry 174: 738-747, 2017.

Liebschutz JM, Xuan Z, Shanahan CW, LaRochelle M, Keosaian J, Beers D, Guara G, O’Connor K, Alford DP, Parker V, Weiss RD, Samet JH, Crosson J, Cushman PA, Lasser KE. Improving adherence to chronic opioid therapy guidelines to reduce opioid misuse in primary care: A cluster randomized controlled trial. JAMA Internal Medicine 177 (9): 1265-1272, 2017.

Medlock MM, Rosmarin DH, Connery HS, Griffin ML, Weiss RD, Karakula SL, McHugh RK. Religious coping in patients with severe substance use disorders receiving acute inpatient detoxification. Am J Addict 26: 744-750, 2017.

Hill KP, Palastro MD, Gruber SA, Fitzmaurice GM, Greenfield SF, Lukas SE, Weiss RD.

Nabilone Pharmacotherapy for Cannabis Dependence: A Randomized, Controlled Pilot Study. Am J Addict 26 (8): 795-801, 2017.

McHugh, RK, Votaw, VR, Barlow, DH, Fitzmaurice, GM, Greenfield, SF, Weiss, RD.

Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods. Contemporary Clinical Trials 60: 105-112, 2017.

Fitzmaurice GM, Lipsitz SR, Weiss RD: Statistical considerations in the choice of endpoint for drug

use disorder trials. Drug Alcohol Depend 181: 219-222, 2017.

Faberman J, Provost SE, Weiss RD, Greenfield SG. Focus group study to examine content of family meetings in short-term substance use disorder treatment programs. Journal of Social Work Practice in the Addictions 18: 231-248, 2018.

Welsh JW, Tretyak V, McHugh RK, Weiss R, Bogunovic O. Adjunctive Pharmacologic Approaches for Benzodiazepine Tapers. Drug Alcohol Depend 189: 96-107, 2018.

Fitzmaurice GM, Lipsitz SR, Weiss RD: Sensitivity analysis for non-monotone missing binary data in longitudinal studies: Application to the NIDA collaborative cocaine treatment study. Statistical Methods in Medical Research, First Published August 27, 2018 https://doi.org/10.1177/0962280218794725

Kiluk BD, Fitzmaurice GM, Strain EC, Weiss RD. What Defines a Clinically Meaningful Outcome in the Treatment of Substance Use Disorders: Reductions in Direct Consequences of Drug Use or Improvement in Overall Functioning? Addiction 114: 9-15, 2019.

McHugh RK, Geyer R, Karakula S, Griffin ML, Weiss Nonmedical benzodiazepine use in adults with alcohol use disorder: The role of anxiety sensitivity and polysubstance use. Am J Addict 27: 485-490, 2018.

Beckwith N, McDowell MJ, Reisner SL, Zaslow S, Weiss RD, Mayer KH, Keuroghlian AS. Psychiatric epidemiology of transgender and non-binary adult patients at an urban health center. LGBT Health 6 (2): 1-11, 2019.

Kiluk BD, Fitzmaurice GM, Strain EC, Weiss RD. Response to commentaries: The quest(ion) remains in the search for a meaningful reduction-based end-point. Addiction 114: 21-23, 2019.

Kneeland ET, Griffin ML, Taghian N, Weiss RD, McHugh RK: Associations between Pain Catastrophizing and Clinical Characteristics in Adults with Substance Use Disorders and Co-occurring Chronic Pain. Am J Drug Alcohol Abuse April 25, 1-7, 2019.

Weiss RD, Griffin ML, Marcovitz DE, Hilton BT, Fitzmaurice GM, McHugh RK, Carroll KM. Correlates of Opioid Abstinence in a 42-Month Post-Treatment Naturalistic Follow-up Study

of Prescription Opioid Dependence. J Clin Psychiatry 80(2), 2019 Mar 26. pii: 18m12292. doi: 10.4088/JCP.18m12292.

Kelly J, Nierenberg A, Weiss RD, Vilsaint C, Hoffman L, Hoeppner B. Peer Support for Mood Disorder: Characteristics and Benefits from Attending the Depression and Bipolar Support Alliance Mutual-Help Organization. J Affect Disord, 255:127-135, 2019.

Kleykamp BA, Weiss RD, Strain EC. Time to Reconsider the Role of Craving in Opioid Use Disorder. JAMA Psychiatry, doi: 10.1001/jamapsychiatry.2019.1839.

Suzuki J, Johnson JA, Montgomery MW, Hayden MC, Price CN, Solomon DA, Liebschutz JM, Schnipper JL, Weiss RD. Long-term outcomes of injection drug-related infective endocarditis among people who inject drugs. J Addict Med. 2019 Oct 18. doi: 10.1097/ADM.0000000000000572. [Epub ahead of print] PMID: 31634202

McHugh RK, Weiss RD. Alcohol use disorder and depressive disorders. Alcohol Res. 2019 Jan 1;40(1). pii: arcr.v40.1.01. doi: 10.35946/arcr.v40.1.01. eCollection 2019 Oct 21.

PMID: 31649834

McHugh RK, Kneeland ET, Edwards RR, Jamison R, Weiss RD. Pain catastrophizing and distress intolerance: Differential prediction of pain and emotional stress reactivity. J Behav Med. 2019 Aug 2. doi: 10.1007/s10865-019-00086-5. [Epub ahead of print] PMID: 31376099

Kleykamp BA, Santis M, Dworkin RH, Huhn AS, Kampman KM, Montoya ID, Preston KL, Ramey T, Smith SM, Turk DC, Walsh R, Weiss RD, Strain EC. Craving and opioid use disorder: a scoping review. Drug Alcohol Depend https://doi.org/10.1016/j.drugalcdep.2019.107639

Connery HS, Taghian N, Kim J, Griffin M, Rocket IRH, Weiss RD, McHugh RK. Suicidal motivations reported by opioid overdose survivors: a cross-sectional study of adults with opioid use disorder. Drug Alcohol Depend, doi: 10.1016/j.drugalcdep.2019.107612.

Beard C, Peckham AD, Griffin ML, Weiss RD, Taghian N, McHugh RK. Associations among interpretation bias, craving, and abstinence self-efficacy in adults with substance use disorders. Drug Alcohol Depend 205; 1016/j.drugalcdep.2019.107644

Pedrelli P, Borsari B, Merrill JE, Fisher LB, Nyer M, Shapero BG, Farabaugh A, Hayden ER, Levine MT, Weiss RD, Fava M. Evaluating the combination of a Brief Motivational Intervention plus Cognitive Behavioral Therapy for Depression and heavy episodic drinking in college students. Psychol Addict Behav, 2019 Dec 19. doi: 10.1037/adb0000538.

McDermott KA, Griffin ML, McHugh RK, Fitzmaurice GM, Jamison RN, Provost SE, Weiss RD. Long-term naturalistic follow-up of chronic pain in adults with prescription opioid use disorder. Drug Alcohol Depend org/10.1016/j.drugalcdep.2019.107675

Copersino ML, Patel R, Price JS, Visser KF, Vitaliano G, Plitman E, Lukas SE, Weiss RD, Janes AC, Chakravarty MM. Interactive effects of age and recent substance use on striatal shape morphology at substance use disorder treatment entry. Drug Alcohol Depend 206, 2020 Jan 1. doi: 10.1016/j.drugalcdep.2019.107728.

Suzuki J, Robinson D, Mosquera M, Solomon DA, Montgomery MW, Price CD, Johnson JA, Martin B, Liebschutz JW, Schnipper JL, Weiss RD. Impact of Medications for Opioid Use Disorder on Discharge Against Medical Advice Among People Who Inject Drugs Hospitalized for Infective Endocarditis. Am J Addict, 2020 Jan 12. doi: 10.1111/ajad.13000.

Fitzmaurice GM, Lipsitz SR, Weiss RD. (2020). Within-treatment frequency of use versus abstinence as a predictor of longitudinal post-treatment follow-up assessments of drug use. Drug Alcohol Depend, 208; 107857. doi: 10.1016/j.drugalcdep.2020.107857.

McHugh RK, Janes AC, Griffin ML, Taghian N, Greenfield SF, Weiss RD. (2020). Clinical correlates of smoking status in men and women with opioid use disorder. Subst Use Misuse, 55(7), 1054-1058. doi:10.1080/10826084.2020.1725056

McHugh RK, Votaw VR, Taghian NR, Griffin ML, Weiss RD. (2020). Benzodiazepine misuse in adults with alcohol use disorder: Prevalence, motives and patterns of use. J Subst Abuse Treatment, 117; 108061. https://doi.org/10.1016/j.jsat.2020.108061

Weiss RD. (2020). Establishing the First Annual Meetings of the American Academy of Addiction Psychiatry. Am J Addict, 29(5); 373-374. https://doi.org/10.1111/ajad.13016

Loflin MJE, Kiluk BD, Huestis MA, Aklin WM, Budney AJ, Carroll KM, D’Souza DC, Dworkin RH, Gray KM, Hasin DS, Lee DC, Foll BL, Levin FR, Lile JA, Mason BJ, McRae-Clark AL, Montoya I, Peters EN, Ramey T, Turk DC, Vandrey R, Weiss RD, Strain EC. (2020). The State of Clinical Outcome Assessments for Cannabis Use Disorder Clinical Trials: A Review and Research Agenda. Drug Alcohol Depend, 212; 107993. https://doi.org/10.1016/j.drugalcdep.2020.107993

Votaw VR, Witkiewitz K, Vowles KE, Weiss RD, Griffin ML, McHugh RK. (2020). Pain interference and catastrophizing are not associated with polysubstance use among treatment-seeking patients with substance use disorders and chronic pain. Am J Drug Alcohol Abuse, 46(5); 604-612. doi: 10.1080/00952990.2020.1757687

King CD, Hilton BT, Greenfield SF, McHugh RK, Griffin ML, Weiss RD, Ressler KJ. (2020). Anxiety Sensitivity and Grit as Mediators between Childhood Abuse and Relapse Risk for Substance Use. Child Abuse Negl, 107; 104568. https://doi.org/10.1016/j.chiabu.2020.104568

Peckham AD, Griffin ML, McHugh RK, Weiss RD. (2020). Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder. Drug Alcohol Depend, 213; 108122. doi: 10.1016

Suzuki J, Weiss RD. (2020). Cannabinoids for the treatment of opioid use disorder: Where is the evidence? J Addict Med, 15(2); 91-92. doi: 10.1097/ADM.0000000000000711

McHugh RK, Geyer RB, Chase AR, Griffin ML, Bogunovic O, Weiss RD. (2021). Sex differences in benzodiazepine misuse among adults with substance use disorders. Addict Behaviors, 112; 106608.

https://doi.org/10.1016/j.addbeh.2020.106608

McHugh RK, Trinh CD, Griffin ML, Weiss RD. (2021). Validation of the Craving Scale in a large sample of adults with substance use disorders. Addict Behav, 113; 106651. https://doi.org/10.1016/j.addbeh.2020.106651

Taghian NR, McHugh RK, Griffin ML, Chase AR, Greenfield SF, Weiss RD. (2021). Associations between childhood abuse and chronic pain in adults with substance use disorders. Substance Use and Misuse, 56(1); 87-92.

https://doi.org/10.1080/10826084.2020.1840590

Kimmel SD, Walley AY, Yijing L, Linas BP, Lodi S, Bernson D, Weiss RD, Samet JH, Larochelle MR. (2020). Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use–Associated Infective Endocarditis. JAMA Network Open, 3(10): e2016228. doi:10.1001

Becker WC, Krebs EE, Edmond SN, Lin LA, Sullivan MD, Weiss RD, Gordon AJ. (2020). A Research Agenda for Advancing Strategies to Improve Opioid Safety: Findings from a VHA State of the Art Conference. J Gen Intern Med, 35(S3); 978-982. doi: 10.1007/s11606-018-4345-6.

Kneeland ET, Peckham AD, McHugh RK, Weiss RD, Beard C, Björgvinsson T. (2020). Tobacco Use Predicts Treatment Dropout and Outcome in an Acute, Transdiagnostic Psychiatric Treatment Setting. Behavior Therapy, 52(4); 897-906. https://doi.org/10.1016/j.beth.2020.11.002

Shulman M, Weiss R, Rotrosen J; Novo P, Costello E, Nunes EV. (2021). Prior National Drug Abuse Treatment Clinical Trials Network (CTN) Opioid Use Disorder Trials as Background and Rationale for NIDA CTN-0100 “Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)”. Addict Sci Clin Pract, 16(1):15. doi: 10.1186/s13722-021-00223-z. PMID: 33676577

Strain EC, Kampman KM, Weiss RD. (2021). The Treatment of Opioid Use Disorder: Moving Beyond Medications that Act at the Mu Receptor. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2021.0259

Hilton BT, Yusufov M, Rosellini AJ, Taghian NR, Weiss RD, Griffin ML, McHugh RK. (2021). Psychometric Properties of the Anxiety Sensitivity Index-3 in Adults with Substance Use Disorders. Journal of Substance Abuse Treatment. 2022 Jan;132:108507. doi: https://doi.org/10.1016/j.jsat.2021.108507. PMID: 34214925.

Sugarman DE, Busch AB, McHugh, KR, Bogunovic, OJ, Trinh, CD, Weiss, RD, Greenfield, SF. (2021). Patients’ Perceptions of Telehealth Services for Outpatient Treatment of Substance Use Disorders During the COVID-19 Pandemic. The American Journal on Addictions. https://doi.org/10.1111/ajad.13207

McHugh RK, Hilton BT, Chase AM, Griffin ML, Weiss RD. Do people with opioid use disorder and posttraumatic stress disorder benefit from adding individual opioid drug counseling to buprenorphine? Drug Alcohol Depend. 2021 Nov 1;228:109084. doi: 10.1016/j.drugalcdep.2021.109084. Epub 2021 Sep 20. PMID: 34607194; PMCID: PMC8595708.

Copersino ML, Slayter E, McHugh RK, Shedlack KJ, Lukas SE, Ressler KJ, Weiss RD. (2021). Clinical utility of a hybrid secondary and relapse prevention program in adults with mild intellectual disability or borderline intellectual functioning in community residential and day habilitation settings. Disability and Health Journal. 2022 Jun;15(2S):101293. doi: https://doi.org/10.1016/j.dhjo.2022.101293. PMID: 35337784.

Weiner SG, Ibrahimi SE, Hendricks MA, Hallvik SE, Hildebran C, Fischer MA, Weiss RD, Boyer EW, Kreiner P, Wright DA, Flores D, Ritter GA. (2021). Factors related to opioid overdose following an initial opioid prescription. JAMA Netw Open. 2022 Jan 4;5(1):e2145691. doi: 10.1001/jamanetworkopen.2021.45691. PMID: 35089351; PMCID: PMC8800077.
McHugh RK, Chase A, Trinh CD, Weiss RD. Are pain and negative affect coping distinct motives for opioid misuse? Subst Use Misuse. 2022 Mar 8;57(6):848-852. doi: https://doi.org/10.1080/10826084.2022.2046094. PMID: 35258408; PMCID: PMC9069863.

Kleinman RA, Weiss RD. Benzodiazepine-involved overdose deaths in the USA: 2000-2019. Journal of General Internal Medicine. 2022 Jun;37(8):2103-2109. doi: https://doi.org/10.1007/s11606-021-07035-6. PMID: 35415793; PMCID: PMC9198172.

Karnik NS, McCluskey C, Boley RA, Campbell CI, Curtis ME, Fiellin D, Ghitza U, Hefner K, Hser Y, McHugh RK, Murphy SM, McPherson SM, Moran L, Mooney LJ, Wu L, Shmueli-Blumberg D, Shulman M, Schwartz RP, Stephens KA, Watkins KE, Weiss RD, Marsden J. Final report on the development of an Opioid Use Disorder Core Outcomes Set (OUD-COS) for the US National Drug Abuse Treatment Clinical Trials Network. Addiction. 2022 Sep;117(9):2438-2447. doi: 10.1111/add.15875. Epub 2022 Apr 25.PMID: 35293064

Connery HS, Weiss RD, Griffin ML, Trinh CD, Kim J, Rocket IRH, McHugh RK. Suicidal Motivations Among Opioid Overdose Survivors: Replication and Extension. Drug Alcohol Depend. 2022 Jun 1;235:109437. doi: https://doi.org/10.1016/j.drugalcdep.2022.109437. PMID: 35427980; PMCID: PMC9106902.

Weiner SG, Hendricks MA, El Ibrahimi S, Ritter GA, Hallvik SE, Hildebran C, Weiss RD, Boyer EW, Flores D, Nelson LS, Kreiner PW, Fischer MA. Opioid-Related Overdose and Chronic Use Following an Initial Prescription of Oxycodone vs. Hydrocodone. PLoS ONE 17(4): e0266561. https://

doi.org/10.1371/journal.pone.0266561

Kleinman RA, Nielsen S, Weiss RD. Is daily supervised buprenorphine-naloxone dosing necessary? BMJ. 2022 Aug 16;378:e071467. doi: 10.1136/bmj-2022-071467

Suzuki J, Martin B, Prostko S, Chai PR, Weiss RD. Cannabidiol effect on cue-induced craving for individuals with opioid use disorder treated with buprenorphine: A small, proof-of-concept, open-label study. Integrative Medicine Reports. In Press.

Provost SE, Griffin ML, Hilton BT, McHugh RK, Taghian NR, Trinh CD, Weiss RD. Correlates of Optimism among Patients in Substance Use Inpatient Treatment. Am J Addict 2022 Nov;31(6):494-501.

doi: 10.1111/ajad.13324. Epub 2022 Aug 16.

McCarthy JM, Wood AJ, Shinners MG, Heinrich H, Weiss RD, Mueser KT, Meyers RJ, Carol EE, Hudson JI, Ongur D. Pilot Development and Feasibility of Telehealth Community Reinforcement and Family Training (CRAFT) for Early Psychosis and Substance Use. Psychiatry Research, 312, 114804. DOI:10.1016/j.psychres.2022.114804

Kiluk BD, Kleykamp BA, Comer SD, Griffiths R, Huhn AS, Johnson MW, Kampman KM, Paretoni M, Preston KL, Vandrey R, Bergeria CL, Bogenschutz MP, Brown RT, Dunn KE, Dworkin RH, Finan P, Hendricks PS, Houtsmuller EJ, Kosten TR, Lee DC, Levin FR, McRae-Clark A, Raison CL, Rasmussen K, Turk D, Weiss RD, Strain EC. Clinical trial challenges and opportunities for emerging treatments for opioid use disorder: a review. JAMA Psychiatry. 2023 Jan 1;80(1):84-92. doi: 10.1001/jamapsychiatry.2022.4020.PMID: 36449315

Pan Y, Feaster DJ, Odom G, Brandt L, Hu M-C, Weiss RD, Rotrosen J, Saxon AJ, Luo SX, Balise RR,

Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment.

DAD Reports. https://doi.org/10.1016/j.dadr.2022.100128

Schuman-Olivier Z, Fatkin T, Creedon TB, Samawi F, Moore SK, Okst K, Fredericksen AK, Oxnard AS, Roll D, Smith L, Lê Cook B, Weiss RD. Effects of a trauma-informed mindful recovery program on co-morbid pain, anxiety, and substance use during primary care buprenorphine treatment: a proof-of-concept study. Am J Addictions. DOI: 10.1111/ajad.13364

Hendricks MA, El Ibrahimi, S, Ritter, GA, Flores D, Fischer MA, Weiss RD, Wright DA, Weiner SG. The Role of Household Opioid Availability in Subsequent Opioid Overdose. JAMA Netw Open. 2023 Mar 1;6(3):e233385. doi: 10.1001/jamanetworkopen.2023.3385. PMID: 36930154

Trinh, C.D., Griffin, M.L., Li, V., McHugh, R.K., Weiss, R.D. (2023). Assessment of the Short Grit Scale in patients with substance use disorder: Psychometric properties and patient characteristics. Am J Drug Alcohol Abuse. 2023 Mar 27:1-7. doi: 10.1080/00952990.2023.2181702. Online ahead of print. PMID: 36972561

Suzuki J, Martin B, Loguidice F, Smelson D, Liebschutz JM, Schnipper JL, Weiss RD. A Peer Recovery Coach Intervention for Hospitalized Patients with Opioid Use Disorder: A Pilot Randomized Controlled Trial.

J Addict Med. 2023 Sep-Oct 01;17(5):604-607. doi: 10.1097/ADM.0000000000001162. Epub 2023 Mar 31.PMID: 37788617

Suzuki J, Prostko S, Szpak V, Chai P, Spagnolo PA, Tenenbaum RE, Ahmed S, Weiss RD. Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial. Front Psychiatry. 2023 Mar 30;14:1155984. doi: 10.3389/fpsyt.2023.1155984. eCollection 2023.PMID: 37065899

Thakrar AP, Pytell JD, Stoller KB, Walters V, Weiss RD, Chander G. Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder. J Subst Use Addict Treat. 2023 Jul;150:209055. doi: 10.1016/j.josat.2023.209055. Epub 2023 Apr 23.PMID: 37088398

Ren B, Lipsitz SR, Fitzmaurice GM, Weiss RD: Permutation tests for assessing potential non-linear associations between treatment use and multivariate clinical outcomes. Multivariate Behav Res. 2023 Jun 28:1-13. doi: 10.1080/00273171.2023.2217662. Online ahead of print.PMID: 37379399

Levy S, Brogna M, Minegishi M, Subramaniam G, McCormack J, Kline M^, Menzin E, Allende-Richter S, Fuller A, Lewis M, Collins J, Hubbard Z, Mitchell SG, Weiss R, Weitzman E. Assessment of screening tools for identifying substance use disorders in adolescents: Results of the Adolescent Screening to Help Eliminate Misuse trial. JAMA Network Open. 2023;6(5):e2314422. doi:10.1001/jamanetworkopen.2023.14422

Ren B, Lipsitz SR, Weiss, RD, Fitzmaurice GM: Multiple Imputation for Non-Monotone Missing Not at Random Data using the No Self-Censoring Model. Stat Methods Med Res. 2023 Oct;32(10):1973-1993. doi: 10.1177/09622802231188520. Epub 2023 Aug 30.PMID: 37647237

Ren B, Lipsitz SR, Weiss RD, Fitzmaurice GM: Methods for handling missing binary data in substance use disorder trials. Drug Alcohol Depend, https://doi.org/10.1016/j.drugalcdep.2023.110897

Castillo F, Hu MC, Liu Y, Balise RR, Weiss RD, Rotrosen J, Nunes EV, Saxon AJ, Feaster DJ, Luo SX. Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: Role of non-opioid substances. Drug Alcohol Depend. 2023 Aug 9;251:110926. doi:10.1016/j.drugalcdep.2023.110926. Online ahead of print. PMID: 37604012

Levy S, Minegishi M, Brogna M, Subramaniam G, McCormack J, Weiss R, Weitzman ER. Comparing the Performance of World Mental Health Composite International Diagnostic Interview Substance Abuse Module in Adolescents to Diagnoses Made by Pediatric Addiction Medicine Specialists. J Addict Med. 2024 Mar-Apr 01;18(2):205-208. doi: 10.1097/ADM.0000000000001271. Epub 2024 Jan 30. PMID: 38289239.

Luo SX, Feaster DJ, Liu Y, Balise RR, Hu M, Bouzoubaa L, Odom GJ, Brandt L, Pan Y, Hser Y, VanVeldhuisen P, Castillo F, Calderon AR, Rotrosen J, Saxon AJ, Weiss RD, Wall M, Nunes EV.

Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry. Published online October 04, 2023. doi:10.1001/jamapsychiatry.2023.3596

McHugh RK, Fitzmaurice GM, Votaw VR, Geyer RB, Ragnini K, Greenfield SF, Weiss RD. Cognitive behavioral therapy for anxiety and opioid use disorder: Development and pilot testing. J Subst Use and Addict Treat. In Press.

McHugh RK, Korte FM, Bichon JA, Weiss RD. Gender differences in the prevalence of stimulant misuse in the United States: 2015-2019. Am J Addict. 2023 Nov 4. doi: 10.1111/ajad.13501. Epub ahead of print. PMID: 37924248.

Rosansky JA, Howard L, Goodman H, Okst K, Fatkin T, Fredericksen AK, Sokol R, Gardiner P, Parry G, Cook BL, Weiss RD, Schuman-Olivier ZD. Effects of live-online, group mindfulness training on opioid use and anxiety during buprenorphine treatment: A comparative effectiveness RCT. Contemp Clin Trials. 2024 Feb;137:107417. doi: 10.1016/j.cct.2023.107417. Epub 2023 Dec 20. PMID: 38135210.

McHugh RK, Bailey AJ, Weiss RD, Fitzmaurice GM. Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder. Drug Alc Depend Rep. In Press.

Glasgow L, Douglas C, Sprunger J, Campbell ANC, Chandler R, Dasgupta A, Holloway J, Marks KR, Roberts S, Martinez LS, Thompson K, Weiss R, Aldridge A, Asman K, Barbosa C, Blevins D, Chassler D, Cogan L, Fanucchi L, Hall M, Hunt T, Jadovich E, Levin FR, Lincourt P, Lofwall M, Loukas V, McAlearney AS, Nunes E, Oga E, Oller D, Rudorf M, Sullivan AM, Talbert J, Taylor A, Teater J, Vandergrift n, Woodlock K, Zarkin G, Freisthler B, Samet J, Walsh SL, El-Bassel N. Effect of the Communities That HEAL intervention on receipt of behavioral therapies for opioid use disorder: A cluster randomized wait-list controlled trial. Drug Alcohol Depend., in press.

Szpak V, Prostko S, Weiss RD, Suzuki J: Developing a remotely delivered intensive outpatient program adapted for hospitalized patients with opioid use disorder: A qualitative study. Addictive Behaviors Reports 19, June 2024, 100546. https://doi.org/10.1016/j.abrep.2024.100546.

Dagnew TM, Tseng C-E J, Yoo C-H, Makary MM, Goodheart AE, Striar R, Meyer TN, RattrayAK, Kang L, Wolf KA,. Fiedler SA, Tocci D, Shapiro H, Provost S, Sultana E, Liu Y, Ding Y, Chen P, Kubicki M, Shen S, Catana C, Zürcher NR, Wey H-Y1, Hooker JM, Weiss RD, Wang C: Towards AI-driven neuroepigenetic imaging biomarker for Alcohol Use Disorder: A Proof-of-Concept Study. I-Science, in press.

Ahmad, NJ, Shapiro H, Griffin ML, Weiss RD, Macias-Konstantopoulos WL. Racial and Ethnic Differences in Self-Reported Barriers to Substance Use Treatment Among Emergency Department Patients. Am J Addictions, https://doi.org/10.1111/ajad.13631

HEALing Communities Study Consortium; Samet JH, El-Bassel N, Winhusen TJ, Jackson RD, Oga EA, Chandler RK, Villani J, Freisthler B, Adams J, Aldridge A, Angerame A, Babineau DC, Bagley SM, Baker TJ, Balvanz P, Barbosa C, Barocas J, Battaglia TA, Beard DD, Beers D, Blevins D, Bove N, Bridden C, Brown JL, Bush HM, Bush JL, Caldwell R, Calver K, Calvert D, Campbell ANC, Carpenter J, Caspar R, Chassler D, Chaya J, Cheng DM, Cunningham CO, Dasgupta A, David JL, Davis A, Dean T, Drainoni ML, Eggleston B, Fanucchi LC, Feaster DJ, Fernandez S, Figueroa W, Freedman DA, Freeman PR, Freiermuth CE, Friedlander E, Gelberg KH, Gibson EB, Gilbert L, Glasgow L, Goddard-Eckrich DA, Gomori S, Gruss DE, Gulley J, Gutnick D, Hall ME, Harger Dykes N, Hargrove SL, Harlow K, Harris A, Harris D, Helme DW, Holloway J, Hotchkiss J, Huang T, Huerta TR, Hunt T, Hyder A, Ingram VL, Ingram T, Kauffman E, Kimball JL, Kinnard EN, Knott C, Knudsen HK, Konstan MW, Kosakowski S, Larochelle MR, Leaver HM, LeBaron PA, Lefebvre RC, Levin FR, Lewis N, Lewis N, Lofwall MR, Lounsbury DW, Luster JE, Lyons MS, Mack A, Marks KR, Marquesano S, Mauk R, McAlearney AS, McConnell K, McGladrey ML, McMullan J, Miles J, Munoz Lopez R, Nelson A, Neufeld JL, Newman L, Nguyen TQ, Nunes EV, Oller DA, Oser CB, Oyler DR, Pagnano S, Parran TV, Powell J, Powers K, Ralston W 3rd, Ramsey K, Rapkin BD, Reynolds JG, Roberts MF, Robertson W, Rock P, Rodgers E, Rodriguez S, Rudorf M, Ryan S, Salsberry P, Salvage M, Sabounchi N, Saucier M, Savitzky C, Schackman B, Schady E, Seiber EE, Shadwick A, Shoben A, Slater MD, Slavova S, Speer D, Sprunger J, Starbird LE, Staton M, Stein MD, Stevens-Watkins DJ, Stopka TJ, Sullivan A, Surratt HL, Sword Cruz R, Talbert JC, Taylor JL, Thompson KL, Vandergrift N, Vickers-Smith RA, Vietze DJ, Walker DM, Walley AY, Walters ST, Weiss R, Westgate PM, Wu E, Young AM, Zarkin GA, Walsh SL. Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths. N Engl J Med. 2024 Jun 16. doi: 10.1056/NEJMoa2401177. Epub ahead of print. PMID: 38884347.

Reviews, Chapters, and Editorials:

Reviews

Weiss RD. Effects of opiates on orgasm. Medical Aspects of Human Sexuality 1982; p. 16: 29.

Mirin SM, Weiss RD. Psychopathology in substance abusers. Medical Aspects of Human Sexuality 1984;18: 72‑6.

Weiss RD, Mirin SM. Subtypes of cocaine abusers. Psychiatr Clin North Am 1986;9: 491‑501.

Mirin SM, Weiss RD, Michael J. Affective illness in substance abusers. Psychiatr Clin North America 1986;9: 503‑514.

Weiss RD. The physician cocaine abuser. Medical Aspects of Human Sexuality 1987;21: 9, 67‑73.

Weiss RD. The Psychiatric Times 1987;4: 7, 2‑4.

Weiss RD. Alcohol and aggression. (Brain PF, ed.). Soc Sci Med 1987;24: 702. (Book Review).

Mirin SM, Weiss RD, Michael J, Griffin ML. Psychopathology in substance abusers and their families. Resident Staff Physician 1988;34(13): 61‑65.

Weiss RD. Cocaine abuse: New directions in treatment and research. (Spitz HI, Rosecan JS, eds.). NY State J Med 1988;88: 211. (Book Review).

Weiss RD, Mirin SM. The use of tricyclic antidepressants in the treatment of patients with alcoholism and drug abuse. J Clin Psychiatry 1989;50 Supple: 7: 4‑9.

Weiss RD. Psychiatric knowledge and addiction research integration necessary in dual‑diagnosis cases. The Psychiatric Times 1990;11: 11, 11‑14.

Weiss RD. Addiction and the vulnerable self: Modified dynamic group therapy for substance abusers. (Khantzian EJ, Halliday K, McAuliffe W, eds.). American Journal on Addictions 1992;1: 1, 89‑90. (Book Review).

Greenfield SF, Weiss RD, Mirin SM. Cocaine: A clinical update. Resident & Staff Physician 1994;40: 21‑24.

Weiss RD. Personality parallels. Professional Counselor 1996;2: 15-41.

Weiss RD. Manual of Therapeutics for Addictions (Miller NS, Gold MS, Smith DE, eds.). Psychiatric Times 1998 15: 4,6. (Book Review).

Kolodziej ME, Weiss RD. Comorbid alcohol dependence and depression. Current Opinion in Psychiatry 2000;13(1): 87-91.

O’Leary G, Weiss RD. Comparison of cocaine and methamphetamine smoking. In: Carson-DeWitt R, Carroll KM, Fagan J, Kranzler HR, Kuhar MJ, eds. Encyclopedia of Drugs, Alcohol, and Addictive Behavior, revised edition. Macmillan Reference USA 2000;2: 508-513.

O’Leary G, Weiss RD. Pharmacotherapies for cocaine dependence. Current Psychiatry Reports 2000: 2: 508-5.

O’Leary G, Nargiso J, Weiss RD. 3,4-methylenedioxymethamphetamine (MDMA): A review.

Current Psychiatry Reports 2001: 3: 477-483.

O’Leary G, Borrow J, Weiss RD. Opioid antagonists in the treatment of alcohol dependence.

Current Psychiatry Reports 2001: 3: 484-488.

Weiss RD, Cogley C. Pharmacotherapy of alcohol dependence. Current Psychiatry Reports

2002: 1: 51-60.

Kolodziej ME, Greenfield SF, Weiss RD. Outcome measurement in substance use disorders. In:

IsHak WW, Burt T, Sederer LI, eds. Outcome Measurement in Psychiatry: A Critical Review.

Washington DC: American Psychiatric Publishing Inc. 2002: pp 207-220.

Weiss RD, Potter JS. Acamprosate in the treatment of alcohol dependence. American Academy of Addiction

Psychiatry News Insert, Summer 2002.

Manwani SG, Weiss RD. 5 keys to improve counseling for dual diagnosis patients. Current Psychiatry Reports

2003: 2: 41-50.

O’Leary Hennessy G, DeMenil V, Weiss RD. Psychosocial treatments for cocaine dependence. Current

Psychiatry Reports 2003;5: 362-364.

Connery HS, Weiss RD. For discomfort of early alcohol abstinence. Current Psychiatry Reports

2005;4: 90-96.

Levy B, Weiss RD. Cognitive functioning in bipolar and co-occurring substance use disorders: a missing piece

of the puzzle. Harv Rev Psychiatry. 2009 ;17: 226-30. Review. PMCID: PMC3150554.

Weiss RD. Identifying and diagnosing co-occurring disorders. CNS Spectr 2008;13: 4-6.

Paul D, Sullivan MA, Weiss RD. Response: Providing relief, avoiding euphoria. Addiction Science & Clinical

Practice, June 2008.

Weiss RD. Handbook of motivation and change: a practical guide for clinicians. Am J Psychiatry

2011;168: 215.

Chapters

Mirin SM, Weiss RD. Substance abuse. In: Bassuk E, Schoonover S, Gelenberg A, eds. The practitioner’s

guide to psychoactive drugs, 2nd edition. New York: Plenum Press; 1983. p. 221‑91.

Frosch JP, Gunderson JG, Weiss RD, Frank A. Therapists who treat schizophrenic patients:

In: Stierlin H, Wynne LC, Wirsching M, eds. Psychosocial intervention in schizophrenia: An international view. Berlin: Springer‑Verlag; 1983. p. 169‑76.

Weiss RD, Mirin SM. Drug abuse emergencies: Intoxication and withdrawal syndromes. In: Hyman SE, A Manual of psychiatric emergencies. Boston: Little Brown; 1984. p. 217‑27.

Mirin SM, Weiss RD. Drug use and abuse. In: Bassuk EL, Birk AW, eds. Emergency psychiatry: Concepts, methods and practices. New York: Plenum Press; 1984. p. 141‑79.

Weiss RD, Mirin SM. Drug, host and environmental factors in the development of chronic cocaine abuse.

In: Mirin SM, ed. Substance abuse and psychopathology. Washington, DC: American Psychiatric Press; 1984. p. 41‑55.

Mirin SM, Weiss RD, Sollogub A, Michael JL. Affective illness in substance abusers. In: Mirin SM, ed. Substance abuse and psychopathology. Washington, DC: American Psychiatric Press; 1984. p. 57‑77.

Mirin SM, Weiss RD, Sollogub A, Michael JL. Psychopathology in the families of drug abusers. In:

Mirin SM, ed. Substance abuse and psychopathology. Washington, DC: American Psychiatric Press; 1984. p.79‑106.

Mirin SM, Weiss RD, Michael JL. Family pedigree of psychopathology in substance abusers. In: Meyer R, ed. Psychopathology and addictive disorders. New York: Guilford Press; 1986. p. 57‑77.

McAuliffe WE, Feldman B, Friedman R, Launer E, Magnuson E, Mahoney C, Santangelo S, Ward W, Weiss R. Explaining relapse to opiate addiction following successful completion of treatment. In:

Tims FM, Leukefeld CG, eds. Relapse and recovery in drug abuse. Rockville, MD: National Institute on

Drug Abuse Research Monograph 72; 1986. p. 136‑56.

Weiss RD. In: Adelman G, ed. Encyclopedia of Neuroscience. Cambridge, MA: Birkhauser Boston; 1987. p. 253‑54.

Weiss RD, Mirin SM. Drug abuse emergencies: Intoxication and withdrawal syndromes. In: Hyman SE, ed. A manual of psychiatric emergencies, 2nd edition. Boston: Little Brown; 1988. p. 233-44.

Mendelson JH, Teoh SK, Lange U, Mello NK, Weiss RD, Skupny A. Hyperprolactinemia during cocaine

withdrawal. In: Problems of drug dependence, 1987, Proceedings of the 49th Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc. Rockville, MD: National Institute on Drug Abuse Research Monograph 81; 1988. p. 67‑73.

Adelman S, Weiss RD. Psychoactive substance use disorders: In: Lazare A, ed. Outpatient

psychiatry, 2^nd Edition. New York: Williams & Wilkins; 1989. p. 471‑87.

Weiss RD, Mirin SM. In: Hyman SE, Jenike MA, eds. Manual of clinical problems in

psychiatry. Boston: Little Brown; 1990. p. 163‑69.

Weiss RD, Mirin SM. Drug abuse. In: Hyman SE, Jenike MA, eds. Manual of clinical problems in

psychiatry. Boston: Little Brown; 1990. p. 169‑74.

Amass L, Lukas SE, Weiss RD, Mendelson JH. Evaluation of cognitive skills in ethanol‑ and

cocaine‑dependent patients during detoxification using P300 Evoked Response Potentials (ERPs). In: Harris LS, ed. Problems of drug dependence, 1989, Committee on Problems of Drug Dependence, Inc. Rockville, MD: National Institute on Drug Abuse Research Monograph 95; 1990. p. 353‑54.

McElroy SL, Weiss RD, Mendelson JH, Teoh SK, McAfee B, Mello NK. Desipramine treatment for relapse

prevention in cocaine dependence. In: Harris LS, ed. Problems of drug dependence, 1989, Committee on Problems of Drug Dependence, Inc. Rockville, MD: National Institute on Drug Abuse Research Monograph 95; 1990. p. 57‑63.

Mendelson JH, Weiss R, Griffin M, Mirin SM, Teoh SK, Mello NK, Lex BW. Some special considerations

for treatment of drug abuse and dependence in women. In: Improving drug abuse treatment, 1989.

National Institute on Drug Abuse Research Monograph 95, Rockville, MD; 1990. p. 57‑63.

Mirin SM, Weiss RD, Greenfield S. Psychoactive substance use disorders. In: Gelenberg A, Bassuk E, Schoonover S, eds. The practitioner’s guide to psychoactive drugs, 3^rd New York: Plenum Press; 1991. p. 243‑316.

Mirin SM, Weiss RD. Psychiatric comorbidity in drug and alcohol addiction. In: Miller N, ed. Comprehensive handbook of drug and alcohol addiction. New York: Marcel Dekker, Inc.; 1991. p. 641‑61.

Adelman SA, Weiss RD. Psychoactive substance use disorders. In: Sederer LI, ed. Inpatient psychiatry: Diagnosis and treatment, 3^rd Baltimore: Williams & Wilkins; 1991. p. 167‑88.

Mirin SM, Weiss RD. Substance abuse and mental illness. In: Frances RJ, Miller SI, eds. Clinical textbook

of addictive disorders. New York: Guilford Press; 1991. p. 271‑98.

Mendelson JH, Weiss RD, Griffin M, Mirin SM, Teoh SK, Mello NK, Lex BW. Some special considerations

for treatment of drug abuse and dependence in women. Rockville, MD: National Institute on Drug Abuse Research Monograph 106; 1991. p. 313‑27.

Weiss RD. The role of psychopathology in the transition from drug use to abuse and dependence. In: Glantz M, Pickens R, eds. Vulnerability to drug abuse. Washington, DC: American Psychological Association; 1992. p. 137‑48.

Weiss RD, Stephens PS. Substance abuse and suicide. In: Jacobs D, ed. Suicide and clinical practice: Multiple perspectives. Washington, DC: American Psychiatric Press; 1992. p. 101‑14.

Weiss RD, Greenfield SF, Mirin S. Intoxication and withdrawal syndromes. In: Hyman SE, Tesar GE, eds. Manual of psychiatric emergencies, 3rd edition. Boston: Little Brown; 1994. p. 279‑93.

Weiss RD. Inpatient treatment: Alcohol and drug abuse. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment. Washington, DC: American Psychiatric Press; p. 359-68.

Weiss RD, Wong EJ. Mood disorders and substance use. In: Lehman AF, Dixon LB, eds. Double jeopardy. Chronic mental illness and substance use disorders. London: Harwood Academic Publishers; 1995.
109-22.

Weiss RD, Greenfield SF, Najavits LM. Integrating psychological and pharmacological treatment of dually diagnosed patients. In: Onken LS, Blaine JD, Boren JJ, eds. Integrating behavioral therapies with medications in the treatment of drug dependence. Washington, DC: National Institute on Drug Abuse Research Monograph 150; 1995. p. 110-28.

Cohen ST, Weiss RD. Substance abuse and mental illness. In: Friedman LS, Fleming NF, Roberts DH, Hyman SE, eds. Source book of substance abuse and addiction. Baltimore, MD: Williams & Wilkins; p. 289-99.

Weiss RD. Inpatient treatment of substance use disorders. In: Gabbard GO, Atkinson SD, eds. Synopsis of treatments of psychiatric disorders: 2^nd Edition, Washington, DC: American Psychiatric Press; p. 378-81.

Zornberg GL, Weiss RD. Substance-related disorders. In: Sederer LI, Rothschild AJ, eds. Acute care psychiatry: Diagnosis and treatment. Baltimore, MD: Williams & Wilkins; 1997. p. 221-48.

Weiss RD. In: Adelman G, Smith BH, eds. Encyclopedia of Neuroscience, 2nd Edition. Amsterdam: Elsevier Science; 1997. p. 413-14.

Greenfield SF, Weiss RD, Mirin SM. Psychoactive substance use disorders. In: Gelenberg AJ, Bassuk EL, The practitioner’s guide to psychoactive drugs, 4th Edition. New York: Plenum Medical Book Company; 1997. p. 291-363.

Weiss RD, Najavits LM. Overview of treatment modalities for dual diagnosis patients: Pharmacotherapy, psychotherapy, and 12-step programs. In: Kranzler HR, Rounsaville BJ, eds. Dual diagnosis and treatment: Substance abuse and comorbid medical and psychiatric disorders. New York: Marcel Dekker, ; 1998. p. 87-105.

Weiss RD, Najavits LM, Mirin SM. Substance abuse and psychiatric disorders. In: Frances RJ, Miller SI, Clinical textbook of addictive disorders, 2^nd Edition. New York: Guilford Press, Inc.; 1998.
291-318.

Weiss RD, Hufford MR. Substance abuse and suicide. In: Jacobs D, ed. Harvard Medical School guide to assessment and intervention in suicide. New York: Simon & Schuster; 1999. p. 300-10.

Weiss RD. Inpatient treatment. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment, 2^nd Washington, DC: American Psychiatric Press; 1999.
413-22.

Weiss RD. Inpatient treatment of substance use disorders. In: Gabbard GO, ed. Treatments of psychiatric

disorders, 3^rd Edition. Washington, DC: American Psychiatric Press, 2001, pages 941-950.

Pillay S, Weiss RD. Drug abuse. In: Rakel RE, Bope ET, eds. Conn’s current therapy, 53^rd (2001) edition.

Philadelphia, PA: W. B. Saunders Co.; 2001. p. 1133-1137.

Weiss RD, Greenfield SF, O’Leary G. Relapse prevention for patients with bipolar and substance use

disorders. In: Graham HL, Copello A, Birchwood MJ, Mueser KT, eds. Substance Misuse in Psychosis:

Approaches to Treatment and Service Delivery. West Sussex, England: John Wiley & Sons, Ltd., 2003,

207-226.

Weiss RD. Pharmacotherapy of coexisting mood and substance use disorders. In: Westermeyer JJ,

Weiss RD, Ziedonis DM, eds. Integrated Treatment for Mood and Substance Use Disorders. Baltimore:

The Johns Hopkins University Press, 2003, p. 122-139.

Pettinati HM, Weiss RD, Madaras J. Models for integrating psychotherapeutic and pharmacological

interventions in the treatment of alcohol dependence. In: Johnson BA, Ruiz P, Galanter M, eds. Handbook of

Clinical Alcoholism Treatment. New York: Lippincott Williams & Wilkins, 2003, p. 131-139.

Weiss RD, Potter JS. Inpatient treatment. In: Galanter M, Kleber HD, eds. The American Psychiatric Press

textbook of substance abuse treatment, 3^rd Edition. Washington, DC: American Psychiatric Press, 2004,

445-456.

Weiss RD, Najavits LM, Hennessy G. Overview of treatment modalities for dual diagnosis patients:

Pharmacotherapy, psychotherapy, and twelve-step programs. In: Kranzler HR, Tinsley J, eds. Dual diagnosis:

Substance abuse and comorbid disorders. 2nd Edition. New York: Marcel Dekker, Inc. 2004, p. 103-128.

Busch A, Weiss RD, Najavits LM. Co-occurring substance use disorders and other psychiatric disorders.

In: Frances RJ, Miller SI, Mack, eds. Clinical textbook of addictive disorders (3^rd ed.). New York: Guilford

Press 2005, p. 271-302.

Weiss RD, Potter JS, Iannucci R. Inpatient treatment. In: Galanter M, Kleber HD, eds. The American

Psychiatric Publishing Textbook of Substance Abuse Treatment, 4^th edition. Washington, DC: American

Psychiatric Press 2008, p. 445-458.

Weiss RD. In: Korsmeyer P, Kranzler HR, eds. Encyclopedia of Drugs, Alcohol and Addictive

Behavior (3^rd ed). Detroit: McMillan Reference USA 2009, p. 176-178.

Weiss RD, Iannucci RA. Cocaine-related disorders. In: Sadock BJ, Sadock VA, Ruiz P, eds. Comprehensive

Textbook of Psychiatry, 9^th edition. Philadelphia: Lippincott Williams & Wilkins 2009, p 1318-1331.

Jaffee WB, Weiss RD. Group Therapy. In: Korsmeyer P, Kranzler HR, eds. Encyclopedia of Drugs, Alcohol

and Addictive Behavior (3^rd ed). Detroit: McMillan Reference USA 2009, p. 164-166.

Daley DC, Douaihy A, Weiss RD, Mercer DE. Group therapies. In: Ries RK, Fiellin DA, Miller SC, Saitz R,

eds. Principles of Addiction Medicine, 4^th edition. Philadelphia: Lippincott Williams & Wilkins 2009,

757-767.

Nunes EV, Weiss RD. Co-Occurring addiction and affective disorders. In: Ries RK, Fiellin DA, Miller SC,

Saitz R, eds. Principles of Addiction Medicine, 4^th edition. Philadelphia: Lippincott Williams & Wilkins 2009,

1151-1181.

Benson TG, Bender RE, Muchowski PM, Weiss RD. Bipolar disorder in patients with substance use

disorders: Diagnosis and Treatment. In: Nunes EV, Selzer J, Levounis P, eds. Substance Dependence and Co-Occurring Psychiatric Disorders: Best Practices for Diagnosis and Treatment. Kingston, NJ, Civic Research Institute, Inc., 2010, pp. 2:2-2:27.

Hill KP, Weiss RD (2011): Amphetamines and other stimulants. In: Ruiz P and Strain E (eds): Lowinson and

Ruiz’s Substance Abuse: A Comprehensive Textbook, 5^th ed. Philadelphia: Lippincott Williams & Wilkins, 2011, pp.238-54.

Weiss RD: Drug Abuse and Dependence. In: Goldman L, Schafer AI, eds. Goldman’s Cecil Medicine, 24^th

Edition. Philadelphia: Saunders Elsevier, 2011, pp. 153-9.

Oetting AI, Levy JA, Weiss RD, Murphy SA. Statistical methodology for a SMART design in the development

of adaptive treatment strategies. In: Shrout PE, Keyes KM, Ornstein K, editors. Causality and Psychopathology: Finding the Determinants of Disorders and their Cures. New York: Oxford University Press, 2011, pp. 179-205.

Weiss RD. In: Adelman G, Smith BH, eds. Encyclopedia of Neuroscience, 3^rd Edition. Amsterdam: Elsevier Science, in press.

Weiss RD. Alcohol withdrawal. In: Barnhill JW, ed. DSM-5 Clinical Cases. Washington, DC: American Psychiatric Press, 2014.

Weiss RD, Dreifuss JA. Inpatient treatment. In: Galanter M, Kleber HD, Brady, KT, eds. The American

Psychiatric Publishing Textbook of Substance Abuse Treatment, 5^th edition. Washington, DC: American

Psychiatric Press 2015, p. 499-510.

Daley DC, Douaihy A, Weiss RD, Mercer DE. Group therapies. In: Ries RK, Fiellin DA, Miller SC,

Saitz R, eds. The ASAM Principles of Addiction Medicine, 5^th edition. Philadelphia: Wolters Kluwer, 2014,

845-857.

Nunes EV, Weiss RD. Co-Occurring addictive and mood disorders. In: Ries RK, Fiellin DA, Miller SC,

Saitz R, eds. The ASAM Principles of Addiction Medicine, 5^th edition. Philadelphia: Wolters Kluwer, 2014,

1300-1332.

McHugh RK, Park S, Weiss RD. Group therapy for substance use disorders. In: el-Guebaly N, Carra G, Galanter M, eds. Textbook of Addiction Treatment: International Perspectives. Milan: Springer-Verlag Italia, 2015, p. 873-888.

Silverman BC, Najavits LM, Weiss RD. Co-occurring substance use disorders and other psychiatric disorders.

In: Mack AH, Brady KT, Miller SI, Frances RJ, eds. Clinical textbook of addictive disorders (4^th ed.). New York: Guilford Press 2016, p. 292-326.

Weiss RD: Drugs of Abuse. In: Goldman L, Schafer AI, eds. Goldman’s Cecil Medicine, 25^th

Edition. Philadelphia: Saunders Elsevier, 2016, pp. 156-162.

Iannucci RA, Weiss RD. Stimulant -related disorders. In: Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, 10^th Philadelphia: Lippincott Williams & Wilkins 2017, pp. 1280-1291.

Iannucci RA, Weiss RD. Depressive and bipolar disorders. In: Avery JD, Barnhill JW, eds. Co-occurring Mental Illness and Substance Use Disorders. Arlington, VA: American Psychiatric Publishing, 2018, pp. 25-38.

Nunes EV, Weiss RD. Co-Occurring mood and substance use disorders. In: Miller SC, Fiellin DA, Rosenthal RN, Saitz R, eds. The ASAM Principles of Addiction Medicine, 6^th Philadelphia: Wolters Kluwer, 2019, p. 1360-1388.

Daley DC, Douaihy A, Weiss RD, Mercer DE. Group therapies. In: Ries RK, Fiellin DA, Miller SC,

Saitz R, eds. The ASAM Principles of Addiction Medicine, 6^th edition. Philadelphia: Wolters Kluwer, 2019,

902-913.

Weiss RD: Drugs of Abuse. In: Goldman L, Schafer AI, eds. Goldman’s Cecil Medicine, 26^th

Edition. Philadelphia: Saunders Elsevier, 2020. Pp.150-156.

McHugh RK, Kim J, Perrins SP, Weiss RD. Group therapy for substance use disorders. In: Textbook of Addiction Treatment: International Perspectives. Springer, 873-887.

Nunes EV, Hasin DS, Weiss R.D. Co-occurring Mood and Substance Use Disorders. In: el-Guebaly N, Carrà G, Galanter M, eds. Textbook of Addiction Treatment. Springer, Cham, 2021.

Connery HS, Albanese MJ, Devido JJ, Hill KP, McHugh RK, Sarvey D, Suzuki J, Weiss RD. Substance use disorders. In: Walker AM, Schlozman SC, Alpert JE, eds. Introduction to Psychiatry: Preclinical Foundations and Clinical Essentials. Cambridge University Press, Cambridge, UK, 2021.

Weiss RD. Alcohol withdrawal. In: Barnhill JW, ed. DSM-5-TR Clinical Cases. Washington, DC: American Psychiatric Press, 2023.

Weiss RD, Liebschutz JM: Drug use disorders. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine, 27^th Philadelphia: Saunders Elsevier, 2024. p. 2360-2365.

Daley DC, Douaihy A, Weiss RD. Group therapies. In: Miller SC, Rosenthal RN, Levy S, Saxon AJ,Tetrault JM, Wakeman SE, eds. The ASAM Principles of Addiction Medicine, 7^th Philadelphia: Wolters Kluwer, 2024, p. 1094-1106.

Editorials

Weiss RD: Contingency management for patients with serious mental illness and stimulant dependence . Am J Psychiatry. 2013 Jan;170(1):6-8. PMID: 23288383.

Weiss RD: Behavioural treatment combined with buprenorphine does not reduce opioid use compared with buprenorphine alone. Evid Based Ment Health. 2014 May; 17(2): e2. PMID: 24591547.

McHugh RK, Nielsen S, Weiss RD. Prescription drug abuse: from epidemiology to public policy. 2015 Jan; 48(1): 1-7. PMID: 25239857. PMCID: PMC4250400.

Greenfield SF, Weiss RD. Harvard Review of Psychiatry. Introduction. 2015 Mar-Apr; 23(2): 61-2. PMID: 25747919.

Connery HS, Weiss RD. Microscopes and telescopes: the societal impact of substance use disorder treatment. Am J Psychiatry. 2018 October; 175: 925-926.

Connery HS, Weiss RD. Discontinuing buprenorphine treatment of opioid use disorder: What do we (not) know? Am J Psychiatry. 2020 February; 177: 104-106.

Connery HS, Weiss RD. Drug overdose prevention: An exercise in optimism. Am J Psychiatry. 2023; 180: 337-339; doi: 10.1176/appi.ajp.20230170.

Books, Monographs, and Textbooks

Weiss RD, Mirin SM, authors. Washington, DC: American Psychiatric Press; 1987.

Weiss RD, Mirin SM, Bartel R, authors. Cocaine, 2nd edition. Washington, DC: American Psychiatric Press; 1994.

Weiss RD, Daley DC, authors. Understanding personality problems and addiction (workbook). Center City, MN: Hazelden Educational Materials; 1994.

Weiss RD, Daley DC, authors. Understanding personality problems and addiction (workbook), 2^nd Center City, MN: Hazelden Educational Materials; 2003.

Westermeyer JJ, Weiss RD, Ziedonis DM, editors. Integrated Treatment for Mood and Substance Use

Disorders. Baltimore: The Johns Hopkins University Press; 2003.

Pettinati HM, Weiss RD, Miller WR, Donovan D, Rounsaville BJ, Ernst D, authors. Medical Management

(MM) Treatment Manual: A Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism Monograph, 2004.

Weiss RD, Connery HS (authors): Integrated Group Therapy for Bipolar Disorder and Substance Abuse. New

York: Guilford Press, 2011.

Proceedings of Meetings

Wapler M, Mendelson JH, Teoh SK, Weiss R, Mello NK, Kuehnle J, Sholar W, Hanjra B, Rhoades E.

Buprenorphine attenuates drug craving in men with concurrent heroin and cocaine dependence. In:

Harris LS, ed. Problems of drug dependence, 1992, College on Problems of Drug Dependence, Inc.

Rockville, MD: National Institute on Drug Abuse Research Monograph 132; 1993. p. 339.

Weiss RD, Griffin ML, Hufford C. Measurement of craving in patients with cocaine dependence. In: Harris LS, ed. Problems of drug dependence, 1993, College on Problems of Drug Dependence, Inc. Rockville, MD: National Institute on Drug Abuse Research Monograph 141; 1994. p. 156.

Wapler M, Mendelson JH, Weiss RD, Teoh SK, Mello NK, Kuehnle J. Interaction of buprenorphine with cocaine and morphine challenge on craving self‑reports. In: Harris LS, ed. Problems of drug dependence, 1993, College on Problems of Drug Dependence, Inc. Rockville, MD: National Institute on Drug Abuse Research Monograph 141; 1994. p. 379.

Weiss RD, Martinez-Raga J, Griffin ML, Hufford C. A comparison of cocaine dependent patients with and

without a coexisting opioid use disorder. In: Harris LS, ed. Problems of drug dependence, 1994, College on Problems of Drug Dependence, Inc. Rockville, MD: National Institute on Drug Abuse Research Monograph 153; 1995. p.15.

Lukas SE, Sholar MB, Martinez-Raga J, Weiss RD. Electrophysiological and behavioral measures after cocaine cue exposure. In: Harris LS, ed. Problems of drug dependence, 1995, College on Problems of Drug Dependence, Inc. Rockville, MD: National Institute on Drug Abuse Research Monograph 162; 1996. p. 345.

Weiss RD, Najavits LM, Soto J, Greenfield SF, Hufford C, Tohen M. What is “treatment as usual” for bipolar

substance abusers? In: Harris LS, ed. Problems of drug dependence 1996, College on Problems of Drug Dependence, Inc. Rockville, MD: National Institute on Drug Abuse Research Monograph 174; 1997. p. 219.

Weiss RD, Najavits L, Greenfield S, Soto J, Wyner D, Tohen M. Relapse prevention group therapy for patients

with coexisting bipolar disorder and substance use disorder: outcome results and treatment themes. Poster presentation at the 28^th Annual Meeting of the Society for Psychotherapy Research, Geilo, Norway, June 25-29, 1997.

Weiss RD, Najavits LM, Greenfield SF, Soto J, Wyner D. Relapse prevention group therapy for patients with

coexisting substance use disorder and bipolar disorder. In: Problems of drug dependence, 1997: Proceedings

of the 59th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Rockville, MD:

National Institute on Drug Abuse Research Monograph 178; 1998. p. 253.

Greenfield SF, Weiss RD, Muenz LR, Vagge LM, Kelly JF, Bello LR. The effect of depression on return to drinking: A prospective study. In: Problems of drug dependence, 1997: Proceedings of the 59th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Rockville, MD: National Institute on Drug Abuse Research Monograph 178; 1998. p. 121.

Weiss RD, Najavits L, Greenfield S. Integrated Group Therapy for patients with bipolar disorder and

substance use disorder: outcome results and treatment themes. Poster presentation at the 30^th Annual

Meeting of the Society for Psychotherapy Research, Braga, Portugal, June 16-20, 1999.

Griffin M, Weiss R, Gallop R. Self-help group attendance among cocaine dependent patients receiving

psychotherapy and/or drug counseling in the NIDA Cocaine Collaborative Treatment Study. Poster presentation at the 30^th Annual Meeting of the Society for Psychotherapy Research, Braga, Portugal, June 16-20, 1999.

Weiss RD, Kolodziej ME, Najavits LM, Fucito LM, Greenfield SF, Griffin ML. Reasons for and effects of

substance use in patients with bipolar disorder and substance dependence. In: Problems of drug dependence, Proceedings of the 62nd Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Drug

and Alcohol Dependence 2000, 60: S234.

Weiss RD, Griffin ML, Mazurick C, Gallop R, Berkman B. The relationship between cocaine craving,

psychosocial treatment, and subsequent cocaine use. In: Problems of drug dependence, Proceedings of the

62nd Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Drug and Alcohol

Dependence 2000, 60: S251.

Greenfield SF, Kolodziej ME, Weiss RD, Sugarman DE, Vagge LM. History of sexual abuse, sex differences,

and drinking outcomes following discharge from inpatient alcohol treatment. In: Problems of drug dependence, Proceedings of the 62nd Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Drug and Alcohol Dependence 2000, 60: S79.

Weiss RD, Griffin ML, Gallop R. Self-help group attendance, and treatment outcome in the NIDA

Collaborative Cocaine Treatment Study. In: Problems of drug dependence, Proceedings of the 63rd Annual

Scientific Meeting, The College on Problems of Drug Dependence, Inc. Drug and Alcohol Dependence 2001,

63: S167.

Gugliotti T, Najavits LM, Weiss RD, Lee CSN, Schmitz MJ. How helpful are treatments for women with

substance dependence and posttraumatic stress disorder? An empirical study. In: Problems of drug

dependence, Proceedings of the 63rd Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Drug and Alcohol Dependence 2001, 63: S60.

Greenfield SF, Sugarman DE, Muenz LR, Patterson MD, He DY, Weiss RD. The relationship between

educational attainment and relapse among alcohol dependent men and women: A prospective study. In: Research Society on Alcoholism, Proceedings of the Annual Meeting, June, 2001, In Alcohol Clin Exp Res June 2001, Supplement.

Weiss RD, Kolodziej M, Griffin ML, Najavits LM, Jacobson LM, Greenfield SF: Substance Use and Perceived

Symptom Improvement in Bipolar Disorder, In: American Psychiatric Association, Syllabus and Proceedings Summary of the Annual Meeting, May, 2002.

Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E,

Nierenberg AA, Calabrese JR, Sachs GS, Pollack MH. Pharmacotherapy for bipolar disorder and comorbid conditions: Baseline data from STEP-BD. 42nd Annual Meeting of the American College of Neuropsychopharmacology, December 2003, San Juan, Puerto Rico.

Potter JS, Hennessy G, Borrow JA, Greenfield SF, Weiss RD. Characteristics of patients with OxyContin

dependence. In: Problems of drug dependence, Proceedings of the 65th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Drug and Alcohol Dependence, 2004.

Shields AL, Campfield Dr, Miller CS, McCall C, Wallace K, Potter JS, Weiss RD. Characterizing the

reliability of scores among alcohol screening tools via meta-analytic integration. Abstract presented at the

27th Annual Scientific Meeting of the Research Society on Alcoholism, Alcoholism: Clinical and Experimental

Research, 2004;48(Suppl): 618.

Shields AL, Miller CS, Campfield D, McCall C, Wallace K, Potter JS, Weiss RD. Reliability reporting

practices among alcohol screening tools in published reports. Abstract presented at the 27th Annual Scientific Meeting of the Research Society on Alcoholism, Alcoholism: Clinical and Experimental Research, 2004;48(Suppl): 619.

Griffin M, Weiss RD, Kolodziej M, Ray H. Assessment of primary substance of abuse in patients with bipolar

disorder and substance dependence. Abstract presented at the 27th Annual Scientific Meeting of the Research Society on Alcoholism, Alcoholism: Clinical and Experimental Research, 2004;48(Suppl): 893.

Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E,

Nierenberg AA, Calabrese JR, Sachs GS, Pollack MH. Pharmacotherapy for bipolar disorder and comorbid conditions: Baseline data from STEP-BD. Presented at the 157th Annual Meeting of the American Psychiatric Association, May 2004, New York, NY.

Weiss R, Griffin M, Kolodziej M, Ray H, Hennen J. A randomized controlled trial of Integrated Group

Therapy for patients with bipolar disorder and substance dependence. In: Problems of drug dependence, Proceedings of the 66th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Drug and Alcohol Dependence, 2004.

Pettinati HM, Weiss RD, Miller WR, Donovan D, Rounsaville BJ, Ernst D. Medical Management (MM)

Treatment Manual: A Guide for Medically Trained Clinicians Providing Pharmacotherapy as part of the

Treatment for Alcohol Dependence. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism,

Research Monograph, 2004.

Weiss RD, Griffin ML, Kolodziej ME, Janis IB, Hennen J. A randomized controlled trial of Integrated Group

Therapy for patients with bipolar disorder and substance dependence. Abstract presented at the 28th Annual

Scientific Meeting of the Research Society on Alcoholism, Alcoholism: Clinical and Experimental Research,

2005;29(Suppl.): 9902.

Ostacher MJ, Nierenberg AA, Perlis RH, Marzilli G, Eidelman P, Hwang CH, Tran TB, Weiss RD, Sachs GS.

The association between smoking and clinical course in bipolar disorder. Poster presented at the 6th

International Conference on Bipolar Disorder, June 16-18, 2005, Pittsburgh, PA.

Weiss, RD. Managing Alcohol and Substance Abuse in Patients with Bipolar Disorder: Psychosocial

Treatment Approaches, at the Seventh International Conference on Bipolar Disorder, June 7-9, 2007, Pittsburgh,

PA.

Weiss RD, Griffin ML, Jaffee WB, Bender RE, Graff F, Gallop RJ. Integrated Group Therapy for Patients with

Bipolar Disorder and Substance Dependence Can be Successfully Delivered by Drug Counselors. Presented at the 2008 American Psychiatric Association Annual Meeting, May 2-8, 2008, Washington, DC.

Weiss RD. Do patients with alcohol dependence respond to placebo? Results from a national treatment trial.

McLean Hospital Grand Rounds, December 11, 2008.

Weiss RD. Treatment of bipolar disorder and substance abuse. University of Massachusetts/Westborough State

Hospital Grand Rounds, February 24, 2009.

Weiss RD. Opioid analgesic dependence and pain: The NIDA Clinical Trials Network Prescription Opioid

Addiction Treatment Study. Presented at the National Conference of the American Association for the

Treatment of Opioid Dependence, Inc., New York, NY, April 25-29, 2009.

Weiss RD. Researchers and practitioners working in partnership to strengthen service delivery. Presented at

Innovations in Addictions: Research to Recovery Conference, May 4, 2009, Boston, MA.

Weiss RD. Using research to improve substance abuse treatment. Presented to The International Meeting of the

All-Party Parliamentary Group on Drug Misuse, London, England, May 13, 2009.

Weiss RD. Treatment of patients with bipolar disorder and substance dependence, presented at the 6th

UK/European Symposium on Addictive Disorders, London, England, May 14-16, 2009.

Weiss RD. Treatment of patients with substance abuse and psychiatric illness. McLean Hospital Psychiatry in

2009 Conference, Boston, MA, June 11-13, 2009.

Maleki N, Upadhyay J, Potter J, Weiss R, Becerra L, Borsook D. A DTI-based assessment of the changes in the

white matter in opioid addict patients: a parcellation based approach. Presented at the Joint Annual Meeting of

the International Society for Magnetic Resonance in Medicine and the European Society for Magnetic

Resonance in Medicine and Biology, Stockholm, Sweden, May 1-7, 2010.

Weiss RD. The prescription opioid addiction treatment study: Description of study and main outcome results. In R. D. Weiss & P. Jacobs (Chairs), The Multi-Site NIDA Clinical Trials Network Prescription Opioid Addiction Treatment Study: Outcomes and Implications. Symposium presented at the CPDD 72^nd Annual Scientific Meeting, Scottsdale, AZ, June 17, 2010.

Weiss RD. Comorbidity of mood disorders and alcohol dependence: Course and treatment. Chair and presenter of Symposium. 15^th World Congress of the International Society for Biomedical Research on Alcoholism, Paris, France, September, 2010.

Griffin ML, Weiss RD. A longitudinal study on the effect of drug use among social network members on drug

use among patients with co-occurring bipolar disorder and substance dependence. Poster presented at the 12^th

Annual Meeting of the International Society of Addiction Medicine, Milan, Italy, October, 2010.

Provost S, Potter JS, Weiss RD, Jacobs P, Ling W. A community-based, two-phase randomized controlled trial

of buprenorphine with and without individual drug counseling for the treatment of opioid analgesic addiction.

Poster presentation (#232452) as part of the 25^th Anniversary of Alcohol Tobacco & Other Drugs Section, 10^th

Anniversary of the National Institute on Drug Abuse Clinical Trials Network at the American Public Health

Association (APHA) 138^th Annual Meeting & Expo, Denver, CO, November 9, 2010.

Weiss RD, Potter J, Griffin M, Connery H, Ling W. Predictors of outcome in the multi-site CTN Prescription

Opioid Addiction Treatment Study, Poster presented at the 73^rd Annual Meeting of the College on Problems of Drug Dependence, Hollywood, FL, June 20-23, 2011.

Provost SE, Potter JS, Weiss RD. Advances in clinical research for prescription opioid dependence. 12^th Biennial Massachusetts Social Work Symposium, Framingham, MA, March 30, 2012.

McHugh K, Greenfield SF, Potter JS, Connery HS, Weiss RD. Gender differences in clinical characteristics of

prescription-opioid-dependent patients. Poster presented at the 74^th Annual Scientific Meeting of the College on Problems of Drug Dependence, Palm Springs, CA, June 9-14, 2012.

McHugh RK, Greenfield SF, Potter JS, Connery HS, Weiss RD. Gender differences in clinical characteristics of prescription-opioid-dependent patients. In L. Cottler & R. K. McHugh (Chairs), The Double Whammy: Chronic Pain and Opioid Abuse. Oral communication presented at the CPDD 74^th Annual Scientific Meeting, Palm Springs, CA, June 10, 2012.

Schuman-Olivier ZD, Borodovsky J, Shaffer HJ, Weiss RD, Albanese M. Benzodiazepine use and

buprenorphine treatment outcomes: A retrospective study. Presented at the 74^th Annual Scientific Meeting of the College on Problems of Drug Dependence, Palm Springs, CA, June 9-14, 2012.

Nielsen S, Hillhouse M, Mooney L, Sharpe Potter J, Weiss R, Lee J, Ling W. Buprenorphine induction for

prescription opioid users: Findings from the Prescription Opiate Addiction Treatment Study (POATS). Presented at the 74^th Annual Scientific Meeting of the College on Problems of Drug Dependence, Palm Springs, CA, June 9-14, 2012.

Weiss R, Griffin ML, Potter J, Connery H. Quality of life over time in the multi-site CTN Prescription Opioid

Addiction Treatment Study. Presented at the 74^th Annual Scientific Meeting of the College on Problems of Drug Dependence, Palm Springs, CA, June 9-14, 2012.

Sparenborg S, Hu L, Sharpe-Potter J, Weiss R. Pre-existing psychiatric severity did not affect likelihood of

success in the Prescription Opiate Addiction Treatment Study (POATS). Presented at the 74^th Annual Scientific Meeting of the College on Problems of Drug Dependence, Palm Springs, CA, June 9-14, 2012.

Weiss RD. The prescription opioid addiction treatment study: secondary analyses. In Khalsa J (organizer), Buprenorphine: New Formulations, Medication Combinations, Indications and Longitudinal Effects. Symposium presented at the American Society of Addiction Medicine 44th Annual Medical-Scientific Conference, Chicago, IL, April 26, 2013.

Weiss RD, Muchowski P, Hamilton J, Bailey G. The National Drug Abuse Treatment Clinical Trials Network (CTN) in New England: Advancing treatment through a partnership between researchers and community treatment programs. Cape Cod Symposium on Addictive Disorders, Hyannis, MA, September 13, 2014.

Hearon A, Pierce C, Bjorgvinsson T, Fitzmaurice G, Greenfield S, Weiss R, Busch, A. Looking Beyond Primary Care: A Single-Question Screening for Drug Use in a Psychiatric Treatment Setting. AHSR, Boston, MA, October 15-17, 2014.

Bogunovic O, McHugh RK, Walsh J, Weiss RD (Chair): Benzodiazepines for patients with other substance use disorders: When (if ever) to use them and how to discontinue them. Presented at the 27^th Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry, Bonita Springs, FL, December 8-11, 2016

Abstracts

Mirin SM, Weiss RD. Character pathology in substance abusers. Personality disorder in substance Presented at symposium of 141st Annual Meeting of the American Psychiatric Association, Montreal, May 7-12, 1988.

Weiss RD, Mirin SM, Najavits LM. Borderline personality and substance abuse. Presented at the

148th Annual Meeting of the American Psychiatric Association, Miami, FL, May 20-25, 1995.

Weiss RD, Najavits LM, Greenfield SF, Soto J, Wyner D, Tohen M. Relapse prevention group

therapy for patients with coexisting bipolar disorder and substance use disorder. Presented at the

28th Annual Meeting of the Society for Psychotherapy Research, Geilo, Norway, June 25-29, 1997.

Najavits LM, Shaw SR, Weiss RD. Why do some women with PTSD develop substance abuse while

others do not? An empirical study. Presented at the 32nd Annual Convention of the Association for

Advancement of Behavior Therapy, Washington, DC, November 5-8, 1998.

Weiss RD. Office treatment of cocaine dependence. Presented at the 154^th Annual Meeting of the

American Psychiatric Association, New Orleans, LA, May 5-10, 2001.

Weiss RD, Kolodziej M, Griffin ML, Najavits LM, Jacobson LM, Greenfield SF. Substance use and

perceived symptom improvement in bipolar disorder. Presented at the 155^th Annual Meeting of the

American Psychiatric Association, Philadelphia, PA, May 19-23, 2002.

Kolodziej ME, Weiss RD, Nargiso J. Anxiety disorders among individuals with bipolar and substance use

disorders. Poster presentation at the American Psychological Association Annual Convention 2003, Toronto, Canada, August 7-10, 2003.

Kalavasir R, Kranzler HR, Gueorguieva R, Yang B-Z, Weiss RD, Brady K, Farrer LA, Gelernter J,

Malison RT. Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. Presented at

the 42^nd Annual Meeting of the American College of Neuropsychopharmacoloty, San Juan, Puerto Rico,

December 12-16, 2004.

Meade CS, Graff FS, Jaffee WB, Copersino ML, Griffin ML, Weiss RD. Gender differences in the course of

mood episodes among patients with co-occurring bipolar and substance use disorders: a 6-month prospective study. Poster presented at the 41^st Annual Convention of the Association for Behavioral and Cognitive Therapies, Philadelphia, PA, November, 2007.

Weiss RD, Griffin ML, Jaffee WB, Bender RE, Graff F, Gallop RJ. Integrated Group Therapy for patients with

bipolar disorder and substance dependence can be successfully delivered by drug counselors. Presented at the 2008 American Psychiatric Association meeting, Washington, DC, May 3-8, 2008.

Weiss RD, Griffin ML, Jaffee WB, Bender RE, Graff F, Gallop RJ. Integrated Group Therapy for patients

with bipolar disorder and substance dependence. Presented at the 31^st Annual Scientific Meeting of the Research Society on Alcoholism: Clinical and Experimental Research 2008;32(Suppl): 200.

Zweben A, Pettinati H, Weiss R, Mattson M, Cox C, Youngblood M, Gorroochum P, Ciraulo D. AA

attendance in a combined medication and behavioral treatment trial. Presented at the 31^st Annual Scientific Meeting of the Research Society on Alcoholism: Clinical and Experimental Research 2008;32(Suppl): 706.

Ostacher MJ, Nierenberg AA, Ametrano RM, Bhagat SM, Desrosiers A, Salloum IM, Sachs GS, Weiss RD.

Re-evaluating DSM-IV criteria for alcohol dependence in bipolar disorder. Presented at the 31^st Annual Scientific Meeting of the Research Society on Alcoholism: Clinical and Experimental Research 2008;32(Suppl): 1009.

Teter C, Falone AE, Lower A, Weiss RD. Does recovery from substance use disorders among patients with

bipolar disorder predict improved medication taking behaviors and drug attitudes? Poster presented at: 49th Annual Meeting of the New Clinical Drug Evaluation Unit NCDEU, Hollywood, FL. June 29-July 2, 2009; NCDEU Poster Session 2009 Web site.

http: //www.cmeinstitute.com/postersession/2009Session5/ABSTeter.asp. Updated November 2009.

Potter JS, Griffin M, Jacobs P, Haler DL, Gardin J, Zakroysky P, Putnins S, Fisher D, Weiss RD. The National

Institute on Drug Abuse Clinical Trials Network Prescription Opioid Addiction Treatment Study. Poster

presented at the 43^rd Annual Meeting of the Association for Behavioral and Cognitive Therapies, New York,

NY, November 19-22, 2009.

Potter JS, Griffin M, Jacobs P, Haller DL, Gardin J, Zakroysky P, Putnins S, Fisher D, Weiss RD. The National

Institute on Drug Abuse Clinical Trials Network Prescription Opioid Addiction Treatment Study: Characteristics of individuals with and without chronic pain. Poster presentation at the 43^rd Annual Meeting of the Association for Behavioral and Cognitive Therapies, New York, NY, November 19-22, 2009.

Weiss RD, Chakrabarti A, Woody GE, Subramanian G, Dodd DR. Predictors of buprenorphine-naloxone

dosing in a twelve-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical

Trials Network study. Poster presented at the 8^th NIDA Blending Conference: Blending Addiction Science and Practice: Evidence-Based Treatment and Prevention in Diverse Populations and Settings, Albuquerque, NM, April 22-23, 2010.

Griffin ML, McDonald LJ, Kolodziej ME, Fitzmaurice GM, Weiss RD. Drug use among social network

members of patients with co-occurring bipolar and substance use dependence. Poster presented at the 2010

American Psychiatric Association meeting, New Orleans, LA, May 22-26, 2010.

Weiss RD. The effectiveness of treatment for prescription opioid abuse – a review of the clinical evidence.

Presented at Tufts Health Care Institute Conference, “Prescription Opioid Abuse: Challenges and Opportunities

for Payers, Boston, MA, June 3-4, 2010.

Meade CS, Sanchez AK, Fitzmaurice GM, Griffin ML, McDonald LJ, Weiss RD. Mania and sexual risk in

patients with co-occurring bipolar and substance use disorders: a 15-month prospective study. Presented

at the XVIII International AIDS Conference, Vienna Austria, July 18-23, 2010.

Provost S, Potter JS, Weiss RD, Jacobs P, Ling W. A community-based, two-phase randomized controlled trial of buprenorphine with and without individual drug counseling for the treatment of opioid analgesic addiction. Poster presented at the 25^th Anniversary of the Alcohol Tobacco & Other Drugs Section and the 10^th Anniversary of the National Institute on Drug Abuse Clinical Trials Network at the American Public Health Association 138^th Annual Meeting & Expo, Denver, CO, November 9, 2010.

Connery HS, Publicker M, Hoyne J, Cohen A, Provost S, Woody GE, Weiss RD. NIDA Clinical Trials Network: Examples of community program buprenorphine dissemination in low-access areas. Poster presented at the American Academy of Addiction Psychiatry Annual Meeting, Boca Raton, FL, December 2-5, 2010.

Weiss RD, Potter JS, Griffin ML, Connery HS, Ling W. Predictors of outcome in the multi-site CTN Prescription Opioid Addiction Treatment Study. Poster presented at the CPDD 73^rd Annual Scientific Meeting, Hollywood, FL, June 20, 2011.

McHugh RK, Greenfield SF, Potter JS, Connery HS, Weiss RD. Gender differences in clinical characteristics of prescription-opioid-dependent patients. Poster presented at the CPDD 74^th Annual Scientific Meeting, Palm Springs, CA, June 9-14, 2012

Weiss RD, Griffin ML, Potter JS, Connery H. Quality of life over time in the multi-site CTN Prescription Opioid Addiction Treatment Study. Poster presented at the CPDD 74^th Annual Scientific Meeting, Palm Springs, CA, June 13, 2012.

Sparenborg S, Hu L, Sharpe Potter J, Weiss RD. Pre-existing psychiatric severity did not affect likelihood of success in the Prescription Opiate Addiction Treatment Study (POATS). Poster presented at the CPDD 74^th Annual Scientific Meeting, Palm Springs, CA, June 14, 2012.

Hill KP, Bennett HE, Griffin ML, Fitzmaurice GM, Subramaniam G, Woody GE, Weiss RD. Association of cannabis use with opioid use outcomes among opioid-dependent youth. Poster presented at the American Academy of Addiction Psychiatry 23^rd Annual Meeting and Symposium, Aventura, FL, December 6-9, 2012.

Weiss RD, Griffin ML, Dreifuss JA, Dodd D, Potter JS, Connery H. Who benefits from more intensive counseling for prescription opioid dependence? Poster presented at the CPDD 75^th Annual Meeting, San Diego, CA, June 17, 2013.

Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, Woody GE, Weiss RD. Lack of association of cannabis use with opioid outcomes among opioid-dependent youth. Poster presented at the CPDD 75^th Annual Meeting, San Diego, CA, June 17, 2013.

Weiss R, Griffin M, Dreifuss J, Dodd D, Potter J, Connery H. Who benefits from more intensive counseling for prescription opioid dependence? Poster presented at the American Academy of Addiction Psychiatry 24^th Annual Meeting, Scottsdale, AZ, December 5-8, 2013.

Konstantopoulos WM, Dreifuss JA, McDermott KA, Parry BA, Howell ML, Mandler RN, Bogenschutz M, Weiss RD. Correlates of drug use problems among substance users presenting in emergency departments: Results of a multi-site study. Poster presented at the CPDD 76^th Annual Meeting, San Juan, Puerto Rico, June 18, 2014.

Weiss RD, McDermott K, Griffin ML, Hilario E, Connery H. Does early response to buprenorphine-naloxone predict treatment outcome in prescription opioid dependence? Poster presented at the College on Problems of Drug Dependence (CPDD) 76^th Annual Meeting, San Juan, Puerto Rico, June 18, 2014.

Clinical Communications

Weiss RD, Gunderson JG. Case reports of McLean Hospital. McLean Hospital Journal 1977; 2: 39-47.

Lukas SE, Weiss RD, Mendelson JH. Changes in P300 evoked response potentials (ERPs) in

cocaine-dependent patients during detoxification. The Pharmacologist 1987; 29: 158.

Weiss RD. Nicotine toxicity misdiagnosed as lithium toxicity. Am J Psychiatry 1996; 153: 132. (Letter to the Editor).

[1] Dr. Weiss is a member of the COMBINE Research Group; COMBINE is an 11-site NIAAA-funded study of combined pharmacotherapies and behavioral therapies for alcohol dependence.

[2] Dr. Weiss is a member of the COMBINE Research Group; COMBINE is an 11-site NIAAA-funded study of combined pharmacotherapies and behavioral therapies for alcohol dependence.